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ABSTRACT 
 
DESIGNING A CALIBRATION SET IN SPECTRAL SPACE FOR EFFICIENT 
DEVELOPMENT OF AN NIR METHOD FOR TABLET ANALYSIS 
 
 
 
By 
Md Anik Alam 
May 2018 
 
Dissertation supervised by Carl A. Anderson 
Designing a calibration set is the first step in developing a spectroscopic calibration 
method for quantitative analysis of pharmaceutical tablets. This step is critical because 
successful model development depends on the suitability of the calibration data. For 
spectroscopic-based methods, traditional concentration based techniques for designing 
calibration sets are prone to have redundant information while simultaneously lacking 
necessary information for a successful calibration model. The traditional method also 
follows the same design approach for different spectroscopic techniques and different 
formulations, thereby lacks the optimizing capability to be technique and formulation 
specific.  
A method for designing a calibration set in the Near Infrared (NIR) spectral space was 
developed for quantitative analysis of tablets. The pure component NIR spectra of a tablet 
 v 
formulation were used to define the spectral space of that formulation. This method 
minimizes sample requirements to provide an efficient means for developing multivariate 
spectroscopic calibration.  
Multiple comparative studies were conducted between commonly employed experimental 
design approaches to calibration development and the newly developed spectral space 
based technique. The comparisons were conducted on single API (Active Pharmaceutical 
Ingredient) and multiple API formulation to quantify model drugs using NIR 
spectroscopy. Partial least squares (PLS) models were developed from respective 
calibration designs. Model performance was comprehensively assessed based on the 
ability to predict API concentrations in independent prediction sets. Similar prediction 
performance was achieved using the smaller calibration set designed in spectral space, 
compared to the traditionally designed large calibration sets. An improved prediction 
performance was observed for the spectrally designed calibration sets compared to the 
traditionally designed calibration sets of equal sizes. Spectral space was also used to 
incorporate physico-chemical information into the calibration design to provide an 
efficient means of developing robust calibration model. Robust calibration model is 
critical to ensure consistent model performance during model lifecycle. A weight 
coefficient based technique was developed for selecting loading vector in PLS model to 
aid in building robust calibration model.  
It was also demonstrated that the optimal structures of calibration sets are different 
between NIR and Raman spectroscopy for the same tablet formulation. The optimum 
calibration structures are also different between two APIs for the same spectroscopic 
technique, indicating the criticality of the calibration design to be formulation and 
 vi 
technique specific. This study demonstrates that a calibration set designed in spectral 
space provides an efficient means of developing spectroscopic multivariate calibration for 
tablet analysis. This study also provides opportunity to design formulation and technique 
specific calibration sets to optimize calibration capability. 
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1 Chapter 1: Introduction 
1.1 Statement of the Problem 
NIR spectroscopy (NIRS) is a well-established analytical tool in the pharmaceutical 
industry for quantitative analysis of tablets [1-5]. NIRS offers substantial advantages in 
terms of time and cost compared to the wet chemical methods. However, successful 
application of this technology depends on an appropriate calibration method, and an 
appropriate calibration method is built upon appropriate calibration sample design. 
Typical steps to develop a NIR quantitative calibration method for pharmaceutical tablets 
are: calibration design, sample set preparation, spectral data collection, reference 
analysis, and model development [2]. Defining the calibration sample set is the first step 
for calibration model development. There are a number of requirements for an 
appropriate calibration set for tablet analysis; examples include spanning the 
concentration range for an active pharmaceutical ingredient (API) and excipients, 
multiple lots of raw materials, different processing conditions, mutually independent 
samples, etc [6]. A proper calibration set is a pre-requisite for generating appropriate 
spectral data and achieving desirable predictive performance from NIRS. Therefore, the 
size and direction of the calibration spectral subspace  is of critical importance for 
successful quantitative model development [7]. 
Other elements of NIR method development have been the subject of many 
comprehensive reviews and continuous advancements (e.g. pretreatment techniques, 
regression methods). Yet, analysis of calibration set design and its effect on model 
performance has received far less attention in the literature and regulatory guidelines. 
There is no standardized reference method for developing spectroscopic calibration sets 
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for quantitative analysis of tablets. Practical approaches used for designing calibration 
sets include experimental design entirely in concentration space (e.g. full-factorial design, 
central composite design)  [8-11], calibration sample selection form large data set based 
on a selection algorithm [12-16], preparation of sample set that spans target 
concentrations and anticipated variance (including physical sources of variance) over the 
product lifecycle [17-21]. The objective of these techniques is to generate an appropriate 
calibration set that contains ‘sufficient’ information about the system to develop a 
successful quantitative model. As sufficient information is challenging to define, the 
general idea is to incorporate as much variance as possible in an effort to ensure that all 
future variance is captured in the calibration set [22]. This idea often leads to the creation 
of a large calibration set. The reported numbers of calibration samples for NIR 
quantitative methods are typically large for pharmaceutical tablets, such as 500 [23], 450 
[24], 414 [25], 297 [26] and 276 [27]. Preparation of such large calibration sets is costly, 
especially in the product development phase when API is expensive. It is also very time 
consuming to perform the reference analysis (typically HPLC) of such large calibration 
sets. A small calibration set with desired predictive performance would be helpful to save 
time and cost associated calibration method development for tablet analysis using NIRS. 
Ironically, the traditionally developed large and expensive calibration sets typically 
contain redundant information. Redundant information is not necessary for developing a 
successful quantitative model. However, samples containing redundant information are 
typically identified in posterior analysis from their spectral responses. An analysist often 
ends up preparing and analyzing samples that are unnecessary for the intended purpose. 
Currently, there is no published technique to identify the redundant samples at the outset 
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of calibration development. Such a technique would be helpful to reduce the efforts in 
preparing redundant calibration samples and save considerable time and cost associated 
with calibration development. 
It is also possible to miss the critical samples in the large calibration sets leading to a lack 
of robustness of the method despite specific efforts to the contrary. A calibration set may 
simultaneously contain redundant spectral information and lack the necessary 
information to provide model robustness. Current approaches for calibration development 
do not provide opportunity to identify the most critical calibration samples at the outset of 
calibration development. Such a technique is useful to identify the smallest possible 
calibration set with desired predictive performance.  
Information about critical sample requirements of a calibration set is most useful at the 
outset of method development to design a small and efficient NIR calibration set for 
tablet analysis. This requirement is formulation specific and is dependent on the spectral 
response of the individual constituent. Current strategies for designing NIR calibration 
sets do not account for variations in pharmaceutical formulations and their spectral 
responses. Regulatory guidelines and general rules of thumb are usually followed for all 
types of formulations resulting in similar concentration ranges, levels and number of 
samples for all types of calibration sets. However, an optimal calibration design for one 
formulation can be sub-optimal for a different formulation. Different NIR responses 
produced by different formulations should be considered during the selection of 
calibration range, size, concentration levels and variance information. Variation of the 
spectrally similar components might give redundant information and need not to be 
varied simultaneously in the calibration set. Concentration of a component with relatively 
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weak spectral response might not need to be varied extensively whereas the component 
with dominant spectral features might require wide variation in the calibration set to 
develop a successful calibration model. Non-linearity between the concentration and 
spectral response can be highly dependent on the formulation and analytical technique of 
interest. The same calibration designs of different formulations can be mapped differently 
into the spectral space of an analytical technique, generating redundant information for 
one formulation while lacking necessary information for the other. A formulation specific 
calibration strategy should be developed to best utilize NIR capability for quantitative 
analysis of tablets. 
A calibration set should also be specific to analytical technique. Currently, little or no 
differences are usually found between NIRS and other spectroscopic calibration designs. 
The same calibration design of the same formulation can perform differently depending 
on the analytical technique. Practically, there is no best calibration design that works for 
all purposes. A great deal depends on the method requirements and resource availability 
[28]. The traditional practices for developing calibration sets are inefficient in utilizing 
the available resources and minimizing redundant information. The calibration strategies 
are also too generalized to account for formulation variability and variation in spectral 
responses. A formulation and technique specific calibration strategy is required to make 
the calibration process efficient and optimize the calibration performance.  
This dissertation demonstrates a strategy for designing a calibration set in spectral space 
for quantitative analysis of tablets using NIRS. This strategy requires fewer calibration 
samples to achieve desired prediction performance of the calibration model. This strategy 
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also offers a formulation and technique specific calibration experiments for calibration 
method development.  
1.2 Hypothesis and Objectives 
The central hypothesis of this dissertation is that designing experiments in spectral space 
provides a more efficient means compared to current practices for developing 
spectroscopic calibrations for quantitative analysis of pharmaceutical tablets. 
Given the central hypothesis, the objectives of this dissertation work were, 
1. Develop a strategy to design NIR calibration sets in spectral space for 
pharmaceutical tablets  
a. Calibration design for a model drug product containing one API. 
b. Calibration design for a model drug product containing multiple API. 
2. Evaluate calibration performance between spectral calibration sets and traditional 
calibration sets for quantitative analysis of tablets using NIR 
a. Comparative studies between calibration strategies for single API. 
b. Comparative studies between calibration strategies for multiple API. 
3. Develop a strategy to incorporate physical information into the spectral design of 
NIR calibration set 
a. Develop strategy to incorporate physical information into the spectral 
space 
b. Evaluate calibration model robustness between spectral calibration sets 
and traditional calibration sets  
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4. Compare optimized calibration sets of NIR and Raman spectroscopy for 
quantitative analysis of pharmaceutical tablets 
1.3 Literature Survey 
The first calibration set development and quantitative analysis of pharmaceutical 
components using NIRS was reported in 1961 [29]. A series of reports followed later on 
the quantification of amine salts (first application in a solid system) [30], 
allylisopropylacetureide and phenacetin [31], meprobamate [32], carisoprodol [33] and 
water content [34] in pharmaceutical compounds using NIRS1. Since then, application of 
this technology has been exponentially expanding due to advancements in computational 
power, multivariate statistics and also information contained in the spectral range [35]. 
The pharmaceutical industry has adapted NIRS due to its potential to offer fast, easy and, 
most importantly, non-invasive and non-destructive analysis technique. However, an 
appropriate calibration set is required to deal with complex and overlapping features of 
NIR spectra and non-specificity inherent to the technique [36]. An appropriate calibration 
set is also critical to ensure consistent calibration performance during product life cycle. 
Any change in the formulations, physical properties of the components or manufacturing 
unit operations may cause the validated NIR method to become unusable [37]. 
Current strategies for developing calibration sets suffer from the redundancy of 
unnecessary information and the inadequacy of critical information in the calibration 
design. Redundancy of the calibration set and appropriateness of the calibration designs 
are critical factors that need to be considered during NIR calibration development. Bondi 
et al. demonstrated improved accuracy of full factorial and I-optimal designs over other 
                                                          
1 Calibration development for these reported methods used a univariate approach 
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types of factorial and optimal designs for NIR calibration development [9]. Although the 
I-optimal design was a subset of the full factorial design, the difference in predictive 
performance was statistically insignificant. This work suggests the presence of redundant 
information in the full factorial calibration design. Xiang et al. analyzed the effect of 
correlated design on the selectivity and robustness of the calibration models [38]. They 
demonstrated that the model selectivity and robustness of a randomized design was 
superior to that of a correlated design. Low correlation in the randomized design was 
critical to avoid fitting of the partial least squares (PLS) model to the non-selective 
correlation between spectra and excipient concentration. Naes et al. compared five 
mixture designs for developing calibration models and concluded that similar variation 
was required between the calibration and the prediction sets for successful model 
development [9, 39]. The same author also demonstrated the tendency of traditional 
calibration methods to contain redundant information in a subsequent paper; similar 
prediction performance was achieved with  20 samples out of 114 samples from the 
calibration set [40]. All of these examples demonstrate that a calibration set may 
simultaneously contain redundant spectral information and lack the necessary 
information to provide calibration model robustness. However, this information is 
available only in retrospective analyses, after considerable time and effort has been spent 
on the calibration development.  
The current strategies for developing NIR calibration set need significant improvement to 
make the calibration process efficient and optimize calibration performance. 
Optimization of the calibration strategy requires an in-depth understanding about the 
requirements of an appropriate calibration set and the effects of calibration structure on 
 8 
 
calibration model performance. This understanding can be helpful to identify the 
necessary information for a calibration set and challenge the current philosophy of 
incorporating all possible variances into the calibration set. The current recommendation 
of a large calibration set can be replaced by an efficient strategy for developing NIR 
calibration set to quantitatively analyze pharmaceutical tablets.  
This chapter is aimed at reviewing the general requirements for an NIR calibration set 
designed to quantitatively analyze pharmaceutical formulations, current strategies for 
developing calibration sets and their effects on calibration model performances based on 
the published literature and regulatory guidelines. This discussion is particularly focused 
on the calibration sets designed to use inverse least squares regression techniques (partial 
least squares, principal component regression), considering their wide applicability and 
most frequent usage for quantitative analysis of pharmaceutical formulation. 
1.3.1 Calibration set requirements 
There are several requirements for an appropriate NIR calibration set. Blanco et al. 
indicated wide concentration variation and physico-chemical variability as critical 
requirements [41]. Mutual independence of samples was added to this list by other groups 
[6, 38]. Naes et al. discussed these requirements in terms of calibration spectral space and 
associated eigenvectors due to inherent collinearity of the NIR spectra [39]. Presence of 
all relevant eigenvectors, wide spanning of the eigenvector’s directions and even spread 
of the spectral space over the eigenvector subspace were considered necessary parameters 
for NIR calibration set. However, calibration set requirements can be further discussed in 
terms of range and level of concentration, number of samples and variance information. 
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1.3.1.1 Range and levels of concentration 
An appropriate concentration range and variability in calibration set is necessary to 
ensure NIR method robustness [42]. The concentration range must be selected 
appropriately to cover the anticipated concentration range in the routine samples. An 
extrapolation due to inappropriate calibration range is detrimental to calibration model 
performance. The effect of extrapolation is more critical to multivariate NIRS method 
compared to univariate counterpart [43]. Although a wide concentration range is 
encouraged, there are limitations in terms of time and resources available to develop a 
large calibration set. The typical production samples do not cover wide concentration 
range as the Pharmacopoeias often allow 5% deviation of the nominal content for the API 
[42]. Synthetic samples are often prepared in lab to extend the concentration range. 
International Conference on Harmonisation (ICH) suggests a range of ±20% of the 
nominal content of API for the assays method and ±30% for the content uniformity 
method [44]. The concentration range can be further extended by the inclusion of pure 
component (100%) or placebo tablets (0%) [45]. However, extreme points have high 
leverage during calibration development. High leverage samples can significantly change 
model direction and affect prediction performance in the concentration range of interest. 
Although a wide concentration range is considered to increase model robustness, it can 
introduce non-linearity. Good fit is almost guaranteed for a small set with narrow region. 
However, the predictions outside this small range are of little value considering the 
samples being outside of the validated range of the method [46]. Multiple ranges of a 
single calibration set are also used for different prediction samples [47]. A prediction 
sample at the calibration center is predicted by a narrow calibration range samples (local 
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calibration) whereas, prediction samples at the edge are predicted by a broad calibration 
range samples (global calibration). This technique is known as bracketing. Bracketing 
can also be performed by selecting an optimal subset from global calibration set [48]. 
Optimal subset can be changed each time a new test sample encountered. 
There is no guideline reported for excipient concentration range in the calibration set. 
Scheibelhofer et al. considered the variation of API more critical than the small deviation 
of the excipients from the target [49]. However, all possible variations in excipient 
concentrations were recommended to be included into the calibration set [49].  
Components having common spectral features were emphasized in this aspect. A 
regulatory guideline for excipient variation would be helpful in designing an appropriate 
calibration set with desired predictive performance. 
The concentration levels of a calibration set are also critical to develop appropriate 
calibration model. Uniform distribution of the concentration levels is favored over 
Gaussian or normal distribution [50, 51]. High leverage samples in the normal 
distribution are considered undesirable during model development. The ICH Guideline 
recommends at least five concentration steps to prove linearity [44]. Several samples 
should be available per source of variance in NIR calibration set [47, 51]. The link 
between API concentration range and clinical performance has not been discussed either 
in literature or in guidelines. The calibration range is selected primarily based on 
acceptable API range in the final dosage forms. A risk-based approach for defining the 
range would be advantageous to bridge the gap between acceptable API range, 
calibration range and clinical performance [52]. 
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1.3.1.2 Number of samples 
Appropriate number of calibration samples is critical to calibration model performance 
[53]. ‘Appropriate number’ has been defined as the number providing sufficient chemical 
and physical variability resulting in appropriate spectral variability [54]. The number is 
formulation, method and technique dependent and usually decided based on experience. 
A set of 20–30 calibration points was considered sufficient for model accuracy by several 
groups [47, 55, 56]. Agelet et al. recommended 100 samples for a robust NIR calibration 
[50]. This requirement can be smaller for homogeneous samples. ASTM recommends 
multiplying the number of principal component (PC) by a factor of 6 to determine 
appropriate sample number [57]. However, a priori data set is a prerequisite to calculate 
the PCs. Mathematical approaches have been reported to determine the number of 
calibration samples [49]. For a mixture system having “P” levels for each chemical 
component, the appropriate number of calibration sample ‘N’ can be calculated as, 
 𝑁𝑁 = 12 ∗ 𝑝𝑝 ∗ (𝑝𝑝 + 1) (1.1) 
Li et al. used full factorial approach to determine the number of calibration samples for a 
system containing “C” chemical components, each at “P” level, using following equation 
[58]. 
 𝑁𝑁 = 𝑃𝑃𝐶𝐶−1 (1.2) 
A degree of freedom is lost due to the mixture constraint. Such approaches give general 
direction for calibration sample number. However, these strategies require each varying 
component to have same number of levels, which may not always be feasible.  
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The appropriate numbers of calibration samples are also determined by splitting the 
available data into calibration and test set. Alvarenga et al. suggested that, the calibration 
should not be smaller than the 2/3 of the data set [59]. A smaller set is preferred to save 
time and cost, however, a minimum number must set to meet the statistical requirement. 
A two-points (extreme) calibration set was also reported during NIRS method 
development [60], for which statistical validity was questionable. 
1.3.1.3 Variance information 
The information content of the calibration set and quality of the calibration samples are 
considered to be more important than the number of calibration samples [22, 61]. A large 
variation in all directions at the region of interest is a critical requirement for an 
appropriate calibration set [59]. The information should include variation due to 
concentrations as well as physical properties, moisture contents [51, 62] of the samples 
and other factors that are bound to influence NIR spectra [63]. The calibration samples 
should have a wider range of variation than the production samples to ensure model 
robustness [19]. The wider range samples can be prepared at the laboratory scale or by 
spiking (under-dosing/over-dosing) the production samples with appropriate amount of 
API and/or excipients. However, lab-engineered samples were criticized due to its 
potential to introduce greater than nominal variances and increase prediction errors [62]. 
A calibration model has the potential to fail during the prediction of future samples 
having different interference information such as temperature effects, season to season 
variation, different tablet for the same active component, and batch effects in industrial 
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production processes [64-67]. The structure and information content of the calibration set 
are critical for achieving appropriate representation of the future samples [46]. 
Several requirements are reported and they provide a general guideline for NIR 
calibration set development. However, many of the calibration requirements can be 
method specific and can vary depending on method requirements. Instead of a general 
calibration design guideline, a standard method specific protocol is essential to meet the 
calibration requirements. It is also critical to establish appropriate metrics to ensure the 
fulfillment of calibration set requirements. 
1.3.2 Strategies for developing calibration set 
The main objective of developing a NIR calibration set is to represent routine production 
samples and aid in developing a successful predictive model. Routine samples should not 
be used alone to develop calibration set as these samples contain API and excipients in 
amounts very close to the target composition, which precludes spanning a wide enough 
concentration range for calibration set [41, 63, 68]. Several strategies are used to develop 
calibration sets. Sarraguca et al. reported four strategies [63] for developing calibration 
set using: 
1) Production samples with a wide concentration range [24, 69, 70]  
2) Production samples spiked with API/excipients [71-73] 
3) Designed laboratory samples [73, 74] 
4) Combined set of production and laboratory samples [42]  
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Blanco et al. discussed similar strategies and recommended a combined approach [75]. 
The author also demonstrated a strategy using laboratory samples with a calculated 
process spectrum to explain the spectral difference between laboratory and production 
samples [41]. Spiking production samples and designing laboratory samples are the two 
most common strategies. These strategies were found to be similar in terms of model 
performance [63, 72, 73, 75]. Spiked samples usually match with the routine production 
samples in terms of physical properties offering additional advantages [73]. However, a 
high correlation between component’s concentrations in spiked samples can lead to poor 
model specificity. Experimental design of the laboratory samples can be used to reduce 
the correlation between component concentrations [42]. Another widely used strategy 
involves the selection of calibrations set samples from a large data using different 
selection techniques [74]. In this report, strategies are classified into three major 
categories based on the techniques used for developing NIR calibration set: 
A. Use of design of experiment to prepare a calibration set 
B. Use of sample selection techniques to select a calibration set 
C. Under dosing/over dosing (spiking) production samples to prepare a calibration 
set 
1.3.2.1 Use of design of experiment to prepare calibration set 
Design of experiments (DoE) is a statistical tool to design a controlled and limited 
number of experiments to gain in-depth understanding about the relationship between 
factors and responses of an underlying system. In the field of multivariate calibration 
(MVC), DoE is used to design calibration samples to define the relationship between 
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concentration and spectral response. The implementation of DoE is challenging in MVC 
due to the inconsistency between the theory and practical application. In the calibration 
design, the concentrations are considered as factors and spectra are considered as 
response. In contrast, in the model system (regression) the concentration and spectral 
response act as response and factors, respectively. Although this inconsistency has been 
previously addressed [76], a practical solution is yet to be introduced. There are several 
types of experimental designs employed to develop NIR calibration set. 
1.3.2.1.1 Full Factorial Design 
During spectroscopic calibration development, a full factorial design is used to prepare 
calibration set using all possible combinations of the varying components. The details of 
full factorial design can be found elsewhere [77]. Although this design is intended to 
provide orthogonality, it is not possible to attain complete orthogonality in calibration 
design of a pharmaceutical system due to the mixture constrain (total is 100%), especially 
in solid samples. Therefore, the orthogonality between API and major excipients are 
emphasized over the minor excipients. Complete orthogonality can be achieved using 
sample solutions. A full factorial orthogonal design was created to build NIR calibration 
dataset for predicting human serum albumin, gamma-globulin and glucose in control 
serum and phosphate buffer solution [78, 79]. However, the calibration set was developed 
by randomly selected 80 samples out of 125. Thus, the orthogonality of the design was 
not maintained in the calibration set. The effect of randomized selection on calibration 
model performance was not analyzed. 
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Selection of design factors and levels are critical during calibration development. In most 
cases, the API and major excipients are considered as the factors of the design, because 
the primary objective of the calibration design is to develop mathematical relationship 
between API concentration and spectral response. The variations in the major excipients 
are required to train the calibration model against non-specific variation in the spectral 
response. Other excipients usually act as fillers to fulfill the constraint. For multiple API, 
only the APIs can act as factors [80]. A component ratio can also act as a factor of the 
calibration design. Using a ratio as factor helps to reduce the number of design points 
while maintaining wide range of concentration. Igne et al. considered API concentration 
and major excipient’s ratios as two factors of the design during the development of a 
calibration set for blend monitoring [81, 82]. The first calibration set contained spectra 
from different time points of blending runs whereas the second set contained spectra at 
the end of the blending runs assuming that the blend reached homogeneity. 
Aside from the compositions, external factors such as moisture content, batch, day, 
operator and collection temperature can also be included in the design to introduce 
external variance into the calibration set [83]. Inclusion of the external factors usually 
leads to a robust calibration model. However, it can also affect model accuracy due to 
spectral sensitivity to the external factors. Kamran et al. included the API concentration, 
particle size distributions (PSD) and compression pressures as the design factors during 
the quantification of ibuprofen in tablets [84]. The calibration performance was found to 
be sensitive to PSD variation. The model performance was improved by developing the 
calibration set on uniform PSD of API and filler. In this study, the sample set was 
randomly split into calibration and validation set. An independent validation set should 
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have been used to retain the orthogonality of the design in calibration set. Such validation 
set was used to assess calibration performance during the quantification of red iron oxide 
in tablets [85]. The calibration model was found to be sensitive to the thickness variation 
built into the calibration design. A uniform distribution of the tablet thicknesses in 
calibration set would be helpful to make the model robust against thickness variation.  
Full factorial design can be combined with a fractional factorial design during calibration 
set development. Cogdill et al. used a combination of full factorial (in production scale) 
and fractional factorial design (in lab scale) during API quantification in tablets [23]. The 
common design factors were the source of API and Magnesium stearate, granules’ 
moisture content and compression force. Additionally, in the fractional factorial design, 
API content was varied at ±30% of the nominal content. The use of a fractional design 
helped to reduce the number of design points. The calibration model was demonstrated to 
be robust against source, time, and compaction pressure variation. Another calibration set 
was developed for predicting Radial Tensile Strength (RTS) of the tablet. Compression 
force was varied in the calibration set to produce tablets with different RTSs. 
1.3.2.1.2 D-Optimal Design 
D-optimal design is widely used for developing calibration set with optimum number of 
samples when the classical symmetrical designs cannot be used because of the large 
number of design points or the irregular shape of the experimental region [86]. This 
technique is used to maximize the information content of a design by maximizing the 
determinant (D) of the information matrix (X’X). The details of the design can be found 
elsewhere [87]. 
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Karande et al. used a D-optimal design to develop a NIR calibration set for blend 
monitoring [88]. A set of 24 design points was created by D-optimal design strategy out 
of which, 3 design points were removed for the test set leaving 21 design points for the 
calibration development. These 21 design points might not be the optimum set of 21 
points that had maximum determinant. It would be ideal to create a separate design for 
the test set to maintain optimality of the calibration set. In this study, the calibration range 
was 2-6 % and the resulting calibration model was used for predicting a full blend run 
where API concentration outside the range was expected to be encountered during the 
blending process. Prediction outside the calibration range should have been considered 
with limited confidence. D-optimal design was also used to create a calibration set for 
monitoring a five component blending run [89]. 
Tomuta et al. used D-optimal design strategy to develop a calibration set for quantitative 
analysis of API and excipients in meloxicam tablets [90]. The ranges of variation were 
kept ± 20% from the target composition for all components and levels of variation were 
different for different components. The calibration model was able to predict meloxicam 
and isomalt concentration accurately, but unable to predict sodium starch glycolate and 
magnesium stearate due to low concentration. However, meloxicam and sodium starch 
glycolate had similar concentrations (6.25% and 5%) but different levels of variation in 
the calibration design. The effect of level variations on prediction performance was not 
analyzed. In another study, D-optimal design was used to prepare a set of placebo 
samples during the determination of ibuprofen content in production granules, tablet 
cores and coated tablets [91]. The calibration samples were prepared by mixing different 
levels of API with randomly selected placebo matrix and compressing them at different 
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pressures. The randomization of the placebo mixture helped to mitigate the possibility of 
compositional correlation in the calibration design. 
D-optimal design was also used to create a calibration set during flow property analysis 
of pharmaceutical powder [92]. A sample set with compositional variations was designed 
to cause variation in flow properties e.g., angle of repose, compressibility index and 
hausner ratio. A similar approach was taken to analyze the PSD of a pharmaceutical 
powder system [93]. Compositional variation was designed and assumed to create 
variation in the PSD of the final formulation. The use of a D-optimal design ensured 
maximum concentration variation with given number of design points. However, it did 
not ensure maximum variation in the PSD with the given design points. D-optimal design 
was also used to prepare a calibration set during the determination of simvastatin and 
excipients in lyposomes [94], diacetylmorphine, Caffeine and Acetaminophen [95] and 
cetirizine dihydrochloride in powder samples [96]. 
1.3.2.1.3 Binary Design 
In the statistical literature, binary design refers to a certain type of block design [97]. In 
this report, binary design is defined as a “design having high correlation between 
concentrations of two/multiple components in the calibration set”. The correlation is 
termed as chance correlation in the literature [38]. Although there is poor model 
specificity associated with this design due to the presence of correlation, it is the most 
widely used design in multivariate calibration development.  
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Patel et al. used binary design to create a NIR calibration set for sulfamethoxazole (SMZ) 
form I prediction in binary polymorphic mixtures and multi-component mixtures [98]. 
Because of the concentration correlation between two forms of SMZ, model predictive 
performance for SMZ form I was depended on signals from both forms of SMZ, leading 
to poor model specificity. Although sample mass has been reported to affect NIR baseline 
[47], sample mass variation between the binary samples (300mg) and multicomponent 
samples (330 to 6000mg) were not considered during the assessment of model 
performance. In the multicomponent mixtures, the diluent concentration was kept 
constant. A mixture design would be appropriate to allow different levels of the diluent 
concentrations with same number of design points. Binary design was used to prepare a 
calibration set for predicting two polymorphs of carbamazepine in bilayer tablets [99]. 
 
Figure 1-1. TNIR spectra of double-layered tablet consisting of various ratios of 
forms I and III CBZ (A) and Model regression vector (B) [100] 
  
A B 
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The calibration set was prepared by varying the ratio of two polymorphs. The spectral 
changes were highly correlated between two polymorphs due to their perfectly correlated 
concentrations as shown in Figure 1-1. 
A positive regression co-efficient explained the appearance of form I (also disappearance 
of form III) and negative regression co-efficient explained the opposite scenario. A 
similar approach was taken to vary crystalline and amorphous cephalexin in a calibration 
set for pharmaceutical powder [101]. Although these studies reported acceptable model 
performance, the effect of chance correlation on model specificity was overlooked in the 
analysis. If the amount of one form were changed while keeping the concentration of the 
other form constant or vice versa, the model would fail in predicting any of the forms 
accurately. An appropriate calibration design without correlation could be helpful to 
overcome this limitation. 
Binary design was used during the comparison between reflectance and transmission 
mode of NIRS based on the ability to predict Theophylline anhydrous concentration in 
tablets [102]. This design was also used to prepare the calibration sets for determining 
meloxicam [103], bromazepam and clonazepam [104] and riboflavin [18] content in 
pharmaceutical preparations. In these studies, several factors such as non-uniform 
distribution of API, tablet weight variation should have been investigated besides the 
chance correlation due to their potentials to affect NIR calibration performance. 
Introducing a small amount of random variation using replication in the design can 
reduce the effect of correlation on model specificity. Varying the excipient mixtures 
instead of an excipient as one factor can also minimize this effect. The correlation 
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between API and excipient mixtures can be less detrimental to model specificity due to 
relatively small changes in a particular component concentration. Replication and 
excipient mixture method was used during a calibration set development for NIR content 
uniformity method [105]. Model specificity can also be improved by selecting 
wavelengths that are unique to the analyte of interest [106]. However, this technique can 
affect model accuracy. In the binary design, full wavelength selection usually provides 
improved accuracy due to all types of correlated signals. Specificity is an important 
figures of merit and should always be assessed since it is the underlying chemistry basis 
for the method [105]. 
Binary design was also used to prepare a calibration set for quantitative analysis of 
mixtures containing components of similar or different PSD [60]. Only the two extreme 
point calibration samples were demonstrated to be sufficient for quantitative analysis of 
components having similar PSD. However, statistical validity of the two-point calibration 
is questionable. A larger sample set was required for components with different PSD. 
Lack of specificity was observed which might be the result of binary calibration design. 
A similar calibration approach was undertaken to monitor powder mixing between two 
components of different PSD [107]. Binary design can be less detrimental to a mixing 
analysis compared to the quantitative analysis of a single component. For a mixing 
analysis, it is desired for the method to be sensitive to all components of the system 
whereas for quantitative analysis it should be sensitive to the analyte of interest only. 
A calibration set can also contain compositional correlation due to the processing of the 
calibration samples. For instance, a NIR method was developed to quantify drug content 
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during a continuous blending process of API, granules and lubricant [108]. Concentration 
of the API was varied by varying the API flow rates whereas flow rates for the granules 
and lubricant were kept constant. However, their concentrations must have been changed 
in the volume of sample scanned by the spectrometer. This change might be directly 
correlated with the API concentration thus introduced binary structure in the calibration 
set.  
1.3.2.1.4 Mixture Design 
Mixture design is also widely used to develop calibration set for NIR method. Mixture 
design reduces the number of calibration samples while applying constraint on mixture 
composition using an optimality criterion. The details of the design can be found 
elsewhere [109].  
A mixture design was used to prepare a calibration set during simultaneous determination 
of chondroitin, glucosamine and ascorbic acid in capsule powder [110] and 
acetylsalicylic acid, ascorbic acid and Caffeine monohydrate in powder mixtures [96]. 
Shi et el. used a mixture design to develop a calibration and prediction sets while 
quantifying Theophylline, MCC and Lactose in tablets [111]. A ternary diagram was used 
to generate six design points as shown in Figure 1-2. The three outmost points were not 
included in the calibration because of their lack of leverage for other components. As the 
same calibration set was used for all components, this led to extrapolated prediction 
outside the calibration range for MCC and Lactose. Component specific calibration set 
would be helpful to avoid extrapolation of prediction range.   
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Figure 1-2. Tablet chemical composition. Squares were the calibration data points, 
and circles were the prediction data points [111] 
Short et el. also used mixture design to develop a calibration set for quantifying 
Theophylline in tablets [11]. A set of 29 calibration sample was designed to cover all 
concentration ranges of a four-component system. The same design was used during the 
prediction of crushing strength and density of tablets using NIR reflectance [112] and 
imaging[113]. Ozdemir et al. used mixture design to develop a calibration set for 
quantitative analysis of a complex mixture [114]. A set of 21 design points was created 
and three sets of samples were prepared at the same composition resulted a total of 63 
samples. Two calibration sets were developed, one using the first set of 21 samples (set 
A) and the other using the first and second set of 21 samples (total 42 samples in set B), 
both predicting the third set of 21 samples (set C). Better model accuracy was observed 
from set A compared to set B. This was contra-indicatory to the statement that more 
number of calibration samples helps to minimize model prediction error [48, 115]. 
Calibration performance does not solely depend on the sample size. 
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Alexandrino et al. used a combined approach of a mixture and D-optimal designs to 
develop a calibration set for quantitative analysis of polymer thin films [116]. An 
experimental domain of polymer mixture was generated by a mixture design with 
constraints on concentration range. Subsequently a D-optimal design was used to 
generate a set of 17 design points inside the domain. Different amounts of API were 
randomly assigned to each design point. Subsequent splitting of the design points into 
calibration and test was performed. This procedure might not generate the optimum 
calibration set with appropriate variance. A straightforward approach would be to use a 
D-optimal design with concentration range constraint. This would allow systematic 
variance of API along with the excipients.  
1.3.2.1.5 Correlation Design 
Correlation design is used to assess the correlation between different variables. Although 
the objective of calibration design is far from finding the correlation between API and 
excipient concentrations, the correlation between component concentrations is critical to 
the specificity of the calibration model. Calibration sets have been designed to reduce 
correlation between component concentrations in NIR calibration set. In this report, such 
designs are termed as correlation designs. Khan et al. used a correlation design to develop 
a calibration set for on line monitoring of pharmaceutical blends [117]. The formulation 
contained API with three major excipients resulted six pairs correlation statistics. A set of 
21 design points was selected from 10,000 simulations based on the minimization of the 
sum of square of six pair correlations. Equal flexibility was given to each component in 
terms of allowable concentration variation. The resulting ranges of concentration 
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variations were different for different components, API being the third in descending 
order. As API concentration variation is more critical than the excipients concentration 
variation [49], large variation in the API concentration and small variation in the 
excipients concentration would be advantageous. In another study, the ranges of 
concentration variations were set higher (70-130%) for the API compared to the 
excipients (90-110%) [118]. The API and excipients were varied such that all correlation 
coefficients were below 0.5. The ranges of variation can also be set according to the 
target concentrations. Correlation design was also used to develop a calibration set for 
monitoring powder blend [17]. The blend contained 7 chemical components including 
two APIs. In the design, concentration variations for the most and least concentrated 
components were ±10% and ±80%, respectively. However, the effect of these range 
variations on NIR model performance was not discussed in any of the studies. 
1.3.2.1.6 Other Designs 
Several other designs have been used to prepare calibration sets for NIR method. Ito et al. 
used a central composite design to develop an NIR calibration set while predicting 
Acetaminophen and Caffeine concentrations in bi-layer tablets [26]. Shi et al. used a 
Placket-Burman design to develop a calibration set for quantitative analysis of powder 
mixture [119] and for blend monitoring [120]. Blend monitoring was also performed 
using an extreme vertices design [121] and a simplex lattice design [122]. A simplex 
lattice design of 5 degree and 21 mixture points was used to generate a set of 126 
calibration samples varying each component at 6 levels. The same design (excluding mg 
stearate) was carried out for determining chlorpheniramine concentration in tablets [123]. 
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Alcala et al. used a multivariate design approach for developing a calibration set during 
API prediction in tablets [124]. The main difference between multivariate design and 
other conventional designs lies in the data structure and subsequent chemometric analysis 
(3-way vs 2-way, respectively). The multivariate designs are analyzed through extended 
modeling techniques (multiway PLS), whereas conventional designs are analyzed 
through traditional PLS. Osorio et al. used a science based calibration technique where a 
small calibration set was demonstrated to be sufficient for monitoring a powder blending 
process [125]. Although a high correlation between component concentrations was 
present in the calibration design, specificity was assured by selecting unique peak of API 
and developing an univariate prediction model. 
1.3.2.2 Use of sample selection techniques to select calibration set 
Calibration sets for a NIR method can also be developed by selecting samples with or 
without constraints from a given dataset. A random selection process without constraint 
was performed during the determination of ginsenosides in pharmaceutical tablets [126]. 
A set of 93 production samples was randomly selected from the manufacturing site for 
method development. Subsequent randomization was performed to split the data into 
calibration and test set. Calibration set selection without constraints usually have limited 
applications. Certain constraints are usually applied during the selection process to ensure 
regulatory compliance, appropriate concentration range, widespread variance and 
sufficient representability of the future dataset.  
Moffat et al. used a random selection method with constraints to prepare a calibration set 
for Acetaminophen tablets [74]. The calibration set was selected from fifteen production 
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and five development batches to include scale variations as well as concentration 
variation into the calibration model. A similar randomized approach was used to prepare 
calibration set ranging 80-120% of the nominal API content [21]. Meza et al. prepared a 
calibration set by randomly selecting samples from specific concentration levels of 
ibuprofen during tablet quantitation [127]. A randomized approach was also used for 
splitting compositionally varying dataset into calibration and test set during the 
quantification of propranolol hydrochloride in powder mixture [128]. 
The random selection method can be combined with an experimental design to develop a 
calibration set. Ferreira et al. selected a set of calibration samples randomly from a 
designed sample set of powder mixtures during hydrochlorothiazide (HCTZ) 
quantification in powder mixtures and tablets [129]. Certain constraints were applied 
during the selection step to ensure homogenous distribution of HCTZ in the calibration 
set. The developed model was used to predict three sets of pharmaceutical samples: 
powder samples before compression, intact tablets and powder samples obtained by 
grinding tablets. Tablet prediction had the least accuracy among three sample sets due to 
the density difference between tablet and powder mixture (calibration samples). This 
study indicated the criticality of the physico-chemical properties of the calibration 
samples. However, high correlation (r2~0.99) between HCTZ and MCC concentrations 
was overlooked during specificity analysis. A similar method was used to prepare two 
calibration sets for the quantification of multiple API and tablet RTS [130]. Certain 
constraints were applied to ensure uniform distribution of APIs and tablet RTS. 
The calibration samples can also be selected via different selection algorithms. The 
Kennard-Stone algorithm was used to select a set of representative calibration samples 
 29 
 
for determining amoxicillin content in suspension [131]. Kennard stone algorithm is a 
widely-used technique for selecting a representative subset from a large dataset. The 
selection algorithm provides uniform coverage over the dataset by selecting the most 
separated samples at successive iterations. The algorithm provides unique solution, 
thereby results in the same representative set for all iterations. The details of the Kennard 
stone algorithm can be found elsewhere [132]. Li et al. used this algorithm to select the 
calibration set during azithromycin quantification in tablets of different colors and shapes 
prepared by different manufacturers [133]. Four different calibration sets were selected 
from four data sets containing spectra of coated tablets, powdered tablets, uncoated 
tablets and powdered uncoated tablets. Among the four calibration sets, prediction errors 
in descending order were coated tablets, powdered coated tablets, uncoated tablets and 
powdered uncoated tablets. Spectral interference from coating component decreased 
model’s prediction performance. The Kennard Stone algorithm was also used to select a 
set of representative samples from calibration set for developing a calibration transfer 
method [134]. 
Principal Component Analysis (PCA) can also be used to select calibration samples based 
on the variance information of individual sample [135]. Blanco et al. performed PCA on 
a dataset containing laboratory and production samples spanning concentration as well as 
physical variability [136]. Samples that showed large variability in the first two PCs, 
were included into the calibration set to incorporate maximum spectral variance. 
However, maximum spectral variance may not always indicate concentration variation. In 
such scenario, PCA based selection should be performed on the PCs that primarily 
explain concentration information. Some other physico-chemical parameters along with 
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PCA analysis can also be used to select the calibration set. Alvarenga et al. prepared a 
calibration set based on PCA and group statistics on API content, water content and tablet 
hardness [59]. Samples having wider variability were included into the calibration set to 
develop a robust calibration model. Shi et al. used PLS scores for selecting the process 
samples to include into the calibration set during content uniformity analysis of tablets 
[137]. This selection strategy was compared with a random selection process. The mean 
difference between two sampling approaches was found insignificant. PLS score based 
selection strategy was found to be cost and time effective. Selecting samples from PCA 
or PLS scores space should be performed carefully, as this can exclude samples with 
extreme concentrations and narrow the concentration range leading to undesired 
extrapolation. 
Feng et al. used a classification technique to select a calibration set during the 
determination of roxithromycin and erythromycin in tablets from different manufacturers 
[27]. The initial calibration set contained samples from random manufacturers. The 
resulting calibration model failed to predict the concentration of APIs in tablets prepared 
by manufacturers that were not included into the calibration set. A cluster analysis was 
performed on average spectra of each batch based on wards algorithm. Samples from 
different clusters were selected for the calibration set such that, uniform distribution of 
API content and manufacturer was maintained. Calibration models were demonstrated to 
be accurate, robust, specific, linear, and transferrable. However, the validity of this 
method was challenged by Bleye et al. due to inappropriate prediction interval [138].  
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Figure 1-3. Accuracy profiles obtained from the work of Feng and Hu [27] for the 
quantification of Roxithromycin (A) and Erythromycin ethylsuccinate (B) using 
different NIRS equipment. Dotted horizontal lines (black): ±5% acceptance limits; 
dotted and dashed horizontal lines (green): ±15% acceptance limits; dashed lines 
(blue): 95% prediction intervals; dots (black): relative predicted concentrations of 
the corresponding NIRS methods [138] 
 
A B 
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Although having low prediction errors, this method was demonstrated unfit for the 
intended purpose, because the 95% prediction intervals were outside the acceptable range 
as shown in Figure 1-3 for two different NIR instruments. The prediction interval should 
be included in the list of figures of merit for assessing model performance. 
1.3.2.3 Under dosing / over dosing (spiking) production samples 
Calibration sets can also be prepared by spiking (under dosing / overdosing) production 
samples. Spiking is performed to extend the concentration range of production samples 
that are typically prepared at target concentration. Moes et al. used spiking strategy to 
prepare two calibration sets for analyzing blend uniformity of powder and content 
uniformity of tablet cores, respectively [139]. A high correlation between the API and 
excipients concentrations was present in both calibration sets. Along with the high 
correlation, calibration samples for content uniformity had uneven distribution of API 
concentration levels and were compressed at different compaction pressures compared to 
the validation samples. Poor prediction performance was observed during the prediction 
of tablets compressed at compaction pressures that were not included into the calibration 
set. Blanco et al. spiked production samples (64.5% amorphous miokamycin) with 
amorphous/crystalline miokamycin and excipients to prepare a calibration set for 
determining crystalline and total miokamycin content in tablets [140]. Different levels of 
PSD were included into the calibration set to make the model robust against particle size 
variations. Calibration design for determining one polymorph in presence of another 
polymorph is challenging. High correlation between the concentrations of different 
polymorphs can diminish calibration model specificity. In this study, the selectivity of the 
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calibration model was demonstrated qualitatively by using spectral correlation co-
efficient method.  
A similar approach was undertaken to develop a calibration set for quantifying Caffeine 
in tablets [141]. Due to the presence of high correlation in calibration set, model 
specificity was assessed by band assignment for Caffeine and comparing spectral features 
of Caffeine with first loading vector. A set of spiked samples was also used to prepare a 
calibration set during ranitidine quantification at different steps of tablet manufacturing 
process; in granules for compression, in tablet cores and in coated tablets [19]. The effect 
of high correlation between ranitidine and excipients was minimized by selecting 
appropriate wavelengths. Sarraguca et al. used spiked samples to prepare multiple 
calibration sets for quantifying Acetaminophen, acetylsalicylic acid, folic acid and 
neomycin in respective tablet formulation [142]. The correlation co-efficient between Net 
Analyte Signal and pure API spectrum was used as a metric for model specificity. 
Specificity was found to be low for all formulations due to the high correlation between 
API and excipients concentrations. A high correlation between API and excipients 
concentrations is usually found after spiking the production samples. The correlation can 
be minimized by using multiple placebo mixtures and randomly select one at a time for 
spiking production samples [135].  
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Figure 1-4. Improvement in calibration performance as a function of the number of 
production sample included into the calibration set with optimized latent variables 
numbers (A) and fixed latent variable numbers (B). Each symbol represents a 
different sequence of sample addition [62].  
The inclusion of production samples in the calibration set can mitigate the difference 
between calibration and routine samples in terms of physical properties. The calibration 
set prepared by spiking the production samples was found to perform better than the 
calibration set prepared from laboratory sample during quantification of commercial 
tablets [143]. Spiking was performed with randomly selected placebo samples form a set 
of placebo mixtures to reduce the correlation between API and excipients concentrations. 
A set of production samples can also be combined with the laboratory samples into the 
calibration set and improve calibration model performance [62, 144].  
B A 
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Figure 1-4 shows the improvement in calibration performance as a function of the 
number of production samples included into the calibration set while predicting otilonium 
bromide in production tablets [62].  
Production samples were also used to develop a calibration set for moisture content 
determination of tablets [145]. The samples were stored in humidity chamber to vary the 
moisture content. The samples were also varied in terms of different APIs, excipients, 
and shapes to develop a global calibration model for moisture content determination. 
Model developed from tablets of API I failed to predict moisture content of tablets 
containing different APIs. The most robust model was found by including tablets from all 
three APIs into the calibration set. However, the effect of uneven distribution of APIs, 
moisture contents and tablet shapes was not investigated.  
A combined strategy of using production and laboratory samples into the calibration set 
can be helpful, because production samples introduce physical variances whereas 
laboratory samples extend the calibration concentration range. Calibration sets containing 
both laboratory and production samples was used for successful quantification of 
tianeptine in coated tablets [146], Acetaminophen in production tablets [68], 
hydrocortisone in pharmaceutical powders [147] and isoniazid and rifampicin in capsules 
[86]. In the last study, production samples from several months were used to introduce 
possible changes in sample composition, suppliers, process changes or variations in 
storage conditions. Placebo samples were also used as calibration samples to deduce the 
interference structure for respective APIs.  
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A similar preparation method between laboratory and production samples can enhance 
the performance of the calibration model developed from laboratory samples only. 
During the determination of dexketoprofen in laboratory and production granules [148], 
model developed from laboratory powder failed due to differences between granules and 
powders in terms of physical properties. Although inclusion of production granules into 
the calibration set improved the prediction performance, the most accurate model was 
developed from laboratory granules that were prepared using similar process of 
production granules. This was due to the wider concentration range of laboratory 
granules compared to production granules. Preparation of laboratory samples 
encompassing similar physical variability of production samples at wider concentration 
range was found to be an effective strategy for developing calibration set with desired 
predictive performance. 
Cardenas et al. used process spectra instead of production sample spectra to introduce 
physical variance into the calibration set during cetirizine quantification in different 
stages of tablet manufacturing process; blending, compaction and coating [149]. The 
calibration set was initially developed with powder samples for blend prediction and 
optimized with process spectra at later stages for core and coated tablet prediction. The 
process spectrum was calculated as the spectral difference between lab scale powder and 
industrial samples (core and coated tablets) following the idea developed by Blanco et al 
[41]. Although this approach offers some advantages for reducing the sample size for 
calibration, some associated assumptions might have been violated during the calibration 
development. The addition of a process spectrum assumes that the extent of the effect of 
physical variation on the spectra remains consistent for all concentration ranges. It also 
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assumes that the physical effect and chemical effect on NIR spectra are orthogonal. These 
assumptions are not often true as the physical properties of the samples can vary with 
compositional variation. The process spectrum approach was compared with 
conventional approaches for preparing calibration set with laboratory, production and 
spiked samples [15]. Although similar model performance was achieved, the new 
strategy was favored for its time and cost effectiveness and simplicity. 
Blanco et al. compared different strategies for developing calibration set while predicting 
nimesulide content in pharmaceutical granulate [75]. Laboratory samples, spiked samples 
and production samples were used for developing the calibration sets. A calibration 
model built from spiked samples predicted the production samples with acceptable 
accuracy; however, model from lab samples failed in the prediction. Prediction 
performances of both models were improved by including production samples into the 
calibration sets. 
 
The discussion on different strategies for calibration set development is summarized in 
Table 1-1 in terms of advantages and disadvantages of each strategy. 
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Strategies for 
developing NIR 
calibration set 
Advantages Disadvantages 
Use of design of 
experiment 
• Generates systematic 
variance into the calibration set. 
• Can be used to minimize 
the effect of chance correlation. 
• Can be optimized to meet 
regulatory requirements in terms 
of calibration range, levels. 
• Usually requires 
large calibration set. 
• Can introduce greater 
than nominal variance 
leading to reduced accuracy. 
• Usually employed 
with laboratory samples 
which leads to poor 
robustness against scale 
variation. 
Use of sample 
selection techniques  
• Can be employed with any 
existing dataset. No prior 
requirements for designing data 
generation. 
• Constraints can be applied 
to meet regulatory requirements.  
• Model performance 
is sensitive to the selection 
techniques. It can be difficult 
to select the appropriate 
combination of selection 
technique and constraints. 
• Appropriate samples 
can be missing in the dataset 
leading to poor model 
performance. 
Under dosing/over 
dosing (spiking) 
production samples  
• Similar physical 
properties of calibration samples 
compared to the routine 
production samples, which leads 
to improved model robustness. 
• Calibration transfer is 
comparatively easier due to 
similarity in physical 
characteristics across scales and 
manufacturing plants.   
• Can introduce chance 
correlation in the calibration 
set leading to poor model 
specificity. 
• Requires more time 
and cost to implement in the 
production floor due to the 
requirements of sample 
preparation (production 
samples and calibration 
samples must be treated in 
the same way). 
 
Table 1-1. Advantages and disadvantages of different strategies for NIR calibration 
set development 
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1.3.3 Effects of calibration set on model performance 
A calibration set has significant effects on NIR model performance. These effects can be 
discussed from three perspectives as the effects of the calibration design structure, effects 
of calibration factors and effects of calibration sample properties. 
1.3.3.1 Effect of calibration design structure 
The structure and parameters of the calibration design can significantly affect NIR model 
performance. The effect of several parameters including distribution of design points, 
absence of relevant information and simulation of natural population on NIR model 
performance were investigated [39]. Although the study did not include pharmaceutical 
samples, it investigated the general aspects of NIR calibration set, that were applicable 
for pharmaceutical materials. Even span and all possible combinations of constituents 
were shown to be necessary for successful model performance. Appropriate experimental 
design was demonstrated to be a prerequisite for accurate estimation of regression co-
efficient and adequate predictability. Prediction in the center and corners of the design 
depended on the sample distribution and overall variance of the design. More samples 
near the center point gave better prediction performance in the center point compared to 
evenly spread sample distribution; a finding similar to that of Araujo et al [28]. This trend 
was opposite while predicting samples outside the center points.  
Chance correlation of the calibration design has been pointed out as a limiting factor of 
multivariate calibration by several researchers [150-154]. Chance correlation can be 
presented in the calibration set due to inappropriate experimental design, sample 
properties and the condition underlying the spectroscopic measurement. Xiang et al. 
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assessed the effect of chance correlation on an NIR model performance [38]. The 
correlation between API and excipients was set high and low in correlated and 
randomized calibration set, respectively. The correlated design performed better than the 
randomized design during calibration development. However, the former design failed 
during cross-prediction of tablets with excipient and density variations. The randomized 
design succeeded in cross-prediction indicating that the predictability achieved with the 
correlated design was dependent on correlated signals not specific to the API. The effect 
of chance correlation on model specificity is often overlooked due to the traditional 
practice of univariate model development using HPLC where specificity is achieved by 
the experimental technique itself.  
The interference structure of a calibration set was demonstrated to be critical during NIR 
calibration development [46]. A poor prediction performance was observed in the 
validation set containing different interference structure. A priori information about the 
component’s pure spectrum and/or interference structure helped to improve the 
calibration model performance. Li et al. compared the performance between two 
calibration sets having different levels of API but same levels of excipients [58]. Model 
performances were similar between the two calibration sets. Quantifications of the minor 
excipients were more accurate compared to the major excipients and API. It was 
concluded that the variation of API and major excipients were used during the 
quantification of the minor excipients leading to improved accuracy. During the 
quantification of API and major excipients, variability of the minor excipients was not 
usable due to low concentration leading to biased prediction. However, prediction using 
other component’s concentration profile might have led to poor model specificity. A 
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modification of the same scheme was used to predict Acetaminophen content in powder 
blends [155]. Following the previous scheme a set of 625 design points was generated 
and 50 most distant points in the PCA scores were selected for the calibration set. 
 
Figure 1-5. Relative residuals (%) plots obtained from the prediction of four 
external sample sets, using also four calibration models with different concentration 
ranges (%, w/w, API). Vertical lines indicate the MDL/MQL for each model. Four 
predictions are shown for calibration ranges: (a) 0–5.00%, (b) 0–2.00%, (c) 0–
0.25%, and (d) 0–0.10% (w/w) [156] 
The concentration range of the calibration set can be critical to model’s predictive 
performance in terms of multivariate detection limit (MDL) and quantification limit 
(MQL) and should be selected based on the prediction set property [156]. The relative 
prediction errors, MDLs and MQLs of four calibration models with different 
concentration ranges are given in Figure 1-5. 
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A narrow range of concentrations should be used for predicting low drug concentration 
and the range should be updated according to the prediction range. Although no 
explanation was provided, mathematically it can be explained from the equation used for 
calculating MDL and MQL. As the concentration range decreased, calibration error 
(SEC) decreased, which in turn decreased the MDL and MQL. Concentration range can 
also affect the calibration structure. In a calibration set for Theophylline prediction, 
Theophylline and Magnesium stearate were varied orthogonally and cellactose was 
considered as filler [157]. However, variation in cellactose concentration had high 
correlation (0.99) with variation in Theophylline concentration due to its larger range 
compared to Magnesium stearate concentration. This undesired chance correlation might 
have led to poor model specificity. Uniform distribution of concentration levels in the 
calibration set is usually encouraged [50, 51]. However, a similar predictive performance 
was observed between similar and random distribution of concentration levels [55]. 
Bondi et al. analyzed the effect of experimental design on the predictive performance of 
NIR calibration model [9]. The five level full factorial and I-optimal models were 
statistically similar and had the lowest errors, followed by the CCD, D-optimal and three 
level full factorial models, respectively. The model generated from the I-optimal design 
was superior considering the balance between performance and efficiency due to low 
sample requirement. A more comprehensive assessment was reported by Scheibelhofer et 
al [49]. Four types of experimental design each with two subtypes were used to develop 
NIR calibration sets. Model performances in increasing order of prediction error were: 
five level factorial < extended CCC < simplex centroid < simplex lattice < CCF < I-
Optimal with center < three level factorial < I-optimal < D-optimal. A calibration set with 
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a regular spread between different concentration levels was preferred. It was also 
concluded that, the similarity between calibration and test structure improves prediction 
performance. However, as crude pre-processing techniques were used for all designs and 
the same model was used for all three components, the results might not be the optimum. 
Araujo et al. also analyzed the effect of experimental design on calibration model 
performance as shown in Figure 1-6 and found that number of unique experimental run is 
more important than the number of replicates, so that the calibration can span a wide 
range of variance [28]. Lorber et al. assessed these effects in terms of a vector “hun”, 
where “hun” is dependent on the orthogonality in the calibration space. In a poorly 
designed calibration set, the reduced orthogonality decreases the net concentration signal 
(orthogonal concentration), which in turns increases “hun” and prediction error [48]. 
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Figure 1-6. Prediction errors of five calibration designs (first column) predicting 
three prediction sets (first row). The asterisks indicate experimental or predicted 
areas [28] 
1.3.3.2 Effect of calibration samples properties 
Different properties of calibration samples can significantly affect NIR calibration model 
performance. The effect of spectral collection state and scale of calibration set samples on 
calibration model performance was assessed during blend monitoring [158]. A calibration 
set was initially developed by collecting spectra at static state. Model performance was 
improved by incorporating dynamic spectra into the calibration set. Dynamic data from 
same scale as prediction set was found to improve model performance in a greater extent 
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compared to the dynamic data from different scale. Sarraguca et al. demonstrated scale 
and physical characteristics of the calibration set as critical to NIR quantitative method 
[42]. Calibration set developed from the lab scale powder failed to predict API 
concentration in the pilot scale powder and tablet due to the scale and physical state 
difference. Variation in scales and physical attributes were also found to affect calibration 
model performance during the determination of mirtazapine [135] and ibuprofen [91, 
131]. A calibration set developed on one set of tablet thickness and shape, was found to 
be spectrally different from other set of tablet thickness and shape for reflectance and 
transmission NIR as shown in score plots in Figure 1-7. This effect was minimized by 
extending the calibration design to include tablets of different thicknesses, shapes and 
embossing. Although inclusion of physical variations into a calibration set increases 
model robustness, it can also affect model accuracy. Model accuracy was found to be 
decreased upon the inclusion of tablet thickness variations into a calibration set [26]. 
Accuracy of a model developed on pilot scale samples was affected upon the inclusion of 
laboratory and production samples of different dosage units into the calibration set [159]. 
These findings demonstrate that, the current philosophy of including as much variation as 
possible into the calibration set, can be detrimental to calibration performance. These 
effects were minimized by bracketing where a local calibration set near the mean tablet 
thickness [26] and calibration set specific to dosage units [159] were developed. Absence 
of variation due to size, shape, thickness, as well as narrow concentration range in the 
local calibration sets helped to improve prediction performances of the respective models. 
Similar to bracketing, selection of an optimal subset from large calibration set was 
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proposed by Lorber et al [48]. However, bracketing or subset selection techniques were 
criticized for causing narrow concentration range and poor robustness of calibration [28]. 
 
Figure 1-7. Score plot from second derivative reflectance (A) and transmittance (B) 
spectra by principal component analysis. Open symbols—calibration set: (○) flat-
faced tablets with various content; closed symbols—prediction set: (●) flat-faced 
tablets with various thickness, (∆) flat beveled edge tablet, (□) convex tablet. The 
numbers by the data points correspond to the batch no [160] 
Granules PSD and hardness of calibration tablets were found critical and recommended 
to be included into the NIR calibration set [25]. However, effects of these factors were 
not analyzed independently. In another study, the effect of PSD was found to be low 
compared to that of hardness on calibration model performance [38]. Pan et al. 
independently assessed the effect of variations in tablet hardness, granules PSD and 
relative humidity on calibration model performance [161]. NIR predictions were found to 
change up to 10% due to 16% variation in tablet hardness between calibration and 
predictions sets. For a 20% increase in RH, the change was around 10-20%. No 
correlation between PSD of granules and NIR predictions were found within the range 
investigated. However, in another study, PSD of calibration samples was found to be 
B A 
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critical to model performance due to its ability to cause variation in tablet hardness [162]. 
Reflectance NIR was found to be more sensitive to tablet hardness and packing density 
compared to transmission NIR [69].  
Pieters et al. assessed the effect of intra and inter batch variability of a calibration set on 
calibration model performance [163]. The presence of these variations in the calibration 
set helped to improve model performance. The performance was further improved by 
augmenting the calibration set with noise matrix calculated from net analyte 
preprocessing. The prediction performance for samples having moisture variation was 
improved by updating the calibration set with samples having different moisture contents. 
Mainali et al. assessed the effect of calibration set complexity during the prediction of 
water content in tablets. The complexity was introduced by using multiple API and tablet 
shapes into the calibration sets [145]. Slight increase in prediction error was observed 
with increased complexity. The most complex calibration set (III) was preferred over 
others due to its increased robustness against API and tablet shape variation. Effect of 
nonhomogeneous distribution of different APIs and tablet shapes in the calibration set II 
and III were not discussed.  
1.3.3.3 Effect of calibration factors 
Although it is recommended to include all factors into the calibration set for developing a 
robust calibration model [51], this approach requires large sample set, which can be 
inconvenient on particular instances [164]. Factors that do not affect NIR spectra should 
be excluded to reduce the size of the calibration set. Factors such as processing 
parameters, temperature, moisture content, raw material variations etc. can have a 
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detrimental effect on NIR prediction performance. Tablet moisture content can vary 
during different steps of the manufacturing process, storage and analysis [165] and 
excipients variation can occur between batches [163]. All these relevant factors should be 
included into the calibration set. A small prediction error can be obtained by including 
relevant information in the calibration set [66]. However, it may not always be possible 
for the calibration set to contain all relevant factors that can occur in the industrial scales 
[166], making the models less robust and requiring frequent updates. Inclusion of non-
relative information into the calibration set can increase model complexity and affect 
mode performance [163].  
Roggo et al. demonstrated process changes as the critical factors for calibration set during 
dissolution study [167]. Four types of process related changes were included into the 
calibration. The changing parameters were time and temperature changes during melt 
granulation, compaction pressure, coating formulation and coating times. Riley et al. 
assessed the effect of number of varying components in the calibration set on calibration 
model performance [168]. An increase in the number of varying components from 2 to 6 
and 2 to 10, increased the error by approximately 50% and 340%, respectively. However, 
a calibration set containing higher number of varying components could be useful for 
predicting complex samples. El-Hagrasy et al. assessed the effect of environmental factor 
such as blend storage time on calibration model performance [169]. The NIR spectra 
were collected immediately after blend preparation and after storing for a week to 
develop two calibration sets, respectively. The predicted blend profiles were significantly 
different between two sets. As the environmental factor was found to be critical for 
developing calibration set for blend monitoring, a D-optimal design was used to vary 
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relative humidity along with concentrations to develop a calibration set in later studies 
[170, 171]. The effects of NIR calibration set on model performance is summarized in 
terms of affected validation characteristics and analytical figures of merit in Table 1-2. 
1.3.4  Conclusion 
There are several strategies for developing NIR calibration sets for tablet analysis. The 
selection of right strategy is critical to model performance, however, less emphasized 
during calibration development. An in-depth understanding about the calibration set 
requirements, interaction between calibration structure and model performance, and a 
formulation and NIRS specific outlines can be helpful for developing an appropriate NIR 
calibration set. Appropriate calibration set is a prerequisite for successful model 
performance and must be designed carefully at the outset of calibration development to 
ensure efficient and maximum utilization of NIRS capability in pharmaceutical analysis. 
  
Calibration set properties Affected calibration metrics 
Calibration design and structure Accuracy, specificity, range, linearity, 
robustness, detection limit and quantitation 
limit. 
Calibration samples properties Accuracy, specificity, robustness and 
linearity. 
Calibration factors Accuracy, specificity, robustness and 
linearity. 
Table 1-2. Advantages and disadvantages of different strategies for NIR calibration 
set development 
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2 Chapter 2: Method development of designing calibration set in spectral space 
In this study, a method was developed to use the pure component spectra of a tablet to 
identify the critical samples necessary for an efficient calibration set development. The 
principal difference between current techniques and the proposed technique lies in the 
space used for designing a calibration set. Calibration sets are typically designed in 
concentration space where orthogonality between component concentrations is imposed 
to minimize collinearity and maximize model specificity. In the proposed method, a 
calibration set is designed in spectral space in order to create orthogonality of the spectral 
response. 
 
 
Figure 2-1. Concentration space of a ternary system 
2.1 Theory 
Concentration space: Concentration space is a multi-dimensional space used to describe 
the composition of a composite structure. The structure of the composite system is 
described by relative positions and directions along each of the dimensions in 
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concentration space coordinates. For example, Figure 2-1 illustrates a concentration space 
describing two composite structures of a ternary system containing A, B and C 
components at [0.2, 0.1, 0.7] and [0.6, 0.3, 0.1] concentration levels. 
 
Figure 2-2. Spectral data (direct spectral space (A)) presented in PCA score space 
(factor space (B)) 
Spectral space: Spectral space is a multi-dimensional space to describe the spectral 
response of a system. The spectral response at each wavelength/frequency is described 
along each dimension of the spectral space coordinates. This space has higher order 
dimensions, typically on the order of 100 to 10,000 depending on the analytical technique 
of interest. Therefore, spectral space is often decomposed to a lower dimensional 
orthogonal subspace using chemometric techniques such as orthonormalization, principal 
component analysis (PCA), singular valued decomposition, eigen value decomposition 
etc. Principal component analysis efficiently describes the spectral variance, revealing the 
maximum variance in the first principal component (PC) and remaining orthogonal 
variance in each succeeding PC in descending order [172]. The scores (projection of each 
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spectrum) on the PCs are used to represent the high-dimensional spectral space into a 
much lower dimensional score space. For example, a typical series of 45 NIR spectra 
(4200 data points in each spectrum) representing 45 Acetaminophen tablets can be 
represented in three dimensional score space instead of 4200 dimensional spectral space 
without losing any significant spectral information as illustrated in  
Figure 2-2 (99.18 % of total spectral variance is explained by 3 PCs). 
The use of pure component spectra during calibration set development follows the 
fundamental theory of spectroscopic multivariate calibration and experimental design. A 
spectroscopic calibration model is developed to predict the chemical/physical properties 
of a sample from its respective spectrum using regression equation. For a system with 
“m” samples and “n” spectral variables (wavelengths), the regression equation is as 
follows, 
 𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗𝐦𝐦∗𝐧𝐧 ∗ 𝐛𝐛𝐧𝐧∗𝟏𝟏 (2.1) 
Where 𝐲𝐲� is the predicted chemical/physical properties, X is the spectral data matrix and b 
is the regression vector. Concentration will be considered as an example of physico-
chemical property in rest of the chapter. The regression equation (2.1) can be expanded as 
follows,  
 ŷ𝑖𝑖=1..𝑚𝑚𝑖𝑖 = 𝑏𝑏0 +  𝑥𝑥1𝑖𝑖 × 𝑏𝑏1 + 𝑥𝑥2𝑖𝑖 × 𝑏𝑏2 + ⋯+ 𝑥𝑥𝑛𝑛𝑖𝑖 × 𝑏𝑏𝑛𝑛 (2.2) 
To approximate the relationship between concentrations (y) and spectral variables (x) by 
estimating the regression coefficients bi, the theory of design of experiments indicates 
that the spectral responses (x1..n) should vary orthogonally and the output concentrations 
(y1…m) measured. Orthogonal variation in the independent variable (spectral response) 
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would allow better estimation of regression coefficients with minimum number of 
samples/ experiments. 
Currently, there is no published technique available for orthogonally varying the spectral 
responses. The conventional approach to multivariate calibration is to vary concentrations 
orthogonally in the concentration space and assume that this orthogonality translates to 
the spectral space. For a system with “k” components, “m” samples and “n” spectral 
variables using C for the concentration of samples, P as the pure component spectra, and 
X for the matrix of spectral responses, the current design follows the equation below, 
 𝐂𝐂𝐦𝐦∗𝐤𝐤 ∗ 𝐏𝐏𝐤𝐤∗𝐧𝐧  →  𝐗𝐗𝐦𝐦∗𝐧𝐧 (2.3) 
 
 Figure 2-3. Hypothetical pure component spectra (A) and respective spectral space 
(B) 
This does not necessarily create orthogonal variance in the spectral space due to external 
factors other than concentrations affecting the spectral signals. Moreover, depending on 
the pure component spectra and their relative contribution to the sample spectrum, 
experimental design points created in a concentration space can result in highly redundant 
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and/or inadequate spectral information. A hypothetical scenario is illustrated for a three 
component system (A, B and C) analyzing with a spectroscopic technique of 3 
wavelength channels (1000 nm, 1100 nm and 1200 nm).  
 Figure 2-3 represents the hypothetical pure component spectra of A, B and C and their 
respective projections on the spectral space. The spectrum of any sample mixture 
containing A, B and C should fall in the triangular plane (shaded region) formed by A, B 
and C in the spectral space due to mixture constraint (sum of A, B and C is always 1). 
 
 
 
Figure 2-4. Hypothetical concentration space (left) and respective spectral space 
(right) 
Experimental design points created in the concentration space should retain its structure 
and linearly mapped in this hypothetical plane. However, this does not occur 
experimentally due to non-linearity between concentration and spectral response, 
32.5
Abs at 1100 nm
21.510.5
4
2
Abs at 1000 nm
2.5
3
2
1.5
0
A
bs
 a
t 1
20
0 
nm
 55 
 
different spectral contribution of each component into the mixture spectrum, physico-
chemical properties of the samples etc.  
Figure 2-4 shows a hypothetical scenario where experimental design points in the 
concentration space (Figure  2-4 (left)) fall outside the hypothetical plane (green) in the 
spectral space (Figure  2-4 (right)). Thus, an orthogonal design in the concentration space 
might lose its orthogonality in the spectral space, provide redundant information as well 
as lack in critical information in the calibration design. 
The proposed approach is an attempt to create the orthogonal variations in the spectral 
space. Orthogonal variation in the spectral space helps to minimize the sample 
requirement by identifying a set of critical samples necessary to develop a successful 
calibration model. For instance, compositional variation in the spectrally similar 
excipients will have unidirectional variation in the orthogonal spectral space. Designing 
calibration samples in that direction by varying either of them would give sufficient 
spectral variation to model against the concentration of API and reduce the calibration 
sample size by a factor of two. Moreover, orthogonal spectral space helps to identify the 
most spectrally dissimilar samples to be included into the calibration set to cover the 
maximum possible spectral variation. Training a model against such variation is critical 
to develop a robust calibration model at the outset of calibration development. The most 
spectrally dissimilar samples are often different from the most compositionally dissimilar 
samples. Building calibration set with compositionally different samples and training a 
model against large compositional variation may not always be successful in developing 
a calibration model that is robust against future spectral variation. 
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However, in NIR spectroscopy, spectral responses at each wavelength cannot be varied 
orthogonally due to highly correlated signals. Alternatively, the correlated spectral 
responses can be decomposed into orthogonal directions using different techniques such 
as Orthonormalization, Principal Component Analysis (PCA), Partial Least Square (PLS), 
Singular Valued Decomposition (SVD) etc. In the proposed method, the pure component 
spectra of a formulation are used to determine the spectral space for that formulation and 
Orthonormalization technique is used to decompose the pure component spectral 
response into orthogonal directions. The spectral projections onto the orthogonal 
directions are termed as “scores”. The score is used as a metric of spectral variance in the 
orthogonal spectral space of the formulation. Designing experiments by varying the 
scores is considered equivalent to the design in orthogonal spectral space. In this study, 
pure component spectra were acquired by compressing the pure components into tablets 
and scanning with NIR instrument. When the pure component tablets are difficult to 
prepare, pure component powders can be used (adjustments for spectral differences may 
be necessary).  
After defining the orthogonal spectral space of a formulation using pure component 
spectra, a model tablet is compressed at the target formulation and an NIR spectrum is 
acquired. The spectrum of the model tablet is projected onto the orthonormal basis 
vectors of the pure component tablet spectra. The projections are termed as “model tablet 
scores.” Scores of the ‘model tablet’ are calculated based on the following equation 
 𝐭𝐭𝟏𝟏∗𝐫𝐫𝐌𝐌𝐌𝐌𝐌𝐌𝐌𝐌l 𝐭𝐭𝐭𝐭𝐛𝐛𝐭𝐭𝐌𝐌𝐭𝐭 = 𝐱𝐱𝟏𝟏∗𝐧𝐧𝐌𝐌𝐌𝐌𝐌𝐌𝐌𝐌𝐭𝐭 𝐭𝐭𝐭𝐭𝐛𝐛𝐭𝐭𝐌𝐌𝐭𝐭 ∗  𝐖𝐖𝐧𝐧∗𝐫𝐫𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐭𝐭𝐛𝐛𝐛𝐛𝐛𝐛    (2.4) 
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Where, t is the scores of the “model tablet” for “r” factors, x is the spectrum of the 
“model tablet” and W is the orthonormal basis of the pure component spectra. 
The idea behind the model tablet score is to design a calibration set such that the scores 
of the calibration samples are centered around the model tablet scores. This ensures the 
calibration model to be centered at the target formulation. An in silico full factorial design 
is created to achieve this objective. In the design, the numbers of factors are kept equal to 
the number of chemical components. We assume that the signal from each component 
contains orthogonal features with respect to other components. Thus, full chemical rank 
is achieved by creating a design where the number of factors is equal to the number of 
components. The numbers of levels in the design are selected to balance between 
computational burden and simulation of spectral variance. Simulation of spectral variance 
is required to select the calibration candidates from a large dataset. Addition of one level 
can significantly increase the design points and subsequent simulation time. For 
instances, five levels for each factor in a five-factor design will result in (55) = 3125 
design points. An increase by one in the number of levels will result (65) = 7776 design 
points. The effect of number of levels is minimal as long as it is kept equal for all the 
factors to prevent any confounding effect and generate all the possible spectral variation 
during simulation.  
The center of the in-silico design is then set equivalent to the model tablet scores t and all 
other design points are scaled from the center. The transformed design is defined as the 
‘target score design’. Centering the design around model tablet scores ensures that the 
target scores span the space around the model drug. The proposed approach centers the 
regression model at the target composition (“model tablet”) and then creates balanced 
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spectral variance around this center. The spectra corresponding these score values vary 
orthogonally (or very nearly so), because the target score design is built from a full 
factorial orthogonal structure. Figure 2-5 shows the procedure for designing scores 
around the model tablet scores. Use of scores as the calibration design factors can also be 
justified from chemometric point view. A mathematical description is given in Appendix 
A.  
Figure 2-5. Procedure for designing scores around the model tablet scores in 
spectral space 
However, the challenge remains to find the compositional requirements for the sample 
from which the spectrum is collected and scores are derived. Although the calibration 
samples are designed in the spectral space, the design must be carried out in the 
concentration space to prepare those samples. 
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 𝐂𝐂𝐦𝐦∗𝐤𝐤
𝐂𝐂𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐛𝐛𝐛𝐛𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗  𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 =   𝐗𝐗𝐦𝐦∗𝐧𝐧𝐒𝐒𝐭𝐭𝐦𝐦𝐜𝐜𝐭𝐭𝐌𝐌 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐫𝐫𝐭𝐭  (2.5) 
The relationship between the compositional points and the spectra can be expressed by 
equation 2.5. However, this relationship is not always true due to different physical and 
chemical contributions to the spectral features in the NIR region. A rotation matrix “R” is 
introduced in the above expression to explain all other contributions on spectral features 
except concentration. The rotation matrix rotates the estimated spectra towards the actual 
spectra. “R” is calculated based on equation 2.7 (the detail derivation is given in 
appendix B). Where, U is the left singular values, S is the singular values and V is the 
right singular values for the concentration matrix, X is the spectral matrix containing the 
pure component tablets and model tablet spectra and P is the pure component tablets 
spectra. 
 𝐂𝐂𝐦𝐦∗𝐤𝐤
𝐂𝐂𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐛𝐛𝐛𝐛𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗ 𝐑𝐑𝐤𝐤∗𝐤𝐤
𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗  𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 =   𝐗𝐗𝐦𝐦∗𝐧𝐧𝐒𝐒𝐭𝐭𝐦𝐦𝐜𝐜𝐭𝐭𝐌𝐌 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐫𝐫𝐭𝐭    
(2.6) 
 
𝐑𝐑𝐤𝐤∗𝐤𝐤
𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 𝐦𝐦𝐭𝐭𝐭𝐭𝐫𝐫𝐛𝐛𝐱𝐱 
= 𝐕𝐕𝐤𝐤∗𝐤𝐤𝐑𝐑𝐛𝐛𝐑𝐑𝐑𝐑𝐭𝐭 𝐛𝐛𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫′ ∗ ��𝐒𝐒𝐤𝐤∗𝐦𝐦𝐒𝐒𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫�′ ∗ �𝐒𝐒𝐦𝐦∗𝐤𝐤𝐒𝐒𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫� ∗ �−𝟏𝟏
∗  �𝐒𝐒𝐤𝐤∗𝐦𝐦𝐒𝐒𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫�′ ∗  �𝐔𝐔𝐦𝐦∗𝐦𝐦𝐋𝐋𝐌𝐌𝐋𝐋𝐭𝐭 𝐛𝐛𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫�′ ∗  𝐗𝐗𝐦𝐦∗𝐧𝐧𝐒𝐒𝐭𝐭𝐦𝐦𝐜𝐜𝐭𝐭𝐌𝐌 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭
∗ �𝐏𝐏𝐧𝐧∗𝐤𝐤
𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐌𝐌𝐧𝐧𝐭𝐭�′
∗ {�𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐌𝐌𝐧𝐧𝐭𝐭� ∗  �𝐏𝐏𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐌𝐌𝐧𝐧𝐭𝐭�′}−𝟏𝟏 
(2.7) 
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The effect of rotation matrix in simulating spectral response is demonstrated in Figure 
2-6.  
Figure 2-6. Effect of rotation matrix in spectral simulation 
 
Equation 2.8 is solved for “C” to calculate the compositional requirements using a global 
optimization technique, assuming that the variation in pure component spectra dictates 
the primary spectral variation in the model, (the detail derivation is given in appendix C). 
Where, C is the compositional matrix for the targeted score design having sample size 
“u”, R is the rotational matrix, T is the target design in the score space, P is the pure 
component spectra, W is the basis vector set and r = k (number of latent variables = 
number of components). Two constraints are applied during the solution by the 
optimization technique. The first one is, for all “u”, ∑ Ciki=1 = 1. This is a general 
constraint for formulation, since the sum of the concentrations of all the components in 
each design point must always be 1. The second constraint is set to each constituent 
individually to meet the appropriate concentration range criteria for a feasible tablet 
preparation and regulatory guidelines. For instances, API concentration ranges should 
vary at a range around 70-130 % w/w of the label claim and the lubricant concentration 
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must be limited to a very small range of concentration. Each row of the resultant matrix 
“C” provides the compositional requirements (concentrations) of a sample that has been 
designed in the orthogonal spectral space. This approach is referred to as spectral design 
throughout the rest of this article. 
 
 
𝐂𝐂𝐏𝐏∗𝐤𝐤
𝐂𝐂𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐛𝐛𝐛𝐛𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗ 𝐑𝐑𝐤𝐤∗𝐤𝐤
𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌n
= 𝐓𝐓𝐏𝐏∗𝐫𝐫𝐒𝐒𝐜𝐜𝐌𝐌𝐫𝐫𝐌𝐌 𝐛𝐛𝐜𝐜𝐭𝐭𝐜𝐜𝐌𝐌
∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 ∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐭𝐭𝐛𝐛𝐛𝐛𝐛𝐛)−𝟏𝟏 
With the constraint: for all “u”,  ∑ Ciki=1 = 1 
   (2.8) 
 
After determining the compositional requirements of the design points, a small 
representative subset is selected from the design points as the calibration candidates. 
Different selection strategies can be employed to select the calibration samples such as 
the Kennard stone algorithm, orthogonal rotation, maximum distance in the score space 
etc. 
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2.2 Spectral calibration set for single API formulation 
The spectral space strategy was used to design a NIR calibration set for quantitative 
analysis of a model drug containing Acetaminophen as Active Pharmaceutical Ingredient 
(API) and Microcrystalline cellulose (MCC), spray dried Lactose, Hypromellose and 
Magnesium stearate as excipients. The spectral design was created based on the theory 
discussed in section 2.1. 
 
Figure 2-7. Pure component spectra and respective basis vectors 
The pure component powders were collected from different sources, Acetaminophen 
(Mallinckrodt Inc., Raleigh, NC, USA), Hypromellose (HPMC; Pharmacoat 606, Shin-
Etsu Chemical Co. LTD, Tokyo, Japan), Lactose (modified spray-dried; Foremost Farms 
USA, Rothschild, WI, USA), Microcrystalline cellulose (MCC; Avicel PH 200, FMC 
Biopolymer, Mechanicsburg, PA, USA) and Magnesium stearate (MgSt; Fisher 
Scientific, Waltham, MA, USA). The pure component powders were compressed using a 
Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb 
force using a 13 mm die and flat-faced punches. The target tablet weight was 700 mg. 
The target formulation was set as Acetaminophen (27.3% w/w), MCC (34.15% w/w), 
Lactose (34.15% w/w), HPMC (3.9% w/w) and MgSt (0.5% w/w). A model tablet was 
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prepared at the target formulation. All these 6 tablets (5 pure component tablets and one 
model tablet) were scanned using a bench top NIR instrument (XDS Rapid Content 
Analyzer, FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at 
0.5 nm increment over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum. 
Spectra from both faces of each compact were averaged to produce a single 
representative spectrum. 
                 
Figure 2-8. A full factorial design around the model tablet score in the orthogonal 
spectral space 
The pure component spectra were orthonormalized to determine the basis vector of the 
pure components. Figure 2-7 shows the pure component spectra and basis vector. These 
basis vectors are orthonormal (orthogonal and unit vector) to each other. The basis 
vectors define the orthogonal spectral space of the pure component. Instead of the 
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orthonormalization technique, PCA can be done on the unscaled pure component spectra 
and the principal component of the PCA would give the exact same vector as the basis 
vectors. The model tablet spectrum was projected on the basis vector set of the pure 
components. The resulted scores are termed as target scores. 
A 5-factor full factorial design with 5 levels per factor was calculated in the orthogonal 
spectral space where the “model tablet” scores were set as the center of the design as 
shown in Figure 2-8 for the first 3 basis vectors. This resulted in a 3125 (55) design 
points. A rotation matrix was calculated from the pure component and model tablet 
spectra. The rotation matrix, pure component spectra and orthonormal basis were used to 
calculate the required composition for the 3125 design points based on equation (2.2.8). 
A sample selection technique was employed to select a small representative subset of 
maximum spectral variance within the full design. NIR spectra were simulated for all the 
3125 design points using the concentrations, rotation matrix and pure component spectra 
following equation (2.6) without adding additional noise. Principal component analysis 
was performed and a 3-dimensional score space was created using scores on PC1, PC2 
and PC3. A set of 3 PCs was able to explain all the variation in the spectra. Delaunay 
triangulation was used to create a convex hull around the calculated score space. A 
straight line through the center was rotated orthogonally and the two most distant samples 
from center along the line were selected to capture maximum possible variance. Figure 
2-9 shows the orthogonal rotation of the line in the PCA score space and selected design 
points. 
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A calibration set composed of 10 design points was selected using this technique. The 
target composition along with the 10 design points provided 11 compositional points for 
the spectral design as indicated in Table 2-1. This design was labeled as the ‘spectral 
design’ and was used to develop a quantitative calibration method. 
Design 
# 
Acetaminophen 
(% w/w) 
Hypromellose 
(% w/w) 
Lactose 
(% w/w) 
Microcrystalline 
cellulose 
(% w/w) 
Magnesium 
Stearate 
(% w/w) 
1 32.02 4.42 31.43 31.95 0.19 
2 20.67 1.00 42.36 35.79 0.19 
3 40.13 7.95 21.66 29.53 0.73 
4 35.17 0.94 36.06 27.63 0.20 
5 30.90 8.05 26.60 33.65 0.80 
6 24.30 4.90 31.11 38.97 0.71 
7 38.02 2.43 33.15 26.17 0.23 
8 21.62 1.01 37.93 39.22 0.21 
9 39.85 8.03 26.77 25.13 0.23 
10 24.17 1.03 42.04 32.54 0.23 
11 27.30 3.90 34.15 34.15 0.50 
Table 2-1.  Composition of the spectral calibration et for single API 
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Figure 2-9. Orthogonal rotation in spectral space to select calibration candidates 
 
The spectral design samples were prepared by direct compression. All the components 
(Acetaminophen, MCC, Lactose, HPMC and MgSt) for each design point were weighed 
and placed in a 10 ml scintillation vial according to Table 2-1. The ingredients were 
mixed by rotating the scintillation vial. Tablets were compressed on a Carver Automatic 
Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb force using a 13 mm 
die and flat-faced punches. The target tablet weight was 700 mg. This tablet set was 
defined as the ‘spectral calibration set’. 
All the tablets were scanned using a bench top NIR instrument (XDS Rapid Content 
Analyzer, FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at 
0.5 nm increment over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum. 
PC
3 
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Spectra from both faces of each compact were averaged to produce a single 
representative spectrum. Spectral calibration set and their respective spectra were used to 
develop a quantitative NIR calibration model to quantify the amount of Acetaminophen 
in tablets of interest. 
2.3 Spectral calibration set for multiple API formulation 
The spectral design strategy was also used to create a calibration set for quantitative 
analysis of multiple API tablets. The multiple API tablets contained two APIs as 
Acetaminophen (Acetaminophen; Mallinckrodt Inc., Raleigh, NC, USA) and Caffeine 
anhydrous (Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA). The excipients 
were Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, 
Mechanicsburg, PA, USA), Lactose (modified spray-dried; Foremost Farms USA, 
Rothschild, WI, USA), Crosscarmellose sodium (Crosscarmellose Na, Spectrum 
Chemical Mfg. Corp., New Brunswick, NJ, USA) and Magnesium stearate (MgSt; Fisher 
Scientific, Waltham, MA, USA). The target formulation was set as Acetaminophen 
(31.25% w/w), Caffeine (4.05% w/w), MCC (37.32% w/w), Lactose (24.89% w/w), 
Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w). All the materials were stored in 
room temperature and relative humidity. Anhydrous caffeine was reported to be stable 
under 75% RH for 7 weeks [173]. No hydration and anhydrous caffeine was expected 
considering lower room RH (~60%) and shorter storage time and analysis. 
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The spectral design was created based on the theory discussed in section 2.1. Initially, the 
pure component tablets (six tablets) and one model tablet at the target composition were 
compressed at 5000 lb using a Carver Automatic Tablet Press. The tablets were stored for 
two weeks for viscoelastic relaxation based on a previous study on similar formulation 
[174]. After the viscoelastic relaxation, tablets were scanned using a bench top NIR 
instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc) in reflectance mode. 
Spectral data were collected at 0.5 nm increment over a range of 400 nm – 2499.5 nm 
with 32 co-adds per spectrum. Spectra from both faces of each compact were averaged to 
produce a single representative spectrum. 
Figure 2-10. Pure component spectra and respective basis vectors 
The pure component spectra were orthonormalized to derive the basis vector of the 
spectral space. Figure 2-10 shows the pure component spectra and basis vector. The 
model tablet spectrum was projected on the basis vector to calculate model tablet scores 
on the orthonormal basis of pure component spectra. A 6-factor full factorial design with 
5 levels per factor was calculated in the orthogonal spectral space where the “model 
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tablet” scores were set as the center of the design. This resulted a total of 15625 (56) 
design points. 
  
Figure 2-11. PCA scores of the simulated spectra and selected calibration candidates 
by KNN 
 
A rotation matrix was calculated from the pure component and model tablet spectra to 
help explaining spectral variance coming from sources other than the spectra of the pure 
components. The rotation matrix, pure component spectra and orthonormal basis vectors 
were used to calculate the compositional requirements for the 15625 target design points 
based on eq. 2.8. 
After determining the compositional requirements of the target design, the target design 
spectra were simulated using the compositional requirements, the pure component spectra 
and the rotation matrix using equation 2.6. A PCA analysis was performed on the 
simulated spectra to determine the principal component scores. 
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Acetaminophen 
(% w/w) 
Caffeine 
(% w/w) 
MCC 
(% w/w) 
Lactose 
(% w/w) 
Crosscarmellose 
Na (% w/w) 
MgSt 
(% w/w) 
34.25 3.79 36.77 21.99 2.40 0.80 
19.17 0.81 38.31 37.40 3.50 0.80 
43.75 7.29 30.17 15.64 2.95 0.20 
30.93 0.81 27.89 38.97 1.20 0.20 
27.88 0.81 51.96 15.49 3.08 0.78 
39.60 7.29 23.23 28.89 0.80 0.20 
24.39 7.29 32.90 31.13 3.50 0.80 
36.59 0.81 24.85 35.74 1.81 0.20 
34.31 7.29 38.61 15.49 3.50 0.80 
24.52 0.81 51.96 21.41 0.50 0.80 
40.49 0.81 24.38 30.62 3.50 0.20 
28.34 7.29 47.58 15.49 0.50 0.80 
35.11 7.29 23.23 33.07 0.50 0.80 
32.39 0.81 39.48 24.52 2.60 0.20 
43.62 1.95 35.83 15.49 2.32 0.80 
24.59 0.81 32.54 37.75 3.50 0.80 
41.67 7.29 34.25 15.49 0.50 0.80 
28.03 2.57 41.25 27.45 0.50 0.20 
41.42 0.81 41.58 15.49 0.50 0.20 
29.53 7.29 27.82 33.43 1.73 0.20 
29.99 7.29 42.93 15.49 3.50 0.80 
33.22 7.29 29.42 26.37 3.50 0.20 
31.08 2.32 46.37 15.93 3.50 0.80 
26.15 5.46 47.05 19.03 1.51 0.80 
43.75 7.29 24.29 23.96 0.51 0.20 
36.55 0.81 31.15 27.79 3.50 0.20 
34.56 0.81 30.85 32.48 0.50 0.80 
41.38 3.23 31.13 23.56 0.50 0.20 
35.95 0.81 43.29 16.25 3.50 0.20 
21.71 4.18 35.95 33.86 3.50 0.80 
 
Table 2-2. Composition of the spectral calibration set for multiple API 
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The Kennard Stone algorithm was used to select 30 design points in the PCA score space 
of the target design spectra (Spectral design). Kennard stone algorithm is a widely-used 
technique for selecting a representative subset from a large dataset. The selection 
algorithm provides uniform coverage over the dataset by selecting the most separated 
samples at successive iteration. The details of the Kennard stone algorithm can be found 
elsewhere [132]. Figure 2-11 shows the simulated scores of the 15625 points and selected 
scores of 30 points by Kennard stone algorithm. The composition of the selected 30 
points is given in Table 2-2.The target forumaltion was compressed at 3 different 
compaction forces resulting in total 33 compositional points for the spectral design.  
The 33 tablets of the spectral design were prepared by direct compression on a Carver 
Automatic Tablet Press using a 13 mm die and flat-faced punches. The target tablet 
weight was 700 mg. The compression forces range was 4000 lb to 6000 lb. The 
compression force for each design point was selected such that the correlation between 
compression force variation and concentration variation of each component is minimal 
and variance in comapction force is maximal.  
Table 2-3 provides the correlation co-efficient between compression force variation and 
concentration variation. This tablet set was defined as the ‘spectral calibration set’. All 
the tablets were scanned using a bench top NIR instrument (XDS Rapid Content 
Analyzer, FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at 
0.5 nm increment over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum. 
Spectra from both faces of each compact were averaged to produce a single 
representative spectrum. 
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2.4 Conclusion 
A method was developed to design calibration set in spectral space using pure component 
spectra. Two calibration sets were designed in spectral space, one for a single API 
formulation and the other for multiple API formulation. The spectral calibrations sets for 
single API and multiple API were used to developed quantitative NIR methods for 
respective APIs. The performances of the methods were compared with traditional 
calibration strategies. The details of the method development and comparative results are 
discussed in the following chapter. 
 
Copyright ©: Part of this chapter has been reprinted from [175]. Copyright clearance is 
provided at the end the dissertation.  
 Acetamino-phen Caffeine MCC Lactose 
Cross 
carmellose 
Na 
MgSt Force 
Acetamino-
-phen 1.00 0.13 -0.46 -0.35 -0.27 -0.48 0.00 
Caffeine 0.13 1.00 -0.23 -0.22 -0.13 0.14 0.02 
MCC -0.46 -0.23 1.00 -0.60 0.10 0.45 0.00 
Lactose -0.35 -0.22 -0.60 1.00 0.01 -0.16 -0.01 
Cross 
carmellose 
Na 
-0.27 -0.13 0.10 0.01 1.00 0.12 0.00 
MgSt -0.48 0.14 0.45 -0.16 0.12 1.00 0.03 
Force 0.00 0.02 0.00 -0.01 0.00 0.03 1.00 
Table 2-3. Correlation co-efficient between composition and compression force 
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3 Chapter 3: Comparison between the model performance of spectral calibration 
and traditional calibration sets 
3.1 Introduction 
The first step in developing NIR quantitative method for tablet analysis is to design the 
calibration set. The performance of the NIR method depends on the suitability of the data 
generated from the calibration set. Calibration sets are traditionally designed in 
concentration space using experimental design plan. Traditional calibration sets are prone 
to have redundant samples while simultaneously lacking necessary samples for a 
successful calibration model. Traditional calibration sets are also developed based on 
generic design. Similar calibration designs are followed for different spectroscopic 
techniques and different formulations. Such a calibration strategy lacks the optimizing 
capability to be technique and formulation specific. A new calibration strategy was 
developed for designing an NIR calibration set for quantitative analysis of tablets. 
Following this strategy, NIR calibration sets were designed in spectral space instead of 
concentration space. The pure component NIR spectra of a tablet formulation were used 
to define the spectral space of that formulation. The performance of this strategy was 
compared with commonly employed experimental design approaches to calibration 
development. The comparisons were conducted on single API (Active Pharmaceutical 
Ingredient) and multiple API formulation to quantify model drugs using NIR 
spectroscopy. 
In the single API formulation, the comparison was based on a system to quantify a model 
drug, Acetaminophen, in pharmaceutical compacts using NIRS. A 2-factor full factorial 
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design (Acetaminophen with 5 levels and MCC:Lactose with 3 levels) was used for 
calibration development as an example of traditional calibration design. Three replicates 
at each design point resulted in a total of 45 tablets for the calibration set. Using the 
newly developed spectral based method, 11 tablets were prepared for the calibration set. 
Partial least squares (PLS) models were developed from respective calibration sets. 
Model performance was comprehensively assessed based on the ability to predict 
Acetaminophen concentrations in multiple prediction sets. One prediction set contained 
similar information to calibration set while the other prediction sets contained different 
information from calibration set in order to assess the model accuracy and robustness. 
In multiple API formulation, NIRS was used to develop a quantitative method for a 
model drug containing two APIs as Acetaminophen and Caffeine. The traditional 
calibration design was developed in the concentration space using concentration-based 
approach. A full factorial design of experiment was used to vary the APIs concentrations, 
each at five levels and excipient concentration ratio at 3 levels. Each tablet was 
compressed at three compaction pressures resulting in a total of 225 tablets in the 
calibration set. Three other calibration sets were also developed using traditional optimal 
experimental designs (central composite, D-Optimal and I-Optimal designs). A 
calibration set of 33 design points was developed from each experimental design. 
Another calibration set containing 33 samples was developed in the spectral space 
following the spectral space based method. Partial Least Square (PLS) models were 
developed from the respective calibration sets to predict APIs concentrations in an 
independent test set. This chapter aims at comparing the performance of the spectral 
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calibration sets with traditionally developed calibration sets. The experimental details and 
results of these comparative studies are provided in the following sections. 
3.2 Single API formulation 
The single API formulation described in chapter 2 was used for this study. The single API 
formulation contained a model drug Acetaminophen and four excipients such as 
Microcrystalline cellulose (MCC), spray dried Lactose, Hypromellose and Magnesium 
stearate. The target formulation was set as Acetaminophen (27.3% w/w), MCC (34.15% 
w/w), Lactose (34.15% w/w), HPMC (3.9% w/w) and MgSt (0.5% w/w). A traditional 
full factorial calibration design and a spectral calibration design were used to develop 
quantitative NIR method for this formulation to predict Acetaminophen concentration in 
pharmaceutical tablets. The prediction performances of the respective calibration models 
were compared to evaluate the utility of the spectral design strategy. 
3.2.1 Material and Methods 
3.2.1.1 Full factorial Calibration  
The traditional calibration design was a 5 by 3 level, 2-factor full factorial design. 
Samples were prepared in the laboratory. The composition of these samples is provided in 
Table 3-1. The factors were Acetaminophen concentration (% w/w) and MCC to Lactose 
ratio. Each design point was replicated three times (45 samples total). The use of a full 
factorial design of experiment for the calibration set provided orthogonality between the 
active ingredient and the excipient ratios.  
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Granules of Acetaminophen (Mallinckrodt Inc., Raleigh, NC, USA), Hypromellose 
(HPMC; Pharmacoat 606, Shin-Etsu Chemical Co. LTD, Tokyo, Japan) and intra-
granular Lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA) 
were manufactured using a fluid bed processor (model WSG 5, Glatt, Binzen, Germany). 
Granules, Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, 
Mechanicsburg, PA, USA) and Lactose (modified spray-dried; Foremost Farms USA,  
Design 
# Acetaminophen 
Hyprome
-llose 
Intra-
granular 
Lactose 
Micro-
crystalline 
cellulose 
Extra-
granular 
Lactose 
Magnesium 
Stearate 
1 19.11 2.73 5.46 51.77 20.43 0.50 
2 23.21 3.32 6.63 48.65 17.70 0.50 
3 27.30 3.90 7.80 45.53 14.97 0.50 
4 31.40 4.49 8.97 42.41 12.24 0.50 
5 35.49 5.07 10.14 39.29 9.51 0.50 
6 19.11 2.73 5.46 38.83 33.37 0.50 
7 23.21 3.32 6.63 36.49 29.86 0.50 
8 27.30 3.90 7.80 34.15 26.35 0.50 
9 31.40 4.49 8.97 31.81 22.84 0.50 
10 35.49 5.07 10.14 29.47 19.33 0.50 
11 19.11 2.73 5.46 25.89 46.31 0.50 
12 23.21 3.32 6.63 24.33 42.02 0.50 
13 27.30 3.90 7.80 22.77 37.73 0.50 
14 31.40 4.49 8.97 21.21 33.44 0.50 
15 35.49 5.07 10.14 19.65 29.15 0.50 
Table 3-1.  Composition (% w/w) of the full factorial calibration set 
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Rothschild, WI, USA) were mixed in a bin blender for 15 min. Magnesium stearate 
(Fisher Scientific, Waltham, MA, USA) was added to this blend and blended for an 
additional 2 min. Tablets were compressed at lab scale on a Carver Automatic Tablet  
Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5500 lb force using a 13 mm die and 
flat-faced punches. The target tablet weight was 700 mg. The manufacturing steps were 
tested to produce reliable tablets and reported in a previous study [174]. 
3.2.1.2 Spectral Design 
The preparation method of the spectral design is described in section 2.2 in chapter 2. The 
spectral calibration set contained 11 tablets. The composition of these 11 tablets is given 
in Table 2-1 in chapter 2. The spectral design samples were prepared by direct 
compression. All the components, Acetaminophen, MCC, Lactose, HPMC and Mg 
stearate for each design point were weighed and placed in a 10 ml scintillation vial. The 
ingredients were mixed by rotating the scintillation vial. The intra tablet homogeneity 
was less of a concern due to the large spot size (~10 mm) of the NIR instrument. Tablets 
were compressed on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, 
IN, USA) at 5000 lb force using a 13 mm die and flat-faced punches. The target tablet 
weight was 700 mg. 
3.2.1.3 Prediction sets 
Multiple prediction sets (3 sets) were used to evaluate the performance of the traditional 
calibration design and spectral calibration design. The first prediction set tablets were 
prepared at lab scale whereas the other two prediction sets were prepared at the 
manufacturing scale. 
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3.2.1.4 Lab scale prediction 
The first prediction set (prediction set 1) was developed using the same full factorial 
design as used for the traditional calibration set; containing 45 samples at five levels of 
Acetaminophen and 3 levels of MCC:Lactose ratio. These samples were prepared using 
the same method as calibration set. Granules of Acetaminophen, Lactose and HPMC 
were prepared and then compressed with MCC and MgSt at lab scale on a Carver 
Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb force using 
a 13 mm die and flat-faced punches. The target tablet weight was 700 mg. 
3.2.1.5 Manufacturing scale prediction 
The second and third prediction sets were prepared at manufacturing scale. Prediction set 
2 was prepared by varying the Acetaminophen concentration at 3 levels and keeping the 
MCC:Lactose ratio constant. A set of 20 tablets was collected from each Acetaminophen 
level, yielding 60 tablets for this set. Four batches of tablets were prepared using this 
design, resulted in 240 tablets. A total of 239 samples were used in subsequent analysis, 
after the accidental destruction of one tablet. Intentional variation resulting from 
manufacturing scale was introduced in prediction set 2 to challenge the calibration set in 
presence of unexpected variance. The target composition was used to create two 
additional batches for the prediction set 3. Tablets were compressed on a weekly basis for 
8 weeks at the target composition. A set of 20 tablets were collected each week yielding 
160 tablets for prediction set 3. These tablets served as the real time prediction samples.  
At the manufacturing scale, after the granulation and blending steps described in the full 
factorial design section, tablets were compressed on a 38-station rotary tablet press 
(Elizabeth-Hata International, Inc., North Huntingdon, PA, USA) using round beveled 
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punches, 3/8 in. (9.5 mm) in diameter. The target tablet weight was 350 mg and the target 
breaking force was 8 kp. 
3.2.1.6 Spectral collection and reference measurements 
NIR reflectance measurements for both sides of each compact were collected using a 
bench top scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS 
NIR Systems, Inc., Laurel, MD, USA) after tablets reached stable dimensions 
(viscoelastic relaxation). Spectra corresponding to each side of a compact were averaged 
to give one spectrum per compact. Acetaminophen reference values for compacts from all 
data sets except the spectral design were determined using High Pressure Liquid 
Chromatography (Waters Alliance 2790, Milford, MA, USA), followed by UV detection 
(Waters 2487). Gravimetric measurement was used as reference for the spectral design 
compacts. 
3.2.1.7 Modeling strategy 
Two calibration models were developed, one from the 45 tablets of the full factorial 
design and another from the 11 tablets of the spectral design. Both calibration models 
were developed from the lab scale tablets only. To compare calibration model 
performance between the full factorial set designed in concentration space and the set 
designed in spectral space, model performance was assessed for lab (prediction set 1 
containing similar information as calibration) and manufacturing scale predictions 
(prediction sets 2 and 3 containing different information from calibration). 
Principal Component Analysis (PCA) was used for spectral investigation and Partial 
Least Squares (PLS) regression was used to develop the calibration models. The NIPALS 
algorithm was employed. All calculations were performed with MATLAB 2011a (The 
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Mathworks, Natick, MA, USA) equipped with the PLS_Toolbox v. 7.9.3 (Eigenvector 
Research Inc., Wenatchee, WA, USA). 
3.2.1.8 Model evaluation and design comparison parameters 
Comparison of the performance of different calibration designs requires the evaluation of 
the resulting models. The full factorial and spectral design were compared based on their 
model predictive performance. Root mean squared error (RMSE) was used to evaluate 
the model predictive performance in the calibration (RMSEC) and prediction sets 
(RMSEP). The RMSEPs were separated into bias and Standard Error of Prediction (SEP). 
The bias and SEPs of the two models (one from full factorial and the other from spectral 
design) were compared using 95% t confidence interval around the bias difference and 
ratio of SEPs respectively; following the method outlined by Fearn et al. and adapted by 
Bondi et al [9, 176]. The 95% confidence interval was calculated based on the following 
equation 
 𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵1 −  𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵2  ±   𝑡𝑡𝑛𝑛−1,0.025 ∗  𝑆𝑆𝑒𝑒 (3.1) 
Where, 𝑆𝑆𝑒𝑒 is the standard error of estimated difference and calculated based on the 
following equation, 
 𝑆𝑆𝑒𝑒 =  �∑ (𝑑𝑑𝑖𝑖 − ?̅?𝑑)2𝑛𝑛𝑖𝑖=1𝑛𝑛 ∗  (𝑛𝑛 − 1)  (3.2) 
Here, 𝑑𝑑𝑖𝑖 represents the difference in residuals for sample “i” estimated by models being 
compared and ?̅?𝑑 represents the mean difference in residuals for two models. The biases 
between two models were considered significantly different only if the confidence 
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interval for bias difference did not contain zero. The confidence interval for SEP ratio 
was calculated based on equation (3.3) [9, 176], 
 
 
𝑆𝑆𝑆𝑆𝑃𝑃1
𝑆𝑆𝑆𝑆𝑃𝑃2
× 1
𝐿𝐿
  𝐵𝐵𝑛𝑛𝑑𝑑 𝑆𝑆𝑆𝑆𝑃𝑃1
𝑆𝑆𝑆𝑆𝑃𝑃2
× 𝐿𝐿 (3.3) 
Where, 
 
𝐿𝐿 = �K + �(𝐾𝐾2 − 1) (3.4) 
and, 
 K = 1 +  2 (1 −  𝑟𝑟2) ∗  𝑡𝑡𝑛𝑛−2,0.0252
𝑛𝑛 − 2  (3.5) 
Here, r represents the correlation co-efficient between the residuals. The SEPs between 
two models were considered significantly different only if the confidence interval of SEP 
ratio did not contain one. The prediction performances between the two models were 
considered significantly different if the bias, or SEPs, or both were significantly different 
between the models being compared. 
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Figure 3-1. Raw data for two calibration sets, solid line (-) represents the full 
factorial design calibration samples and broken line (--represents the spectral design 
calibration samples. 
 
3.2.2 Results  
3.2.2.1 Spectral investigations  
Figure 3-1 illustrates the raw NIR spectra of the two calibration sets, traditional full 
factorial and spectral design calibration set. Prediction sets prepared at the manufacturing 
scale (prediction set 2 and 3) exhibited a baseline shift compared to the lab scale samples 
(data not shown). The observed differences in baseline were attributed to shape, density 
and hardness differences between the lab and manufacturing samples. Density differences 
in the samples are known to cause baseline shift in NIR spectra [177, 178]. Figure 3-2 
illustrates the score plots of PCA analysis of the preprocessed spectra from two 
calibration sets and three prediction sets (total 500 spectra). Multiplicative scatter 
correction (MSC) followed by Savitzky Golay 1st derivative in a second order polynomial 
fit over a window size 19 was used as the spectral processing technique. Other 
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preprocessing methods showed similar results in the PCA analysis. The 95% confidence 
interval was dominated by the prediction set samples (444 out 500 tablets). Full factorial, 
spectral design and prediction set 1 had similar variance explained by PC1 and PC2 and 
were grouped together by PC scores except for the fact that the full factorial design and 
prediction set 1 tablets had wider range of variance compared to the spectral design 
tablets. The full factorial design and prediction set 1 tablets were prepared at the exact 
same design points and showed similar projections in the PC space. Their wider spectral 
variance was attributed to the wider range of the excipient concentrations and physical 
variance compared to the spectral design tablets. The prediction sets prepared at the 
manufacturing scale (prediction set 2 and 3) grouped separately in the scores plot due to 
differences in the physical properties such as density, hardness, surface texture and mass.  
 
Figure 3-2. Projection of the full factorial calibration, spectral calibration and three 
prediction sets samples on the PC1 and PC2 of the combined PC space. 
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The different ranges of score values between the two calibration designs and the separate 
group of scores for manufacturing scale prediction sets were largely spanned in PC2 
whereas all the samples had similar score values in PC1. It is critical for the calibration 
and prediction samples to have similar score values in the principal components that 
explain analyte concentration variation to achieve acceptable predictive performance. In 
this study, PC1 primarily explained the concentration variation of Acetaminophen (the 
absolute correlation co-efficient between Acetaminophen concentration and scores on 
PC1 was 0.9125). The different projections on PC2 did not affect the prediction at a large 
extent due to poor correlation with the Acetaminophen concentration (the absolute 
correlation co-efficient between Acetaminophen concentration and scores on PC2 was 
0.2525). 
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Figure 3-3. Measured vs predicted plot of Acetaminophen concentration for full 
factorial calibration and prediction set 1 (upper panel). Measured vs predicted plot 
of Acetaminophen concentration for spectral calibration and prediction set 1 (lower 
panel). 
3.2.2.2 Model optimization 
 
Models developed from each calibration design were independently optimized. The range 
of the wavelength used was 1100-2500 nm for both calibration designs. The pre-
processing and model optimization focused on maximizing the potential to predict 
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samples manufactured at different scales. Multiplicative Scatter Correction (MSC) 
followed by Savitzky-Golay first derivative (window size 19 and second polynomial 
order) and mean centering was used as the optimized preprocessing technique. Other 
preprocessing methods were also tried, but scatter correction followed by derivatives 
provided better predictive performance for the calibration models. This preprocessing 
technique minimized the baseline shift caused by scale variation in the tablet preparation 
methods between calibration and prediction sets. However, the spectral difference could 
not be completely removed as evident by the different projections of calibration and 
predictions sets (after applying same preprocessing technique) on the PC score space in 
Figure 3-2. Selection of the latent variables is critical for PLS model performance. A 
minimum number of latent variables with acceptable prediction performance was 
selected. The optimum numbers of latent variables for the spectral and full factorial 
calibration design sets were two (spectral) and three (full factorial), respectively.  
3.2.2.3 Prediction performance 
The calibration models from the full factorial and spectral design were used to predict the 
Acetaminophen concentrations in prediction sets. Prediction set 1 samples were prepared 
at the lab scale; and samples for prediction sets 2 and 3 were prepared at the 
manufacturing scale.  
3.2.2.4 Lab scale prediction 
Figure 3-3 shows the reference vs prediction plot for full factorial and spectral designs. 
The model developed from the full factorial design predicted Acetaminophen in 
prediction set 1 with RMSEC and RMSEP value of 1.13% and 1.34%, respectively.  
 87 
 
 
Figure 3-4. Measured vs predicted plot of Acetaminophen concentration for full 
factorial calibration and prediction set 2 (upper panel). Measured vs predicted plot 
of Acetaminophen concentration for spectral calibration and prediction set 2 (lower 
panel). 
The model developed from the spectral design had a lower RMSEC of 0.89% but higher 
RMSEP of 2.70 %. The improved prediction performance for the full factorial design was 
due to the chemical and physical similarity between prediction set 1 samples and the full 
factorial design. The spectral design samples had compositional and physical 
dissimilarities from prediction set 1 that include composition and preparation method. 
 88 
 
The full factorial design and prediction set 1 samples were prepared using wet 
granulation method whereas the spectral design samples were prepared using dry mixing 
method. 
3.2.2.5 Manufacturing scale prediction 
Robustness was tested for models developed from the full factorial and spectral designs. 
Samples with new sources of variation (manufacturing scale) were predicted using the 
models developed at the calibration step (lab scale) to test the robustness. Figure 3-4 
shows the reference vs prediction plot of Acetaminophen concentrations in prediction set 
2 for both models. The model developed from the full factorial design had a RMSEP of 
4.68 % compared to the RMSEP of 2.21 % for the model developed from spectral design.  
A bias is observed in the prediction of samples at the top figure of Figure 3-4 for the full 
factorial design model. The bias was due to an interference introduced by the scale of the 
sample preparation method. No significant bias was observed while predicting these 
samples by the model developed from spectral design as shown at the bottom of Figure 
3-4. 
Figure 3-5 shows the reference vs prediction plots of prediction set 3, containing 160 
tablets. This prediction set was prepared at the target concentration to mimic routine 
production. Full factorial design model had a higher RMSEP of 5.05 % compared to the 
RMSEP of 1.68 % of the spectral design model. Table 3-2 shows the prediction results 
for both full factorial and spectral design. 
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Figure 3-5. Measured vs predicted plot of Acetaminophen concentration for full 
factorial calibration and prediction set 3 (upper panel). Measured vs predicted plot 
of Acetaminophen concentration for spectral calibration and prediction set 3 (lower 
panel). 
3.2.2.6 Design comparison 
The predictive performances of the optimized models from the traditional concentration 
based full factorial design and the spectral design were compared. Figure 3-6 shows the 
confidence intervals for bias and SEP comparison between the optimized models. The 
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two models were significantly different in terms of both bias and SEP. Full factorial 
design predictions had a lower bias for the lab scale samples (prediction set 1) and  
higher bias for the 
manufacturing scale samples 
(prediction set 2 and 3), 
compared to the spectral 
design model. While 
comparing SEPs, full 
factorial design had lower 
SEP for prediction set 1 and 
3 compared to the spectral 
design. For prediction set 2, 
the spectral design had a 
lower SEP. Although full 
factorial design had a lower 
SEP, it had a higher RMSEP 
due to the higher bias in the 
prediction sets. For all the manufacturing scale predictions, full factorial design always 
had a higher RMSEP compared to the spectral design. The spectral design approach was 
found to be more robust than the traditional full factorial design in spite of having fewer 
calibration samples. 
 
Calibration Design Spectral design Full factorial design 
No. of samples 11 samples 45 samples 
No. of latent variable 2 LV 3 LV 
RMSEC % (w/w): 0.889 1.133 
RMSECV % (w/w): 1.625 1.288 
Prediction Set 1   
RMSEP % (w/w): 2.701 1.342 
Prediction Bias 1.270 0.071 
SEP 2.384 1.340 
Prediction Set 2 
  RMSEP % (w/w): 2.212 4.682 
Prediction Bias -0.578 -3.938 
SEP 2.135 2.531 
Prediction Set 3 
  RMSEP % (w/w): 1.676 5.046 
Prediction Bias -0.786 -4.882 
SEP 1.480 1.274 
Table 3-2.  Model performance comparison between 
two methods of experimental design; spectral and full 
factorial 
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Figure 3-6. Confidence interval for bias (A) and standard error of prediction (B) 
comparison between full factorial design and spectral design for prediction sets 
analysis. 
3.2.2.7 Discussion 
The main objective of this project was to develop and test a spectral design method and 
compare it with a traditional full factorial design method for NIR spectroscopic 
multivariate calibration. The use of a traditional design, such as full factorial, in 
concentration space is a common practice for calibration sample preparation. However, 
this practice is inefficient and includes redundant information in the calibration model. 
The spectral design approach offers an efficient enhancement for NIR calibration 
development by using pure component spectra. Information about the pure component 
spectra was used to define an orthogonal spectral space for the formulation and identify a 
set of critical samples necessary for successful calibration model development.  
Designing a calibration sample set in this orthogonal spectral space was found to be an 
efficient approach for developing an NIR calibration method for pharmaceutical tablets. 
Fewer samples were required when this approach was used. A reduction of 75% in raw 
material requirement was demonstrated (11 vs 45) while achieving similar (if not 
improved) predictive performance compared to the traditional full factorial design. 
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Considering the RMSEPs in manufacturing scale samples, the spectral design was found 
to be more robust than the full factorial design. The full factorial design was very 
sensitive to latent variable selection, scale variation and prone to biased prediction. The 
sensitivity of this concentration based design was due to the information that is unique to 
the calibration set and not always exists in the prediction sets. Fitting this information 
into the model introduced biased predictions in the presence of new information (lack of 
robustness). Biased corrected prediction performance (SEP) of the full factorial design 
were found to be similar to the spectral design for manufacturing samples. 
The spectral calibration set showed similar SEP to the full-factorial calibration set due to 
similar span of Acetaminophen concentration between two calibration sets. The full-
factorial calibration set contained wider range of excipient variation compared to the 
spectral calibration set, however, such information was redundant for calibration 
performance. The limited excipient variation in the spectral calibration set was 
representative of the additional excipient variation in the full factorial calibration set. 
Prediction results at lab scale emphasized the similarity between the calibration and 
prediction samples. For the full factorial design, calibration and lab samples came from 
the same exact design points and were prepared using the same methodology. As 
expected, the calibration model was very accurate in predicting this set of samples. In 
spectral design method, errors from the lab scale predictions based on the spectral design 
model were within errors observed in other prediction sets due to the inherent robustness 
of the design. 
Selection of the latent variables is critical to model performance. However, in practice, 
this selection process occurs only during model development. Once the model is 
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developed and optimized, further investigations of predictive performance are conducted 
based on that optimized model only. The number of latent variable does not change 
during the assessment of prediction performance. Following this practice, the 
comparative analyses were performed between the optimized models with fixed latent 
variables from respective designs. 
3.2.3 Conclusion 
A technique for designing a calibration set using pure component spectra for NIR 
spectroscopic calibration method was described and tested for quantitative analysis of 
pharmaceutical tablets. This technique was found to be efficient in terms of sample 
requirements compared to the traditional (full factorial) concentration based technique. A 
reduced number of calibration samples yielded a model with improved predictive 
capabilities for this individual system. In particular, a calibration model developed in 
spectral space demonstrated improved robustness in presence of variation introduced by a 
change of manufacturing scale, with respect to a model developed using full factorial 
design. 
Calibration model performance can be highly system specific. The improved prediction 
performance of the spectral calibration set is not expected for every formulation.   
However, it is expected that the spectral calibration set will provide equivalent prediction 
performance with fewer number of samples while comparing with traditional calibration 
sets. It is also expected that the spectral calibration set will provide improved prediction 
performance with an equal number of calibration samples while comparing with 
traditional calibration sets. In general, spectral calibration is expected to be efficient in 
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sample number compared to the traditional calibration sets.  Such efficiency is more 
critical for multiple API formulation, since the traditional calibration sets for multiple 
API requires larger calibration sets compared to the single API. The following section 
describes a comparative study conducted on multiple API system to assess the 
performance of spectral calibration set and compare with traditional calibration sets.
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3.3 Multiple APIs formulation 
The utility and performance of the spectral calibration technique was assessed for a multiple API 
formulation. The performance of the spectral calibration set (33 calibration samples) was 
compared with traditional full factorial calibration set of larger size (225 calibration samples) as 
well as traditional optimal calibration sets of similar sizes (33 calibration samples) to further 
investigate the applicability of the newly developed spectral calibration strategy. The multiple 
API formulation described in section 2.3 in chapter 2 was used for this study. The multiple API 
formulation contained two model drug Acetaminophen (Acetaminophen) and Caffeine and four 
excipients such as Microcrystalline cellulose (MCC), spray dried Lactose, Crosscarmellose Na 
and Magnesium stearate. A full factorial calibration design and three optimal calibration designs 
were used as examples of traditional calibration set. A spectral calibration design was used to 
develop another calibration set. All these calibration sets were used to develop quantitative NIR 
methods for this formulation to predict Acetaminophen and caffeine concentration in 
pharmaceutical tablets. The prediction performances of the respective calibration models were 
compared to evaluate the utility of the spectral design strategy. 
3.3.1 Material and Methods 
3.3.1.1 Full factorial Calibration  
The model drug product contained two APIs as Acetaminophen (Mallinckrodt Inc., Raleigh, NC, 
USA) and anhydrous Caffeine (Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA), and 
four excipients as Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, 
Mechanicsburg, PA, USA), Lactose (modified spray-dried; Foremost Farms USA, Rothschild, 
WI, USA), Crosscarmellose sodium (Crosscarmellose Na, Spectrum Chemical Mfg. Corp., New 
Brunswick, NJ, USA) and Magnesium stearate (Fisher Scientific, Waltham, MA, USA). The 
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target formulation was set as Acetaminophen (31.25% w/w), Caffeine (4.05% w/w), MCC 
(37.32% w/w), Lactose (24.89% w/w), Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w). 
The traditional calibration design was developed using a 4-factor full factorial design. The 
factors were Acetaminophen concentration, Caffeine concentration, MCC: Lactose ratio and 
compaction force. Each of the APIs (Acetaminophen and Caffeine) concentrations was varied at 
five levels and other two factors (MCC: Lactose ratio and compaction force) were varied at three 
levels resulting in 225 design points in the traditional full factorial calibration set. A test set was 
developed by varying all the factors except MCC: Lactose ratio, each at three levels resulting in 
total 27 design points. Table 3-3 provides the details of the full factorial calibration and test 
design. 
Tablets were individually prepared by direct compression. All the components for a single design 
point were weighed using a digital weighing machine (Data Range, Model No. AX504DR, 
Mettler Toledo) and placed in a 10 ml scintillation vial. The ingredients were mixed in a bin 
 Design Factors Design Levels 
Calibration Design 
(5x5x3x3) 
225 
samples 
Acetaminophen 
(%) 
L.C.-
40% 
L.C.-
20% L.C. L.C.+20% L.C.+40% 
Caffeine (%) L.C.-80% 
L.C.-
40% L.C. 
L.C. 
+40% L.C.+80% 
MCC/Lac 1 1.5 2 
Force (lb) 4000 5000 6000 
Test Design 
(3x3x3) 
27 
samples 
Acetaminophen 
(%) L.C.-35% L.C. L.C.+35% 
Caffeine (%) L.C.-70% L.C. L.C.+70% 
Force (lb) 4000 5000 6000 
MCC/Lac 1.5 
Table 3-3. Full-factorial calibration design and test set 
  97  
blender (L.B. Bohle LLC, Warminster, PA, USA) for 10 mins followed by a high shear mixing 
using a vortex machine (Vortex-2 Genie, Model G-560, Scientific Industries, IN, USA). The final 
mixing was done in the bin blender before compression. Additional blending steps were included 
in the process to ensure well mixing of the low dose caffeine. Tablets were compressed on a 
Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at respective 
compression forces (4000/ 5000/ 6000 lb) using a 13 mm die and flat-faced punches. The target 
tablet weight was 700 mg. 
3.3.1.2 Optimal calibration designs 
Three optimal calibration designs were developed in this study as examples of traditional 
calibration designs. The factors of the designs were Acetaminophen concentration, Caffeine 
concentration, MCC: Lactose ratio and compaction force. The CCD design was developed by 
creating a CCD structure containing 11 design points in the concentration space and varying the 
compaction force at three levels for each design point resulting a total of 33 design points in the 
calibration set. The D-Optimal and I-Optimal designs were developed using JMP (v. 12, SAS, 
Cary, NC, USA). A set of 33 design points was selected from a full factorial space such that the 
determinant of the information matrix is maximized (D-Optimal) and average prediction 
variance is minimized (I-Optimal). All the calibration design tablets were subsets of the full-
factorial design described earlier. 
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Figure 3-7. Experimental procedures for designing a calibration set in spectral space 
3.3.1.3 Spectral Design 
The preparation method of the spectral design of multiple API is described in section 2.3 in 
chapter 2. Figure 3-7 illustrates the procedure for designing a calibration set in the spectral space. 
In summary, the pure component tablets (six tablets) and one tablet at the target composition 
were compressed at the middle compression force (5000 lb) using a Carver Automatic Tablet 
Press. A spectrum at the target composition was used for calculating model tablet scores (target 
scores) on the orthonormal basis of pure component spectra. A 6-factor full factorial design with 
5 levels per factor was calculated in the orthogonal spectral space where the “model tablet” 
scores were set as the center of the design. The full factorial structure resulted a total of 15625 
(56) design points. The compositional requirements for the target design were calculated using 
eq. 3.6 (same as equation 2.8). 
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𝐂𝐂𝐏𝐏∗𝐤𝐤
𝐂𝐂𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐛𝐛𝐛𝐛𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗ 𝐑𝐑𝐤𝐤∗𝐤𝐤
𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌n
= 𝐓𝐓𝐏𝐏∗𝐫𝐫𝐒𝐒𝐜𝐜𝐌𝐌𝐫𝐫𝐌𝐌 𝐛𝐛𝐜𝐜𝐭𝐭𝐜𝐜𝐌𝐌 ∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 ∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐭𝐭𝐛𝐛𝐛𝐛𝐛𝐛)−𝟏𝟏 
 
(3.6) 
Here, C is the compositional matrix for the targeted score design having sample size “u”, R is the 
rotational matrix, T is the target design in the score space, P is the pure component spectra, W is 
the basis vector set and r = k (number of latent variables = number of components). 
After determining the compositional requirements ‘C’ of the target design, the target design 
spectra were simulated using the compositional requirements, the pure component spectra and 
the rotation matrix. The Kennard Stone algorithm was used to select 30 design points in the PCA 
score space of the target design spectra (Spectral Design) [132]. The composition of these 30 
design points is provided in Table 2-2 in section 2.3 of chapter 2. The target formulation was 
replicated 3 times resulting in 33 design points in the spectral design. The 33 tablets of the 
spectral design were prepared by direct compression on Carver Automatic Tablet Press using a 
13 mm die and flat-faced punches. The target tablet weight was 700 mg. The compression forces 
were selected such that the correlation between compression force variation and concentration 
variation of each component is minimal and variance in compaction force is maximal. 
3.3.1.4 Experimental control 
Intra homogeneity of the tablets can be critical in case the respective spectrum represents only a 
portion of the tablet. The blending was performed in three steps in a bin blender followed by 
high shear mixing and subsequent blending to avoid inhomogeneity of the tablet. The intra 
homogeneity of the tablet was analyzed to test the appropriateness of the blending process. A set 
of 15 tablets were selected from the 225 calibration samples. NIR images of these tablets were 
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collect by NIR chemical imaging system (MatrixNIR, Malvern Inc., MD) with 0.5× objective 
lens (field of view 1.72 cm × 2.15 cm). An integration time of 256 ms and a count of 16 co-adds 
were utilized throughout the image collection of all 15 tablets. The wavelength range was from 
1050 to 1620 nm with a 5 nm interval. A typical Classical Least Square approach was used to 
develop a quantitative method for image analysis. 
All the materials were stored in room temperature and relative humidity. Anhydrous caffeine was 
reported to be stable at 75% RH for 7 weeks [173]. No hydration and anhydrous caffeine was 
expected considering lower room RH (~60%) and shorter storage time and analysis. The tablets 
were stored for 2 weeks to allow viscoelastic relaxation. Two weeks duration was set based on a 
previous study [174]. 
Solid fraction of each of the 225 tablets was calculated based on the following equation  
to test the appropriateness of the compaction force range. A wide range of solid fraction was 
expected as a result of compaction force variation. 
 𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵𝑑𝑑 𝑓𝑓𝑟𝑟𝐵𝐵𝑓𝑓𝑡𝑡𝐵𝐵𝑆𝑆𝑛𝑛 𝑆𝑆𝑓𝑓 𝑡𝑡𝐵𝐵𝑏𝑏𝑆𝑆𝑡𝑡𝑡𝑡 =  𝑇𝑇𝐵𝐵𝑏𝑏𝑆𝑆𝑡𝑡𝑡𝑡 𝑑𝑑𝑡𝑡𝑛𝑛𝐵𝐵𝐵𝐵𝑡𝑡𝑑𝑑 𝑇𝑇𝑟𝑟𝑇𝑇𝑡𝑡 𝑑𝑑𝑡𝑡𝑛𝑛𝐵𝐵𝐵𝐵𝑡𝑡𝑑𝑑�  (3.7) 
 
3.3.1.5 Spectral collection and reference measurements 
NIR reflectance measurements for both sides of each compact were collected using the bench top 
scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc., 
Laurel, MD, USA) after tablets reached stable dimensions (viscoelastic relaxation). Spectra 
corresponding to each side of a compact were averaged to give one spectrum per compact. 
Gravimetric measurement was used as reference for all tablets. 
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In the gravimetric method, all the weights of the individual chemical components at each design 
point were recorded from digital weighing machine (Data Range, Model No. AX504DR, Mettler 
Toledo). The tablet weights were recorded after compression using the same digital weighing 
machine. The concentrations % (w/w) were calculated for APIs from the respective individual 
weights and tablet weights, and used as reference values for model development. 
3.3.1.6 Modeling strategy and optimization 
Quantitative models were developed using Partial Least Squares (PLS) modeling technique in 
MATLAB 2015a environment (The Mathworks, Natick, MA, USA) using PLS_Toolbox v. 7.9.3 
(Eigenvector Research Inc., Wenatchee, WA, USA). Data independent spectral preprocessing 
techniques were used to optimize model performance. Two calibration models were developed 
for each API, one from the 225 tablets of the full factorial design and another from the 33 tablets 
of the spectral design. Models developed from each calibration design were independently 
optimized for each API. The processing techniques and loading vectors were selected 
independently. Selection of the loading vector is critical for PLS model performance. Latent 
variables were chosen based on a parsimonious approach. A minimum number of latent variables 
with an acceptable performance level was selected. Model performance was assessed based on 
the prediction of Acetaminophen and Caffeine concentration in calibration and test set tablets. 
3.3.1.7 Model evaluation and design comparison parameters 
Comparison of the performance of different calibration designs requires the evaluation of the 
resulting models. Root mean squared error (RMSE) was used to evaluate the model predictive 
performance in an independent test sets (RMSEP). A two-way analysis of variance (ANOVA) 
test was performed to compare the prediction errors of the full factorial and spectral calibration 
designs for each API [22]. The underlying model for the ANOVA analysis was following, where 
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index ‘i’ refers to the calibration model and index ‘j’ refers to the sample number. The symbol 𝛼𝛼𝑖𝑖 
and 𝛽𝛽𝑗𝑗 refer to the effect of model number i and sample number j on prediction error, 
respectively.  
 (𝑑𝑑�𝑖𝑖𝑗𝑗 − 𝑑𝑑𝑖𝑖𝑗𝑗)2 =  𝜇𝜇 + 𝛼𝛼𝑖𝑖 + 𝛽𝛽𝑗𝑗 + 𝑡𝑡𝑖𝑖𝑗𝑗 (3.8) 
The calibration models are considered significantly different in terms of prediction performance, 
if the calibration model parameter 𝛼𝛼 is found to be significant in the ANOVA analysis.  
Robustness of the calibration models from respective calibration designs were tested based on 
cross design prediction. During cross design prediction, calibration model was developed from 
spectral calibration set and used to predict the API concentration in traditional calibration sets. 
Subsequently, calibration models were developed traditional calibration sets and used to predict 
the API concentration in spectral calibration set. The objective was to assess the prediction 
performance of a calibration model in presence of new test structure. Robustness of the 
calibration model was tested for both Acetaminophen and Caffeine PLS model. 
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Figure 3-8. Quantitative predictions of NIR images of tablet at target formulation and 
center compaction force.   
 
3.3.2 Results and Discussion 
3.3.2.1 Experimental control 
Figure 3-8 shows the quantitative predictions of APAP and caffeine at both sides of the tablet 
prepared at the target formulation and center compaction force. The quantitative results were 
obtained from the NIR images of the tablet and CLS model of the pure component images. It was 
shown that the APAP and caffeine were homogeneously distributed in the tablet. The red circle 
shows the spot size (10 mm) of the NIR diffuse reflectance measurement. It was shown that the 
NIR diffuse reflectance measurement reflects majority of the tablets due to large spot size. The 
criticality of the intra tablet homogeneity was minimized by such large spot size. 
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Figure 3-9. Solid fraction of tablets compressed at different compaction forces.   
Figure 3-9 shows the solid fraction measurements of 75 tablets at each compaction force. The 
compaction force range (4000 lb-6000 lb) results in a wide range of solid fraction (0.83-0.92). 
This range of solid fraction was able to produce wide range of spectral variation related to tablet 
density.  
3.3.2.2 Calibration design comparison between full factorial and spectral calibration sets 
Figure 3-10 shows the tablet compositions for the traditional full factorial calibration design, 
spectral calibration design and test design. The resultant compositions from the spectral design 
approach contained similar ranges of Acetaminophen and Caffeine concentrations. Spectral 
design had wider range of excipient variation compared to the traditional full factorial design. 
The wider excipient ranges were the result of distant design points in the target score space, that 
could only be obtained by large variation in the excipient concentrations. Although wide 
concentration range is considered to increase calibration model robustness, it can introduce non-
linearity and affect prediction performance. Good fit is almost guaranteed for a small set with 
Compaction force (lb)
4000 4500 5000 5500 6000
S.
F.
0.82
0.84
0.86
0.88
0.9
0.92
0.94
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narrow region. Moreover, a typical production batch is manufactured at the target composition 
and large excipient variation is not expected. So, it is recommended to use two calibration sets, 
one for coarse prediction of concentration (global calibration set) and the other for precise and 
accurate prediction in the critical range (local calibration set). This technique is known as 
bracketing [47]. However, maintaining two calibrations and selecting which one to use is 
challenging. A single robust calibration capable of predicting at the critical range would be 
advantageous over the bracketing technique. In this study, spectral calibration set containing 
large excipient variation was tested for the critical range prediction around target composition. 
Successful model performance from the spectral calibration set would offer a single calibration 
set with sufficient robustness and accuracy. 
 
 
Figure 3-10. Tablet compositions of the traditional full factorial calibration, the spectral 
calibration and the test set. 
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3.3.2.2.1 Prediction performance 
The calibration models from the full factorial and spectral design were used to predict the 
Acetaminophen and Caffeine concentrations in the prediction set. 
3.3.2.2.1.1 Acetaminophen prediction 
 
 
Figure 3-11. Calibration model performance for traditional full factorial design during 
Acetaminophen prediction 
Figure 3-11 shows the calibration performance of the traditional full factorial design for 
Acetaminophen prediction in the calibration and test set. Figure 3-11 (right) shows the projection 
of the calibration and test samples on the first two loading vectors of the PLS model. The 
calibration set and test set had similar spectral variance as indicated by their similar projections 
on the first two loading vectors. The calibration set had wider range of scores on LV2 compared 
to the test set. This effect was attributed to the wide excipient variation present in the calibration 
set.  
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Figure 3-12. Calibration model performance for spectral design during Acetaminophen 
prediction 
The RMSEP for the traditional Acetaminophen calibration was around 1% (w/w) and no 
significant bias was observed during prediction. Figure 3-12 shows the calibration performance 
of the spectral design for Acetaminophen prediction in the calibration and test set. The score plot 
(Figure 3-12 (right)) shows similar projections of the calibration and test set on LV1 and 
different projections on the LV2. However, this difference in the scores on LV2 did not affect the 
prediction performance due to compensating effect of LV4 on the opposite direction (data not 
shown). The information in LV2 and LV4 was majorly attributed to the wide range of excipient 
variation in spectral calibration set. The RMSEP was 0.83% (w/w) and no significant bias was 
observed. The prediction errors of the full factorial and spectral calibration design for 
Acetaminophen prediction was found to be similar in the ANOVA analysis (p value 0.1968). 
Table 3-4 provides the details of the calibration models developed from traditional full factorial 
and spectral design. 
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3.3.2.2.1.2 Caffeine prediction 
Figure 3-13 shows the calibration performance of the traditional full factorial design for Caffeine 
prediction in the calibration and test set. The calibration set and test set had similar spectral 
variance; indicated by their similar projections on the first two loading vectors as shown in 
Figure 3-13 (right). The score ranges were similar in both latent variable directions as opposed to 
the scenario in the Acetaminophen prediction model. 
 
Traditional 
(225 samples) 
Spectral 
(33 samples) 
Preprocessing techniques 
X block 
Y block 
 
MSC*, Auto scale 
Auto scale 
 
MSC*, SG (15,2,1)**, Auto scale 
Auto scale 
LV 6 4 
RMSEC (% w/w) 0.829 1.092 
RMSECV (% w/w) 0.867 1.336 
RMSEP (% w/w) 0.982 0.832 
Bias (% w/w) 0.221 0.115 
R2 Calibration 0.991 0.973 
R2 Prediction 0.989 0.991 
p values (ANOVA)  0.1968 
Table 3-4.  Model performance comparison between full factorial and spectral 
calibration design for quantitative analysis of Acetaminophen 
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Figure 3-13. Calibration model performance for traditional full factorial design during 
Caffeine prediction 
This effect was attributed to the similar ranges of APIs (Acetaminophen and Caffeine) 
concentrations between the calibration and test set. The first two loading vectors primarily 
explained the direction of variation in Caffeine concentrations even at low dose, due to 
maximization of covariance between spectra and Caffeine concentrations. These loading vectors 
also explained the direction of variation in Acetaminophen concentrations due to its unique 
spectral feature and relatively large dose. The RMSEP for the traditional Caffeine calibration was 
0.41% (w/w) and no significant bias was observed during prediction. Figure 3-14 shows the 
calibration performance of the spectral design for Caffeine prediction in the calibration and test 
set. Similar trend in the score plot Figure 3-14 (right)) was observed as compared to the 
traditional calibration design. The first two loading vectors primarily explained the direction of 
the variation in APIs concentrations. The RMSEP was 0.41% (w/w) and no significant bias was 
observed. The prediction errors of the full factorial and spectral calibration design for Caffeine 
prediction were found to be similar in the ANOVA analysis (p value 0.9527). Table 3-5 provides 
the details of the calibration models developed from traditional full factorial and spectral design. 
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Figure 3-14. Calibration model performance for spectral design during Caffeine prediction. 
3.3.2.2.2 Discussion 
The main objective of this project was to develop and test a spectral design method and compare 
it with a traditional full factorial design method for NIR spectroscopic multivariate calibration 
for multiple API system. The use of a traditional design such as full factorial in concentration 
space is a common practice for calibration sample preparation. However, this practice is 
inefficient and provides redundant information to the calibration model. This effect is 
exacerbated for the tablets containing multiple API. The spectral design approach offers an 
efficient enhancement for NIR calibration development by using pure component spectra. 
Information about the pure component spectra defined an orthogonal spectral space for the 
formulation and was used to identify a set of critical samples with necessary compositional 
variation for successful calibration model development. 
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Variation in the physico-chemical properties of the tablet (tablet density) was also added into this 
study as a potential source of variation for NIR analysis of tablets. The objective was to test the 
performance of the spectral calibration design technique in presence of physical variation. 
Physical variation was added into the spectral design by minimizing correlation between 
composition and compaction pressure to maximize design orthogonality. Physical variation can 
also be added into the spectral space by compressing pure components using different 
compaction forces. While this effort helps to build robustness against density variation, effect of 
 
Traditional 
(225 samples) 
Spectral 
(33 samples) 
Preprocessing techniques 
X block 
Y block 
 
MSC*, Auto scale 
Auto scale 
 
MSC*, SG (15,2,1)**, Auto 
scale 
Auto scale 
LV 6 6 
RMSEC (% w/w) 0.394 0.261 
RMSECV (% w/w) 0.410 0.473 
RMSEP (% w/w) 0.406 0.411 
Bias (% w/w) 0.087 0.232 
R2 Calibration 0.971 0.991 
R2 Prediction 0.976 0.979 
p values (ANOVA)  0.9527 
Table 3-5.  Model performance comparison between full factorial and spectral 
calibration design for quantitative analysis of Caffeine 
  112  
tablet density variation on NIR spectra were also minimized by preprocessing techniques (scatter 
correction and derivatives). Both spectral and traditional calibration models were found to be 
robust against density variation. However, density variation was added more efficiently in the 
spectral design technique (minimizing correlation) compared to the traditional full factorial 
technique (replicating each design at different compaction forces). 
Designing a calibration sample set in spectral space was found to be an efficient approach for 
developing a NIR calibration method for tablets containing multiple API. Fewer samples were 
required when this approach was used. A reduction of 85% in raw material requirement was 
demonstrated (33 vs 225 samples) while achieving similar predictive performance compared to 
the traditional full factorial design. 
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Figure 3-15. Tablet compositions of the spectral and traditional calibration designs (filled 
circles), and the test set (open circles) 
3.3.2.3 Calibration design comparison between optimal and spectral calibration sets 
Figure 3-15  shows the tablet compositions for the spectral and traditional designs along with the 
test set compositions. The CCD design had maximum resemblance with the test set design. The 
other designs have wider range of excipient variation compared to the CCD and test design. The 
wide excipient range in the spectral design and traditional optimal designs (D-Optimal and I-
Optimal) were incorporated to maximize the spectral variance and concentration variance, 
respectively. 
3.3.2.3.1 Prediction performance 
The calibration models from the optimal designs and spectral design were used to predict the 
concentration of Acetaminophen and Caffeine in the prediction set. 
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3.3.2.3.1.1 Acetaminophen prediction 
 
Figure 3-16. Calibration model performance of the spectral design and traditional designs 
during Acetaminophen prediction. 
 
Figure 3-16 shows the calibration performance of the traditional and spectral calibration designs 
for Acetaminophen prediction in the calibration and test set. The traditional calibration sets 
(CCD, D-Optimal and I-Optimal) and test set had similar spectral variance as indicated by their 
similar projections on the first two loading vectors. For the spectral design, the score plot shows 
similar projections of the calibration and test set on LV1 and different projections on the LV2. 
Large excipient variation in the spectral design could contributed to the score differences. 
However, this difference in the scores on LV2 did not affect the prediction performance due to 
its small weight coefficients and minimal contribution to the regression vector and prediction. 
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The ascending order of the prediction error of Acetaminophen (RMSEP) was Spectral design < 
CCD < D-Optimal < I-Optimal. 
 
Figure 3-17. Calibration model performance of the spectral design and traditional designs 
during Caffeine prediction. 
3.3.2.3.1.2 Caffeine prediction 
Figure 3-17 shows the calibration performance of the traditional and spectral calibration designs 
for Caffeine prediction in the calibration and test set. All the calibration sets and the test set had 
similar spectral variance as indicated by their similar projections on the first two loading vectors. 
The score ranges were similar in both latent variable directions as opposed to the scenario in the 
Acetaminophen prediction model. This effect was attributed to the similar range of APIs 
(Acetaminophen and Caffeine) concentrations between the calibration and test sets. The first two 
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loading vectors primarily explained the direction of variation in Caffeine concentrations even at 
low dose, due to maximizing the covariance between spectra and Caffeine concentrations. These 
loading vectors also explained the direction of variation in Acetaminophen concentrations due to 
its unique spectral feature and relatively large dose. The ascending order of the prediction error 
of Caffeine (RMSEP) was CCD < Spectral design < D-Optimal < I-Optimal. 
 
Figure 3-18. Cross design performance of acetaminophen model (left) and caffeine model 
(right) 
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3.3.2.3.1.3 Assessment of model robustness 
Model robustness was assessed by cross design prediction. The calibration model developed 
from spectral calibration set was found to be more robust than the calibration models developed 
from optimal calibration sets. The robustness between spectral and full factorial calibration set 
was found to be similar. Figure 3-18 shows the results of the cross design prediction for both 
Acetaminophen (left) and Caffeine (right). The blue bars indicate the prediction errors of the 
spectral calibration model while predicting API in traditional calibration sets. The yellow bars 
indicate the prediction errors of the traditional calibration model while predicting API in spectral 
calibration. The spectral calibration model showed prediction errors similar to the full factorial 
calibration model in spite of having fewer sample number (33 vs 225). The full factorial 
calibration model was trained with larger sample size resulting in a robust calibration model. The 
prediction error was relatively low when a different test structure (spectral calibration set) was 
presented in front of the calibration model. The spectral calibration set was robust due to its wide 
range of spectral variation built into the calibration set. The CCD and I-optimal calibration 
models showed poor prediction performance for both Acetaminophen and Caffeine when a 
different test structure (spectral calibration set) was presented. D-optimal calibration model 
showed poor prediction performance while predicting Caffeine concentration in spectral 
calibration set. The spectral calibration model showed reasonable prediction performance while 
predicting Acetaminophen and Caffeine in all of the traditional calibration sets (Full factorial 
(FFT), CCD, I-optimal and D-optimal) indicating model robustness against different types of test 
set structure as shown in Figure 3-18. 
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3.3.2.3.2 Discussion 
The main objective of this project was to develop and test a spectral design method and compare 
it with traditional calibration design methods for NIR spectroscopic multivariate calibration for 
multiple API system. Table 3-6 provides the calibration performances of the spectral and 
traditional designs for Acetaminophen and Caffeine. Spectral design and CCD were found to 
outperform the optimal designs in terms of prediction performance. The use of a traditional 
design in concentration space is a common practice for calibration sample preparation. However, 
this practice is inefficient and provides redundant and deleterious information to the calibration 
model as seen in the case of D-Optimal and I-Optimal design.  
 
Acetaminophen prediction Caffeine prediction 
 
Spectral CCD D-Opt 
I- 
Opt Spectral CCD 
D-
Opt 
I- 
Opt 
RMSEC 1.092 1.187 0.758 0.611 0.260 0.286 0.335 0.368 
RMSECV 1.336 1.381 1.004 0.882 0.473 0.345 0.456 0.513 
RMSEP 0.832 0.893 1.050 1.110 0.410 0.379 0.463 0.481 
Bias 0.115 0.259 0.085 0.484 0.232 0.090 0.084 0.174 
R2 Cal 0.973 0.967 0.993 0.995 0.991 0.971 0.977 0.974 
R2 Pred 0.991 0.991 0.987 0.988 0.979 0.977 0.967 0.975 
Table 3-6. Calibration performance of spectral and traditional calibration designs 
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The optimality in the concentration space does not guarantee optimality in the spectral space. 
This effect is exacerbated for the tablets containing multiple API. In multiple API formulation, 
two individual APIs might have respective optimal design spaces that are very different from 
each other. However, in the optimal concentration based design, the optimality is defined in a 
single compositional space and same weightages are used for all chemical components including 
APIs and excipients to generate the optimality criterion (e.g. levels 1,2,3… to calculate D-
optimal or I-optimal criterion). The resultant design points of concentration based optimal design 
are only indicative of optimal compositional structure but lack critical information specific to 
APIs. 
The improved performance of the CCD calibration set compared to the other optimal calibration 
sets emphasizes the importance of similarity between calibration and prediction set structures. 
The calibration model provides improved prediction performance when it encounters known 
information in the prediction set. The CCD calibration model was trained on the information that 
was available in the prediction set, resulting in improved performance. However, such similarity 
is not always guaranteed. The calibration model from CCD calibration set showed poor 
prediction performance when a different test structure (spectral calibration set) was presented 
during cross design prediction for both Acetaminophen and Caffeine. Although the 
recommendation is to include all anticipated variations into the calibration set, there is always a 
possibility for the calibration set to encounter new information in the prediction set during model 
life cycle. It is advantageous to practice robust modelling technique instead of anticipating 
similarity between calibration and prediction set during calibration development. 
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3.3.3 Conclusion 
A technique for designing a calibration set for NIR spectroscopic calibration method for tablets 
containing multiple API was described and tested. The pure component spectral information of 
the tablet was used to develop a spectral design method to design the critical calibration samples 
necessary for desired prediction performance. The spectral design strategy was found to be 
efficient in terms of sample requirements compared to the traditional full factorial technique. A 
reduced number of calibration samples yielded a model of similar predictive capabilities for both 
APIs. The spectral design strategy was found to provide better performance compared to the 
traditional optimal designs such as D-optimal and I-optimal designs. The spectral design strategy 
was found to provide similar prediction performance compared to the CCD design. Overall, the 
spectral design approach offers an efficient enhancement for the NIR calibration development for 
pharmaceutical tablets. 
This approach has the potential to be useful for other tablet formulations and spectroscopic 
techniques. Infrared, Raman and THz spectroscopy have been used frequently to develop 
quantitative method for pharmaceutical tablets. Spectral design strategy can be useful to 
minimize the calibration sample requirements for such techniques.  
PLS modeling technique was used in all comparatives studies. Selecting the appropriate number 
of loading vector is a critical step during PLS model development. Appropriate number of 
loading vector is critical to define the model variance space. The current strategies for selecting 
the appropriate number of loading vector include cross-validation and total variance techniques. 
However, these techniques were unable to select the appropriate number of loading vector for 
traditional PLS model in section 3.2.1 for single API formulation. The poor model performance 
was due to inappropriate number of loading vector in the PLS model.  A new strategy was 
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developed to select the appropriate number of loading vector based on weight co-efficient 
technique. This strategy was tested on multiple NIR dataset. The details of the new method and 
its performance are provided in the next chapter.  
An improved prediction performance with lower RMSEPs was achieved from the traditional PLS 
model for single API formulation following the new method of loading vector selection 
(RMSEP2: 2.21 vs 4.68 and RMSEP3: 1.43 vs 5.05). The improved performance was found to 
be similar to the spectral design calibration model (RMSEP2: 2.21 vs 2.21 and RMSEP3: 1.43 vs 
1.68). Spectral design was considered to be efficient considering its fewer sample requirement 
(11 vs 45) compared to the traditional calibration design.  
Selecting the appropriate number of loading vector was critical to find the optimum calibration 
models and compare the respective calibration strategies. The weight based co-efficient 
technique was found to be an efficient alternative to the current loading vector selection 
techniques. The following chapter discusses this technique in further details. 
 
 
 
 
 
 
 
Copyright ©: Part of this chapter has been reprinted from [175]. Copyright clearance is provided 
at the end the dissertation. 
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4 Chapter 4: Selecting loading vector for PLS model during quantitative analysis of 
tablets using NIRS 
4.1 Introduction 
NIR spectroscopy is a well-established analytical tool in the pharmaceutical industry for 
quantitative analysis of tablets [1-3, 5]. It is fast, non-destructive and requires little or no sample 
preparation. However, successful implementation of this technique requires analytical insight 
and chemometric tools to analyze the complex dataset. The broad overtones and combination 
vibrations in the NIR region are very difficult to assign to a specific chemical feature. Besides, 
NIR spectra are very sensitive to both physical and chemical properties of the samples [47, 135, 
178, 179]. A quantitative model developed to extract the chemical information from the tablet 
spectrum is often affected by different sources of variations such as physical, chemical, scale, 
instrumental and environmental variations during tablet analysis. Batch-to-batch variation in the 
raw material properties such as particle size distribution of the granules and excipients, different 
vendors of the same excipient leading lot to lot variation, polymorphic conversion of the API and 
excipients during the manufacturing steps, all serve as potential sources of physico-chemical 
variation in the samples affecting NIR model performance. Environmental variations such as 
differences in relative humidity between different batches also affect NIR model performance. 
Difference in the scales of tablet preparation is a very common source of variation in the NIR 
spectra. It is quite possible for the analyst to develop a calibration model at one scale during the 
product development phase and intent to predict samples throughout the product life cycles from 
a different scale. A robust NIR model is critical to encounter such scale variations. In addition to 
table manufacturing scale, relative tablet density of the tablet have significant impact on NIR 
spectra [112]. Variation in the tablet density serves as a potential source of spectral variance. It is 
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also possible for the API in tablets to undergo degradation and produce degradants during its 
shelf life. The presence of a new chemical entity such as a degradant in the sample, can affect 
NIR model performance. Similar spectral features of the API and degradant can have detrimental 
effect on model selectivity. All these types of variation have the potentials to affect spectral 
shapes and thereby NIR model performance. So, model robustness has long been discussed as a 
critical merit during quantitative analysis using NIR spectroscopy [38, 54].  
Special pre-processing techniques and multivariate calibration methods are often employed to 
develop robust modeling technique and extract desired information from the NIR spectra [180-
182]. Besides, the analyst seeks to include as much variance as possible in the calibration step to 
train the model against all possible variances within defined scopes of drug product, NIR 
instrument and measurement environment that are forthcoming [183]. While, it is often 
impossible to forecast all the possible variances at the outset of calibration development, 
updating a calibration model with the newly encountered variance is a well-established practice 
[184]. Calibration update is a slow process and requires re-validation. Moreover, it is often 
difficult to get modification of an already approved method from the regulatory agencies [185]. 
So, it is desired to undertake the most robust modeling approach at the outset of calibration. 
Partial Least Squares (PLS) is a widely used chemometric modeling technique used for 
quantitative analysis. PLS is used to develop a quantitative model in the calibration step that can 
be used to predict any future samples. A critical step during PLS model development is the 
selection of optimum number of loading vectors (model components) [186]. A parsimonious 
approach is frequently undertaken for this purpose. The minimum number of loading vector with 
acceptable model performance is selected to mitigate the model complexity and prevent over 
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fitting of the calibration model. Cross-validation technique is mainly employed to indicate the 
model over fitting and select the optimum number of loading vectors for the model development 
[187]. In addition to the cross-validation error, the amount of spectral and concentration variance 
explained by each loading vector is also considered during the selection process.    
There are various cross-validation techniques including random subset, venetian blinds, 
contiguous blocks etc. However, all these techniques describe the error rate only in the 
calibration subspace. These techniques cannot anticipate model predictive ability in any future 
data set bringing new information to the calibration. The current techniques of cross-validation 
may fail to indicate the optimum number of loading vector to develop the most robust model at 
the outset of calibration development.  In this study, a new method using the weight coefficient 
of each loading vector is proposed during calibration development of a pharmaceutical tablet. 
This method was tested to develop a calibration model robust against scale variation, 
environmental variation, physico-chemical variation, chemical variation and raw material 
variation. The robustness of the calibration model was compared with a traditionally built 
calibration model using current cross-validation techniques. The new weight coefficient based 
method was demonstrated to be more efficient than the current cross-validation techniques to 
develop the most robust model at the outset of calibration development.  
4.2 Theory 
A quantitative spectroscopic calibration model is developed to quantify physico-chemical 
properties of a sample from its respective spectrum using regression model. For a system with 
“m” samples and “n” spectral variables (wavelengths), the regression model is as follows, 
 𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗𝐦𝐦∗𝐧𝐧 ∗ 𝐛𝐛𝐧𝐧∗𝟏𝟏 (4.1) 
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Here, “𝒚𝒚�” is the predicted physico-chemical property, “X” is the spectral data matrix and “b” is 
the regression vector. Concentration will be considered as an example of physico-chemical 
property in rest of the chapter. 
In PLS, spectral data (X) and concentration data (y) are decomposed into scores and loading 
vectors. The loading vectors describe the covariance structure between the spectra and 
concentration. The scores serve as a metric for spectral variance of the individual sample in the 
direction of the respective loading vectors. The details of the PLS theory is discussed elsewhere 
[188]. 
 𝐗𝐗𝐦𝐦∗𝐧𝐧 = 𝐓𝐓𝐦𝐦∗𝐤𝐤 ∗ 𝐏𝐏𝐧𝐧∗𝐤𝐤′  (4.2) 
 𝐘𝐘𝐦𝐦∗𝐏𝐏 = 𝐔𝐔𝐦𝐦∗𝐤𝐤 ∗ 𝐐𝐐𝐏𝐏∗𝐤𝐤′  (4.3) 
Here, “T” and “U” are the scores of the spectral matrix “X” and concentration matrix “Y” 
respectively and “k” is the number of loading vectors and weight vectors to be included into the 
model. “P” and “Q” are the loading vectors for “X” and “Y” as well. For a single predictor, the 
concentration matrix “Y” is a vector and does not need to be decomposed.  
NIPALS is a widely used algorithm in PLS model development [189]. In NIPALS, the loadings 
and scores are iteratively solved. The first loading “P” indicates the primary direction of 
covariance between spectra and concentrations, and the first set of scores “T” indicates the 
projections of samples into that “P” direction. The second loading vector indicates the direction 
of maximum covariance between the residual spectra and residual concentration after spectral 
reconstruction with the first loading vector. The third loading vector indicates the same after 
spectral reconstruction with the first and second loading vector. Once the number of loading 
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vector is fixed, the regression model of Eq (4.1) is developed by calculating the regression vector 
as follows,[190] 
 
 𝐛𝐛𝐧𝐧∗𝟏𝟏 = 𝐖𝐖𝐧𝐧∗𝐤𝐤 ∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧′ ∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤)−1 ∗ (𝐓𝐓𝐤𝐤∗𝐦𝐦′ ∗ 𝐓𝐓𝐦𝐦∗𝐤𝐤)−1 ∗ 𝐓𝐓𝐤𝐤∗𝐦𝐦′ ∗  𝐲𝐲𝐦𝐦∗𝟏𝟏 (4.4) 
 
Here, “W” is the weight vectors expressing both the “positive correlation” between spectral 
matrix “X” and concentration matrix “Y” and the “compensation correlation” needed to predict 
“Y” from “X” clear from the secondary variation in “X” [191]. In the PLS toolbox from 
Eigenvector Research Inc., the weight vector “W” is expressed as “W*”, 
 𝐖𝐖𝐧𝐧∗𝐤𝐤∗ = 𝐖𝐖𝐧𝐧∗𝐤𝐤 ∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧′ ∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤)−1 (4.5) 
which provides the same information as “W”. So, Eq 4.5 can be written as, 
 𝐛𝐛𝐧𝐧∗𝟏𝟏 =  𝐖𝐖𝐧𝐧∗𝐤𝐤∗ ∗ (𝐓𝐓𝐤𝐤∗𝐦𝐦′ ∗ 𝐓𝐓𝐦𝐦∗𝐤𝐤)−1 ∗ 𝐓𝐓𝐤𝐤∗𝐦𝐦′ ∗  𝐲𝐲𝐦𝐦∗𝟏𝟏 (4.6) 
 
 𝐛𝐛𝐧𝐧∗𝟏𝟏 =  𝐖𝐖𝐧𝐧∗𝐤𝐤∗ ∗ 𝐛𝐛𝐤𝐤∗𝟏𝟏 (4.7) 
Here, “s” is considered as the weight coefficients and “k” is the number of loading vector to be 
included in the PLS model. The same weight coefficient is also used in the prediction equation as 
follows (replacing “b” in Eq 4.1, 
 𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐓𝐓𝐦𝐦∗𝐤𝐤 ∗ 𝐛𝐛𝐤𝐤∗𝟏𝟏 (4.8) 
In a PLS model, each weight vector, its associated loading vector and scores are associated with 
a weight coefficient which can serve as a metric for its contribution in regression vector 
calculation (Eq (4.7)), as well as in prediction equation (Eq (4.8)). 
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Optimum selection of the loading vector number “k” is critical for model performance. 
Traditional methods for selecting “k” involve either one of the two approaches or both: 
1. Root Mean Squared Error of Calibration (RMSEC) and Root Mean Squared Error of 
Cross Validation (RMSECV) at each loading vector and weight vector inclusion into 
the model. 
2. Variance explained by each loading vector during the model development. 
However, these two techniques have the potential to fail in selecting the appropriate number of 
loading vectors to develop a robust PLS model at the outset of calibration development. The new 
method uses the weight coefficients “s” as the basis for selecting appropriate number of loading 
vector “k” to be included into the model. It uses the weight coefficients ‘s’ for isolating loading 
vectors that explain a small percent of the spectral and concentration variance while having high 
influence (high weight coefficient) in the regression vector calculation and prediction equation. 
Inclusion of such loading vectors can be detrimental to the model performance, because such 
inclusion tends to over fit the model towards a direction that explains minimal spectral and 
concentration variations. Overfitting model towards irrelevant information can affect model 
specificity and prediction performance.  
According to the new weight coefficient based method, any weight coefficient larger than the co-
efficient of the maximum variance explaining loading vector (often the first one) was considered 
inappropriately high and PLS model was developed with the preceding loading vectors. If ‘nth’ 
weight co-efficient is higher than the co-efficient of the maximum variance explaining loading 
vector, the optimum number of loading vectors was considered to be “n-1” according to the 
weight coefficient based method. 
  128  
In the traditional method, PLS models were developed following the current two techniques for 
selecting the optimum number of loading vector. In the new weight coefficient based method, 
PLS model was developed using the weight coefficient along with the associated percent of 
variance explained by each loading vector. The performances of the new and old methods were 
compared in selecting the optimum number of loading vectors and developing the most robust 
PLS model at the outset of calibration development. 
4.3 Material and Methods 
Five different datasets were used to test the NIR model robustness against different types of 
critical variations including scale variation, environmental variation, physical variation, chemical 
variation and raw material variation. The details of the dataset are given below  
4.3.1 Scale Variation 
The scale variation test was designed to analyze and compare model performance between the 
traditional method and new weight coefficient based method while predicting Acetaminophen 
concentrations in tablets prepared at different scales. The calibration set was prepared at 
laboratory scale while the prediction set was prepared at manufacturing scale. The calibration 
design was a 5 by 3 level, 2-factor full factorial design to make 45 tablets. The prediction set was 
prepared over consecutive eight weeks at the label claim. 20 tablets collected from every week’s 
run resulted in a total of 160 tablets in prediction set. These samples are the same samples as 
traditional calibration set and prediction set 3 for single API. The details of the experimental 
method are described in section 3.2.1.1 (calibration set) and 3.2.1.5 (prediction set). 
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4.3.2 Environmental Variation 
The environmental variation test was designed to analyze and compare model performance 
between the traditional method and new weight coefficient based method while predicting 
Acetaminophen concentrations in tablets prepared in different environmental conditions. The 
calibration set was prepared in the winter (November, 2012) whereas the prediction set was 
prepared in the summer in 3 consecutive months (May, June and July 2013).  
The same calibration set mentioned in the scale variation test was used for calibration model 
development. A 3 by 1 level full factorial design was used to generate the monthly prediction 
sets. The factors of the design were kept same as in the calibration and the levels were inside the 
calibration range. A set of 20 tablets at each design point resulted in a total of 60 tablets for each 
month’s prediction set. The tablets were prepared at the manufacturing scale in the same fashion 
described in the scale variation section in section 4.3.1. 
 
4.3.3 Physical Variation (Density) 
The density variation test was designed to analyze and compare model performance between the 
traditional method and new weight coefficient based method while predicting Theophylline 
concentrations in tablets of different densities. The capability of these two methods in selecting 
the optimum number of loading vector were compared during calibration development and 
calibration update. A previously published dataset was used for this purpose [112]. 
A fully balanced, quaternary mixture design comprising of Theophylline anhydrous, Lactose 316 
Fast Flo Monohydrate, Microcrystalline cellulose and soluble starch was generated. A set of 29 
design points was chosen to cover a wide range of all constituents. At each design point, five 
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tablets were compressed at five compaction pressures (67.0, 117.3, 167.6, 217.8, and 268.1 MPa) 
on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) using a 13-mm 
die and flat-faced punches. One additional tablet was also compressed at each design point, with 
a compaction pressure chosen pseudo-randomly from the five levels resulted in a total of 174 
tablets. This calibration set was divided into five groups (Cal 01 to Cal 05) based on the 
compaction pressure levels. The first group contained samples compacted at 67.0 MPa, while the 
second group contained samples compacted at both 67.0 and 117.3 MPa, and subsequently, the 
fifth group contained samples compacted at all five compaction pressures. The primary 
calibration was developed only using samples compacted at 67.0 MPa and then the calibration 
set was updated by samples compacted at different compaction levels.  
The same quaternary design was used to create a test set. At each design point, two tablets were 
compressed at two randomly chosen compaction pressure out of five (67.0, 117.3, 167.6, 217.8, 
and 268.1 MPa) using a Carver Automatic Tablet Press. A total of 58 samples were prepared in 
the test set and used for assessing the prediction performance of all the models prepared in the 
calibration step. Tablet density was measured for each compact and solid fraction was calculated. 
A wide range of solid fraction (0.8 – 0.98) was reported along the range of the compaction forces 
[112]. 
The performance of the traditional method and new weight coefficient based method were 
compared in selecting the appropriate number of loading vectors for the models developed from 
these five calibration sets (primary and updated sets).  
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4.3.4 Chemical Variation (Degradant) 
The chemical variation test was designed to analyze and compare the model performance 
between the traditional method and new weight coefficient based method while predicting 
Niacinamide concentration in tablets prepared with and without its degradant Niacin. The 
calibration set was prepared using samples containing Niacinamide and excipients including 
starch, Microcrystalline cellulose (MCC), Di-tab and Magnesium stearate. The prediction set was 
prepared using samples containing Niacinamide, Niacin and excipients including starch, 
Microcrystalline cellulose (MCC), Di-tab and Magnesium stearate. 
The Niacinamide concentration was varied at 7 levels in the calibration set while keeping the 
excipients ratios (starch:MCC:Di-tab) constant. The concentration of Magnesium stearate was 
kept constant at 1%. The nominal target tablet weight was 500 mg. 
At each design point, 5 gm samples mixture was prepared and placed in a 15 ml scintillation vial. 
The samples were mixed by placing the vial in a bin blender and rotating for 15 minutes. At each 
design point, three tablets were compressed from the same mixture on a Carver Automatic Tablet 
Press (Model 3887.1SD0A00, Wabash, IN, USA) at 5000 lb. using a 13-mm die and flat-faced 
punches.  
A 3 by 3 levels, two-factor full factorial design was used to prepare the test set. The factors were 
Niacinamide concentration and Niacin concentration. At each design point, 3 tablets were 
compressed in the same fashion as mentioned earlier. Out of the total of 27 tablets, tablets from 
one design point were damaged leaving 24 tablets in the test set. The test set was subdivided into 
three sets based on the degradant (Niacin) concentration.  
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4.3.5 Raw Material Variation 
The raw material variation test was performed on a previously published dataset to analyze and 
compared model performance between the traditional method and new weight coefficient based 
method while predicting Theophylline concentration in tablets prepared with different raw 
material properties [164]. The calibration set was prepared with a specific polymorph of API as 
Theophylline anhydrous, a specific particle size distribution of Lactose as 100 microns and a 
specific source of starch as EMD Chemicals. The prediction set was prepared using a different 
polymorph of API as Theophylline monohydrate, different particle size distribution of Lactose as 
50 micron and different vendor of starch as Acros Organics.  
A fully balanced, quaternary mixture design comprising of Theophylline anhydrous, Lactose 316 
Fast Flo Monohydrate, Microcrystalline cellulose and soluble starch was generated. A set of 29 
design points were chosen to cover a wide range of all constituents. At each design point, 2 
tablets were compressed at 2 randomly selected pressures out of five (67.0, 117.3, 167.6, 217.8 
and 268.1 MPa) on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) 
using a 13-mm die and flat-faced punches. In total, 58 tablets were compressed for calibration set 
with a target weight of 800 mg. 
A 2 by 2 by 3 levels, three-factor full factorial design was used to prepare the test set at a single 
composition inside the calibration range. The factors were selected as API polymorphs, sources 
of starch and Lactose particle size distributions to ensure different types of raw material 
variability in the test set. All the tablets were compressed at 167.6 MPa using the same setup as 
calibration. At each design point, 3 tablets were compressed, resulted in a total of 36 tablets. 
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The test set was subdivided into three sets based on the difference with calibration set in raw 
material properties. The first set was comprised of all the samples containing Theophylline 
monohydrate, second set comprised of all the samples containing Lactose of 50 microns particle 
size distribution and third set comprised of all the samples containing starch from vendor 2 
(Acron Organics).   
4.3.6 Spectral collection 
NIR reflectance measurements for both sides of each compact were collected using a bench top 
scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc., 
Laurel, MD, USA).  Spectra were collected over the wavelength range of 400 – 2,500 nm at 0.5-
nm increments, averaging 32 co-adds per spectrum.   Spectra corresponding to each side of a 
compact were averaged to give one representative spectrum per compact. 
4.3.7 Modeling strategy 
All calculations were performed with MATLAB 2015a (The Mathworks, Natick, MA, USA) 
equipped with a PLS Toolbox v. 7.9.4 (Eigenvector Research Inc., Wenatchee, WA, USA). 
4.3.8 Cross validation 
PLS Toolbox was used to implement 3 different cross-validation techniques as random subset, 
contiguous block and venetian blind. For each technique, the data set was divided into 3 different 
ways to remove the aliasing effect between data subset and cross-validation error. The details of 
the cross-validation technique using PLS toolbox can be found elsewhere [192]. 
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4.3.9 Model evaluation and design comparison parameters 
The root mean squared error (RMSE) was used to evaluate model predictive performances in the 
calibration (RMSEC), cross-validation (RMSECV) and prediction (RMSEP) sets.  
 RMSE =  �∑ (ŷ − 𝑑𝑑)2𝑛𝑛1
𝑛𝑛
 ;    (4.9) 
 
 
 
 
 
Figure 4-1. RMSECs and random subset (left), contiguous block (middle) and 
venetian blind (right) RMSECVs during calibration development for scale 
variations. 
  
4.4 Results 
4.4.1 Scale Variation 
Figure 4-1 shows the RMSECs and RMSCEVs for loading vectors 1 to 10 calculated by different 
cross-validation techniques such as random subset (left), contiguous block (middle) and venetian 
blinds (right). The no. of splits was also changed as the optimization parameter as shown in the 
figures. All the techniques (except contiguous block with 2 splits) showed a plateau between 
RMSEC and RMSECV at fifth loading vector and there was no significant reduction in cross-
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validation errors after that. A PLS model was developed using five loading vectors as per current 
technique for selecting optimum number of loading vectors for model development. 
Figure 4-2 shows the cumulative percent of variances explained after the addition of each 
loading vector into the model. Besides RMSECV, this metric was also used for selecting 
appropriate number of loading vectors. It was shown that, most of the variances in spectral 
matrix (X) and concentration matrix (Y) were explained by five loading vectors, indicating five 
as the optimum number of loading vectors for model development.  
 
Figure 4-2. Cumulative variances explained at each loading vector during calibration 
development for scale variations. 
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Figure 4-3. Weight co-efficient and percent of variances explained by each loading vector 
during calibration development for scale variations. 
Figure 4-3 shows the percent of variances explained by each loading vector and its respective 
weight coefficient. It was found that, the third loading vector had a much higher weight 
coefficient than first two loading vectors. High weight coefficient of the third loading vector 
indicated its large influence on the regression vector calculation and prediction equation 
compared to the first and second loading vector. However, only a small portion of the total 
variances was explained by the third loading vector indicating that, inclusion of this loading 
vector could over fit model using irrelevant information and affect model performance in the 
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future samples. Two loading vectors were considered optimum according to the new weight 
coefficient based method and a PLS model was developed using first and second loading vector. 
Another PLS model was also developed with three loading vectors to analyze the effect of 
including third loading vector into the model. These three PLS models were developed on lab 
scale tablets and used to predict tablet set prepared at manufacturing scale for eight consecutive 
weeks. The RMSEPs served as a metric for the model performance and robustness.  
 
Figure 4-4. RMSEPs of models predicting Acetaminophen in weekly runs prepared at 
different scale. 
Figure 4-4 shows the RMSEPs for models developed according to traditional method (5 LV 
model), new weight coefficient based method (2 LV model) and model showing the effect of 
third loading vector inclusion (3 LV model). The model developed using the new weight 
coefficient based method was found to be more robust against scale variation and more accurate 
through eight weeks compared to the traditional method. Inclusion of the third loading vector 
affected the mode performance as anticipated during model development. 
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Figure 4-5. RMSEPs of models predicting Acetaminophen in monthly runs prepared at 
different environment. 
4.4.2 Environmental Variation 
The robustness of these calibration models were also tested against environmental variation. All 
of the three models were developed in November, 2012 and used to predict the tablets prepared 
in May, June and July 2013 at the manufacturing scale. Figure 4-5 shows the RMSEPs for all 
three models predicting the tablets from different months. The model developed according to the 
new weight coefficient based method (2 LV model) was found to be more robust and accurate 
compared to other two models.  
4.4.3 Physical Variation (Density)  
Model robustness was tested against density variation as the physical source of variation in NIR 
analysis. The primary calibration set contained samples made at a single compaction force and 
then the calibration set was sequentially updated using samples made at four different 
compaction forces. 
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A total of 5 calibration sets were prepared. For each calibration set, two PLS models were 
developed following the traditional and new weight coefficient based method, respectively. The 
calibration models were used to predict the test set containing samples made at five different 
compaction forces. This analysis compared the performance of the traditional method and new 
weight coefficient based method in selecting optimum number of loading vectors during 
calibration development and calibration update. 
In the traditional method, the optimum number of loading vectors for each of the five models 
was selected based on RMSEC and RMSECV plots and the percent of variances explained by 
each loading vector. In the new weight coefficient based method, weight coefficient of each 
loading vector was used to select the optimum number of loading vectors to be used during 
model development. 
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Figure 4-6. Weight co-efficient of each loading vector during calibration development for 
density variations. 
Figure 4-6 shows the weight coefficient of each loading vector for five calibration models. The 
red arrows indicate the number of loading vectors used during model development following the 
new weight coefficient based method. For “Cal 01”, four loading vectors were used, because the 
fifth loading vector had higher weight coefficient than the previous four, indicating its large 
influence on the regression vector calculation and prediction equation with very little information 
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on the spectral and concentration variance. This approach was followed for the rest of the 
calibration sets (Cal 02 to Cal 05). 
Calibration 
set 
Sample 
no. 
Sample Force 
Included (MPa) 
in Calibration 
Set 
Loading Vector RMSEP % (w/w) 
Traditional 
Method 
New 
Weight 
Coefficient 
Based 
Method 
Traditional 
Method 
New 
Weight 
Coefficient 
Based 
Method 
Cal 01 35 67.0 7 4 3.48 2.82 
Cal 02 70 67.0, 117.3 8 4 3.31 2.37 
Cal 03 105 67.0, 117.3, 167.6 9 4 2.94 2.26 
Cal 04 139 67.0, 117.3, 167.6, 217.8 5 6 2.39 2.26 
Cal 05 174 
67.0, 117.3, 
167.6, 217.8, 
268.1 
6 6 2.23 2.23 
Table 4-1. Calibration for Density variation 
Table 4-1 provides a summary of the calibration sets, the respective number of loading vectors 
used by the traditional method and new weight coefficient based method and the RMSEPs of the 
respective models. Figure 4-7 shows the RMSEPs of the calibration models developed by the 
traditional method and new weight coefficient based method. The models developed by the new 
weight coefficient based method were found to be more robust and accurate compared to the 
models developed by the traditional method while predicting the same test set having density 
variation. For the global set “Cal 05”, that contained samples prepared at all compaction forces, 
both methods indicated the same optimum number of loading vector thereby providing equal 
RMSEP. It was found that, with a fewer samples, the model developed using the new weight 
coefficient based method was able to achieve similar prediction performance compared to the 
global model (new method for Cal 03 (105 samples) vs traditional method for Cal 05 (174 
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samples)). This indicated that, the new weight coefficient based method of model development 
has the potential to reduce the burden of calibration update. 
 
Figure 4-7. RMSEPs of models predicting Theophylline in tablets with density variations. 
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Figure 4-8. RMSECs and random subset (right), contiguous block (middle) and venetian 
blinds (left) RMSECVs during calibration development for chemical variations. 
4.4.4 Chemical Variation (Degradant) 
Model robustness against chemical variation was tested by introducing a new chemical entity in 
the prediction set. A degradant of the API was included in the prediction samples whereas the 
calibration model was developed using samples without the degradant.  shows the RMSEC and 
RMSECVs of each loading vector calculated by different cross-validation techniques during 
calibration development. For all these techniques, RMSEC and RMSECV reached a plateau at 
second loading vector. A PLS model was developed using two loading vectors as per the 
traditional method of model development. 
Figure 4-9 shows the cumulative percent of variances explained after the addition of each 
loading vector into the model. Five loading vectors explained most of the variances and no 
significant variance was added after that. Another PLS model was developed using five loading 
vectors as per the traditional method of model development. 
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Figure 4-9. Cumulative variances explained at each loading vector during calibration 
development for chemical variations 
Figure 4-10 shows percent of variances explained by each loading vector and its respective 
weight coefficient. It was found that, the second loading vector had higher weight coefficient 
than the first loading vector indicating its higher influence on the regression vector calculation 
and prediction equation. However, it explained a small portion of the X and Y variance 
compared to the first loading vector. Inclusion of the second loading vector was expected to over 
fit the model towards a direction that explained a small portion of the spectral and concentration 
variances. A third PLS model was developed using only one loading vector as per the new 
weight coefficient based method. 
Two models developed by the traditional method and one model developed by the new weight 
coefficient based method were used to predict Niacinamide concentration in test samples 
containing different amount of Niacin. The RMSEPs served as a metric of the model 
performance and robustness in presence of chemical variation coming from the Niacin as a 
degradant of the API. Figure 4-11 shows the RMSEPs for all three models predicting 
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Niacinamide concentration in samples containing 2%, 5% and 10% w/w of Niacin. It was found 
that, for all concentrations of Niacin samples, the model developed by the new weight coefficient 
based method was more robust and accurate in comparison to the other two models developed by 
the traditional methods. As expected, all model performances deteriorated as the Niacin content 
increased in the test samples. 
 
Figure 4-10. Weight co-efficient and percent of variances explained by each loading vector 
during calibration development for chemical variation 
4.4.5 Raw Material Variation 
Model robustness was tested against raw material variation. The calibration models were 
developed using the samples containing a specific polymorph of API as Theophylline anhydrous, 
a specific particle size distribution of Lactose as 100 microns and a specific vendor of starch as 
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EMD Chemicals. The models were used to predict the samples containing different polymorph 
of API, different particle size distribution of one excipient and different vendor of the other 
excipient. 
 
Figure 4-11. RMSEPs of models predicting Niacinamide in presence of chemical variations 
(Niacin) 
In this analysis, both the traditional method using RMSEC and RMSECV plot and the new 
weight coefficient based method using weight coefficient indicated five loading vectors as the 
optimal number for model development. Figure 4-12 shows the percent of variances explained 
by each loading vector and its respective weight coefficient. Five loading vectors were selected 
for model development because the sixth loading vector had higher weight coefficient than the 
preceding loading vectors indicating its high influence on the regression vector calculation and 
prediction equation. Inclusion of such loading vector would over fit the model towards a 
direction that explained a very small portion of the spectral and concentration variance. Although 
fourth and fifth loading vectors did not explain a significant portion of spectral or concentration 
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variances individually, they were kept into the model due to their smaller weight coefficients 
compared to the first loading vector. 
 
Figure 4-12. Weight co-efficient and percent of variances explained by each loading vector 
during calibration development for raw material variation 
Figure 4-13 shows the cumulative percent of variances explained at each successive loading 
vector addition into the model. It was found that, after the third loading vector inclusion, no 
significant variance was explained with the addition of a new loading vector. So, three loading 
vectors were used for model development as per one of the traditional techniques. 
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Figure 4-13. Cumulative variances explained at each loading vector during calibration 
development for raw material variation 
Figure 4-14 shows the RMSEPs of the two models developed by one of the traditional methods 
(3 LV model) and the new weight coefficient based method (5 LV) for predicting Theophylline 
concentration in test set containing new variances coming from different polymorph of API 
(Theophylline monohydrate), different particle size distribution (Lactose 50 micron) and 
different source (Starch vendor 2).  
4.5 Discussion 
In the above case studies, the new weight coefficient based method was found to be more 
effective in selecting the optimum number of loading vectors and indicating the most robust PLS 
model compared to the current techniques of cross-validation and variance calculation. Cross 
validation provides the error rate at successive loading vectors, however, that error rate is 
specific to the calibration space. Although cross-validation indicates model performance as a 
function of loading vector and prevents over fitting of the model in the calibration space, it 
provides little or no information about the model performance on any future data set containing 
new information to the calibration. Thus, cross-validation often fails to aid in the development of 
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the most robust PLS model at the outset of calibration. Upon such failure, it is usually assumed 
that the working model is the best case in place and model update is necessary. This is often not 
the case as shown in this paper. Moreover, it is also shown that, calibration update might not 
even be necessary at some points (density variation) following the new weight coefficient based 
method. This can be helpful in saving time and cost associated with calibration model update. 
 
Figure 4-14. RMSEPs of models predicting Theophylline in presence of raw material 
variations. 
During PLS model development, the goal is to maximize co-variance between the spectra and 
the concentration. Being an iterative technique, the first iteration of PLS seeks to estimate the 
direction of maximum co-variance between the spectra and the concentration, and the succeeding 
steps seek to estimate the co-variance between the residual information of the spectra and the 
concentration left from the preceding steps. Most often, the initial loading vectors explain 
majority of the variance presented in the spectra and concentration assuming that appropriate 
pre-processing has already been applied to mitigate other effects. While later loading vectors 
explain a blend of information that is a small part of the total calibration variance, they still help 
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to improve the model performance in the calibration space. However, outside the calibration 
space, it is often possible that the new samples show different projections on the direction of the 
later loading vectors for being different in terms of any of the blended information explained. 
This might be detrimental, especially when the particular loading vector has high influence (high 
weight co-efficient) in the regression vector calculation and the prediction equation. In that case, 
the regression vector will be sensitive to the information that might not be related with the 
concentration. The prediction can also be biased by the difference in sample scores on that 
loading vector. Exclusion of these loading vectors is expected to prevent the model from poor 
predictability for new samples and improve model robustness as demonstrated in this study. The 
weight coefficient based method is mostly applicable when certain loading vector has high 
weight coefficient but explains little spectral and concentration information. This method can 
identify and eliminate such loading vector from model space. If no such latent variable exists in 
the model space, the weight coefficient based method and current cross validation technique 
would provide similar solution to the loading vector selection problem. 
4.6 Conclusion 
Model robustness is very critical for successful implementation of NIR method. Different 
sources of variation can be present during product lifecycle and affect the NIR model 
performance. It is best practice to develop the most robust model at the outset of calibration 
development. Optimum number of loading vectors selection is necessary for indicating the most 
robust model. A new method using the weight coefficient was found to be more effective in 
selecting the optimum number of loading vectors and developing the most robust model 
compared to the current techniques of cross-validation and  
variance calculation. 
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5 Chapter 5: Method development for incorporating physico-chemical variation into the 
spectral calibration set 
5.1 Introduction 
The NIR spectral response of a pharmaceutical tablet is affected by its physico-chemical 
properties such as PSD of the API and excipients, tablet density, tablet hardness, moisture 
content etc [26, 42, 159]. These physico-chemical properties are critical factors for calibration 
design due to their effects on NIR spectra [25, 161, 162]. A calibration model typically shows 
poor accuracy in quantifying tablets with new physico-chemical properties that were not built 
into the calibration set. A calibration set should contain variation in the physico-chemical 
properties of the tablets in order to develop a robust calibration model. In the previous chapters, 
calibration sets were not controlled for certain critical factors such PSD of the API and raw 
materials. Calibration sets were also used to predict samples with different physico-chemical 
properties (lab scale vs manufacturing scale). The objective was to test and compare spectral 
calibration strategy with traditional calibration strategy in presence of new information in the test 
set. It was found that the presence of new information showed similar impacts on the spectral 
calibration set and traditional calibration set. Thus, the spectral calibration strategy was 
considered efficient due to its fewer sample requirements. However, the best practice for 
calibration set development is to incorporate the critical physico-chemical information into the 
calibration set. The current approach for incorporating physico-chemical variation into the 
calibration set is to allow a systematic variation of the respective factors in the calibration design 
[164]. This approach often leads to a large calibration set with redundant information; a 
limitation observed during the incorporation of compositional variation as well. Designing 
calibration set in the spectral space minimizes redundancy and offers an efficient strategy to 
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incorporate compositional variation into the calibration set. However, it is also critical for the 
spectral space calibration strategy to efficiently incorporate physico-chemical variation into the 
calibration set to build a robust calibration model. Incorporation of physico-chemical variation 
into the spectral calibration set requires the spectral space to contain physico-chemical 
information. The NIR spectral signature of the physico-chemical properties of the samples can be 
utilized to incorporate such information into the spectral space. A spectral space containing 
physico-chemical information provides the basis for selecting a small set of calibration samples 
with critical physico-chemical information. Such small calibration set would be efficient in 
sample requirement to develop a robust calibration model for quantitative analysis of 
pharmaceutical tablets.  
 
Figure 5-1. Effects of tablet density and hardness on reflectance and transmission NIR 
[193]. 
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In this study, a method was developed to incorporate physico-chemical variation into the spectral 
calibration design strategy. Tablet density was selected as an example of critical physico-
chemical property of the tablet. Tablet density variation affects the NIR spectral signal due to the 
changes in air-particle interfaces associated with density variation [11]. As the tablet density 
increases, the number of air-particle interfaces inside the tablet decreases. Air-particle interface 
acts as a scattering center for NIR light. As the number of air-particle interface decreases, the 
extent of scattering also decreases, causing the NIR light to penetrate deeper into the sample and 
resulting in an increased absorbance. The opposite effect is also observed when the tablet density 
decreases. Reflectance NIR method was found to be affected more by the tablet density 
compared to the transmission method [69]. Figure 5-1 shows the effect of tablet density and inter 
particle interface on the reflectance and transmission NIR spectra. 
It is critical for the calibration set to contain information regarding table density variation in 
order to build a robust calibration model. Tablet density variation is usually incorporated into the 
calibration set by compressing calibration samples at different compaction forces to prepare 
tablets of different densities. In the spectral calibration design strategy, tablet density variation 
was incorporated into the calibration set by selecting calibration samples from a spectral space 
that contained information regarding tablet density variation. Tablet density variation was 
incorporated into the spectral space by compressing pure component tablets at different 
compaction forces. The pure components tablet spectra were used to simulate spectra of 
compositionally varying tablets at different densities. The simulated tablet spectra of different 
densities were decomposed to derive the spectral space for selecting calibration samples. The 
covariance between spectra and API concentration was maximized prior to spectral 
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decomposition in order to incorporate compositional variation besides the tablet density variation 
into the spectral space.  
  
Figure 5-2. Spectral calibration strategy for incorporating tablet density variation into the 
spectral space 
The Kennard Stone algorithm was used to select a representative subset of samples as calibration 
candidates from the spectral space. This strategy was tested to quantify API in tablets with 
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different densities. This strategy was also compared with the current strategy for incorporating 
density variation into the calibration set. The following diagram depicts the spectral calibration 
strategy for incorporating tablet density variation into the spectral space. 
5.2 Material and method 
5.2.1 Incorporation of physico-chemical information 
 
Figure 5-3. Effect of compression force on the pure component tablet spectra 
The multiple API formulation was selected for this study. The multiple API tablets contained 
two APIs as Acetaminophen (Mallinckrodt Inc., Raleigh, NC, USA) and Caffeine anhydrous 
(Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA). The excipients were 
Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA), 
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Lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA), Crosscarmellose 
sodium (Crosscarmellose Na, Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA) and 
Magnesium stearate (MgSt; Fisher Scientific, Waltham, MA, USA). The target formulation was 
set as Acetaminophen (31.25% w/w), Caffeine (4.05% w/w), MCC (37.32% w/w), Lactose 
(24.89% w/w), Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w). The pure component 
tablets and a tablet at target formulation were compressed at three different compaction forces 
(2000, 4000 and 6000 lb) on a Carver Automatic Tablet Press using a 13 mm die and flat-faced 
punches. The target tablet weight was 700 mg.  
The experiments were controlled for tablet homogeneity and viscoelastic relaxation as described 
in section 3.3.1.4 in chapter 3. All the materials were stored in room temperature and relative 
humidity. Anhydrous caffeine was reported to be stable at 75% RH for 7 weeks [173]. No 
hydration and anhydrous caffeine was expected considering lower room RH (~60%) and shorter 
storage time and analysis. After a viscoelastic relaxation period of two weeks, tablets were 
scanned using a bench top NIR instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, 
Inc) in reflectance mode. Spectral data were collected at 0.5 nm increment over a range of 400 
nm – 2499.5 nm with 32 co-adds per spectrum. Spectra from both faces of each compact were 
averaged to produce a single representative spectrum. Figure 5-3 shows the pure component 
tablet spectra at different compaction forces. The pure component spectra showed consistent 
increases in absorbance with increases in compaction pressure except the two cases of 
Crosscarmellose Na and MgSt. Crosscarmellose Na and MgSt were very difficult to compress, 
leading to some inconsistent behavior between compaction pressures and spectral responses. 
However, this spectral effect was expected to be insignificant in the matrix tablet due to very 
small concentration of Crosscarmellose Na and MgSt in the target formulation tablet.  
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Figure 5-4. Effect of compression pressure on the tablet of target formulation 
Figure 5-4 shows the target tablet spectra at three different compaction pressures. A consistent 
increase in absorbance with the increase in compaction force was observed in the target tablet 
formulation.  A full-factorial experimental design was created to vary the concentration of 
Acetaminophen, Caffeine and MCC:Lactose ratio. The Acetaminophen and Caffeine 
concentrations were varied at 5 levels and MCC:Lactose ratio was varied at 3 levels resulting in 
a total of 75 design points. The details of the design is given in Table 5-1 
 Design factors Factor levels 
Calibration 
(5x5x3) 
75 samples 
Acetaminophen (%) L.C.-40% L.C.-20% L.C. L.C.+20% L.C.+40% 
Caffeine (%) L.C.-80% L.C.-40% L.C. L.C. +40% L.C.+80% 
MCC/Lac 1 1.5 2 
Table 5-1. Full factorial calibration design 
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Figure 5-5. Effect of residual spectra on the simulation of spectral response 
The spectra of these 75 design points were simulated using equation 5.1. The pure component 
spectra of each compression force were used during the simulation, resulting in 3 sets of 
simulated spectra for 3 compression forces (2000, 4000 and 6000 lb). 
Significant differences were observed between the simulated spectral response and actual 
spectral response of the target tablet formulation at all three compaction forces. The spectral 
difference was calculated between the actual and simulated spectral response of the target 
formulation for each compaction force. These residual spectra (3 residual spectra from 3 
compaction forces) were added to the respective simulated spectral responses. Figure 5-5 shows 
the actual and simulated spectral responses of the compaction pressure 2000 lb with and without 
the contribution from the residual spectrum. The actual spectral response were obtained by 
preparing 75 actual tablets at the compositional points and collecting NIR spectra following the 
method described in section 2.3 in chapter 2. In total, there were 225 simulated spectra (5 levels 
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of Acetaminophen, 5 levels of Caffeine, 3 Levels of MCC : Lactose, and 3 levels of compaction 
forces). Figure 5-6 shows the simulated spectra of 225 design points. 
 
Figure 5-6. Simulated spectral response of 225 design points 
The spectral data was truncated from 1100-2499.5 nm. A Principal component analysis was 
performed on the simulated data using MATLAB 2015a (The Mathworks, Natick, MA, USA) 
equipped with the PLS_Toolbox v. 7.9.3 (Eigenvector Research Inc., Wenatchee, WA, USA). 
 
Figure 5-7 shows the score plot of first two principal components. In the PCA score space (left), 
the in-silico samples are separated based on the compaction forces indicating that the majority of 
the simulated spectral variation was generating from different compaction forces.  
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Figure 5-7. Principal component analysis of the simulated spectra of 225 design points. 
Left: Color coded based on compaction forces (2000, 4000 and 6000 lb), Right: Color coded 
based on Acetaminophen concentration levels (18.75%, 25%, 31.25%, 37.5% and 43.75% 
w/w) 
The later principal components also explained variation related to composition as shown in  
Figure 5-7 (right) (Acetaminophen), Figure 5-8 (left) (Caffeine) and Figure 5-8 (right) 
(MCC:Lactose ratio). However, the spectral variation was dominated by compaction force 
variation. The PC1 that explained 97.60% of the total spectral variation, clearly separated the in-
silico samples based on the compaction forces. The objective of this study was to incorporate 
physico-chemical information into the calibration design by selecting the calibration candidates 
from a score space (aka spectral space) that contained information related to physico-chemical 
properties. In this score space, such selection would be dominated by compaction force 
information only. The selected calibration design points would represent insufficient information 
related to compositional variation. However, the compositional variation is also critical to 
calibration set, since the primary objective of the calibration set development is to build a 
Scores on PC 1 (97.60%)
-8 -6 -4 -2 0 2 4 6 8
S
co
re
s 
on
 P
C
 2
 (2
.0
2%
)
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
Force 2K
Force 4K
Force 6K
95% Confidence Level
-5
Scores on PC 1 (97.60%)
0
5
Scores on PC 4 (0.08%)
0.2
0.1
0
-0.1
-0.1
-0.05
0
0.05
0.1
-0.2
Sc
or
es
 o
n 
PC
 5
 (0
.0
3%
)
Scores on PC 4 (0.08%)
18.75
25
31.25
37.5
43.75
  161  
quantitative calibration model for compositional analysis. A balance between compositional and 
physico-chemical variation is desired to develop a robust calibration model. 
 
Figure 5-8. Principal component analysis of the simulated spectra of 225 design points. 
Left: Color coded based on Caffeine concentration, Right: Color coded based on MCC to 
Lactose ratio 
Signal preprocessing technique can be utilized to minimize the spectral effect due to compaction 
force and offer a balance between physico-chemical and compositional variation. Multiple 
scattering corrections were applied to minimize the baseline variation caused by the compaction 
force variation. A PCA analysis was performed on the preprocessed spectra. The PCA analysis 
showed that the information related to compaction force variation was minimized after 
preprocessing.  
Figure 5-9  shows the PCA score plots after applying MSC correction on the spectral data. No 
dominance of a single source of spectral variation was observed (no separation in the first two 
PCs). However, it was also critical for the relevant information to be present in the spectral space 
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for guiding the calibration candidate selection. A comprehensive PCA analysis was performed. 
Figure 5-10 shows the PCA score plots generated from subsequent PCs. 
 
Figure 5-9. Principal component analysis of the MSC corrected simulated spectra of 225 
design points. Left: Color coded based on compaction forces, Right: Color coded based on 
Acetaminophen concentration 
 Figure 5-10 (left) and Figure 5-10 (right) show that the spectral data set contained information 
related to compaction force and Acetaminophen concentration variation. Figure 5-11 shows that 
the spectral response also contained information related to the MCC to Lactose ratio of the in-
silico samples. The simulated spectra of in-silico samples were found to contain both physical 
and chemical variation and it was possible to incorporate a balance between these two sources of 
spectral variation by implementing an appropriate preprocessing technique. 
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Figure 5-10. Principal component analysis of the MSC corrected simulated spectra of 225 
design points. Left: Color coded based on compaction forces, Right: Color coded based on 
Acetaminophen concentration 
5.2.2 Selection of calibration candidates 
The next step was to find the calibration candidates for developing quantitative methods for 
Acetaminophen and Caffeine. It was assumed that the optimum calibration sets are different for 
different APIs. In other words, the optimum calibration set for Acetaminophen is different from 
the optimum calibration set for Caffeine (this assumption was tested and the result is shown in 
the next chapter). However, selecting the calibration candidates in the PCA score space would 
result the same calibration design points for Acetaminophen and Caffeine. It was also observed 
that the PCA score space contained little/no information regarding the variation of Caffeine 
concentration. Selecting the calibration candidates in the PCA score space would result a 
calibration set without appropriate variation in Caffeine concentration. It is critical to select the 
calibration candidates from a score space that contains information regarding the variation in the 
respective API concentration. In PLS, the covariance between respective API (Acetaminophen / 
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Caffeine) and spectral response is maximized to generate the score space. Therefore, PLS 
technique was used to generate separate score spaces that are specific to Acetaminophen and 
Caffeine. 
 
Figure 5-11. Principal component analysis of the MSC corrected simulated spectra of 225 
design points. Figure is color coded based on MCC to Lactose ratio 
 
5.2.2.1 Calibration candidates for Acetaminophen 
PLS model was developed from the in-silico samples to maximize the covariance between 
Acetaminophen concentration and simulated spectral variation. MSC and mean centering were 
used as the preprocessing techniques for spectral data as indicated by the PCA analysis. Auto 
scaling was used to preprocess the concentration data. The resultant score space from PLS model 
is shown in Figure 5-12. It was observed that, the first set of LVs explained spectral variation 
related to Acetaminophen concentration due to the maximization of covariance between 
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Acetaminophen concentration and spectral response. The spectral variation related to compaction 
force and excipient variation was also explained by other LVs (LV 3 and LV5) as shown in  
Figure 5-13. 
 
Figure 5-12. Score plot from the PLS model. The figure is color coded based on 
Acetaminophen concentration level 
From this score space, a set of 60 design points was selected as the calibration candidates for 
Acetaminophen calibration model using the Kennard Stone algorithm. Kennard Stone algorithm 
selected a representative sub set of in-silico samples from the large dataset based on Euclidian 
distances. The details of the Kennard stone algorithm can be found elsewhere [132]. Figure 5-14 
shows the selected points using Kennard stone algorithm in the score space. It was shown in the 
score plot that, calibration candidates were selected from all potential sources of variation during 
the selection process. All levels of Acetaminophen concentrations, MCC:Lactose ratios and 
compaction forces were included into the selected calibration candidates. It is critical to include 
all sources of variation into the calibration set to make a robust calibration model against all 
potential sources of variation. The current strategy to incorporate such variation is to create a 
wide range of systematic variation in all sources of variation during calibration design. 
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Following such strategy, the traditional method of incorporating compaction force variation 
would be to prepare tablets at 3 compaction forces for each of the 75 compositional design 
points, resulting in a total of 225 calibration points in the calibration set. This traditional 
calibration set will be referred as ‘global calibration set’ throughout the rest of the chapter. The 
global calibration set may contain redundant information since tablets of all three compaction 
forces at each compositional design point might not be necessary to incorporate sufficient 
amount of spectral variation into the calibration set. The selection of calibration candidates in the 
simulated score space would allow the incorporation of compaction force variation into the 
calibration set using limited number of samples. 
 
Figure 5-13. Score plot from the PLS model. Left: Color coded based on compaction force. 
Right: Color coded based on MCC:Lactose ratio 
The set of 60 calibration candidates had critical sources of spectral variation including 
Acetaminophen concentration variation, Caffeine concentration variation, MCC:Lactose ratio 
and compaction force. In the traditional calibration design approach, the variation of such critical 
factors is not guided by a priori information and largely depends on user choice (e.g. no of levels 
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for each factor). However, in the spectral design strategy, such variations in the calibration set 
were guided by the spectral information from each individual factor and their interaction.  
 
Figure 5-14. Selection of calibration candidates (indicated by black circle) in the PLS score 
space. The figures are color coded based on compaction force (Left), Acetaminophen 
concentration level (upper right) and MCC:Lactose ratio (bottom right) 
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The selection of the calibration candidates was also guided by maximizing the covariance 
between Acetaminophen concentration and spectral variation. The effect of this guided selection 
strategy was investigated by analyzing the distribution of different critical factors such as 
Acetaminophen concentration, Caffeine concentration, MCC:Lactose ratio and compaction force 
variation  in the selected calibration candidates. 
 
Figure 5-15. Distribution of Acetaminophen in global calibration set and spectrally selected 
calibration set 
Figure 5-15-17 shows the distribution of the critical factors in the global calibration set (225 
samples) and in the selected calibration set (60 samples). In the global calibration set (225 design 
points), all five concentration levels were presented at 45 occurrences (5x45=225) as shown in 
Figure 5-15 in red bars. In the spectral calibration set, a set of 60 design points was selected in 
which all the concentration levels were homogeneously distributed and occurred around 12 times 
for each concentration level as shown in Figure 5-15 in blue bars. 
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Figure 5-16. Distribution of Caffeine in global calibration set and spectrally selected 
calibration set 
The Caffeine concentrations in the selected design points were mostly distributed at the extreme 
levels to make the calibration model robust against Caffeine concentration variation as shown in  
Figure 5-16. Mid-level concentration points were mostly excluded as the sensitivity to Caffeine 
concentration was not critical for the calibration performance during Acetaminophen prediction. 
Also, the low dose of Caffeine was not able to contribute a significant portion of the spectral 
variation after the preprocessing and maximization of covariance between spectra and 
Acetaminophen concentration. The extreme design points were sufficient to cover such small 
spectral contribution from the Caffeine concentration. The excipient concentrations (MCC and 
Lactose) were widely distributed in the selected design points as shown in Figure 5-17. Excipient 
variation contributed to a significant portion of spectral variation as shown in the score plots. 
Excipient variation also causes variation in the physical properties such as density, porosity, 
hardness, moisture content of the tablets. An even distribution of excipient variation in the design 
points is critical to cover such variation in the calibration set. 
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Figure 5-17. Distribution of MCC (left) and Lactose (right) in global calibration set and 
spectrally selected calibration set 
The objective of this study was to incorporate physico-chemical information such as variation in 
tablet density into the calibration set. The compaction force is usually varied to introduce 
variation in the tablet density into the calibration set. Traditionally, compaction force is varied 
comprehensively without any prior direction or optimization in the calibration set. In this study, 
the spectral effect of the compression force was analyzed and a small representative subset was 
selected based on the spectral effect of the compression force.  The distribution of the 
compaction forces in the traditional global calibration set and in the spectrally selected 
calibration set is shown in Figure 5-18. A large number of design points were selected in the low 
compaction force region compared to the high compaction force region. A lower compaction 
force causes wider distribution of solid fractions in the tablet set compared to the high 
compaction force. As the solid fraction affects the NIR spectral response, it was assumed that, 
more design points were required / selected at the low compaction force region to cover wider 
distribution of solid fractions and associated spectral responses. 
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Figure 5-18. Distribution of compaction forces in global calibration set and spectrally 
selected calibration set 
5.2.2.2 Calibration candidates for Caffeine 
A similar strategy was used to select calibration candidates for developing a quantitative method 
for Caffeine. A PLS model was developed from the simulated spectral response of the in-silico 
tablets and respective Caffeine concentration. A set of 60 design points was selected from the 
PLS score space using the Kennard stone algorithm. The distribution of critical factors such as 
Caffeine concentration and Acetaminophen concentration in the global calibration set (225 
samples) and selected calibration set (60 samples) are shown in  
Figure 5-19. In this calibration set, a homogeneous distribution of Caffeine concentration was 
observed; contrary to the calibration set of Acetaminophen. A homogeneous distribution of 
Caffeine concentration was selected from the latent variable score space due to maximization of 
covariance between Caffeine concentration and spectral variance. Such distribution of Caffeine 
concentration was critical to make the model sensitive to Caffeine concentration. 
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Figure 5-19. Distribution of Acetaminophen (left) and Caffeine (right) concentration in 
global calibration set and spectrally selected calibration set 
Similar distributions of MCC and Lactose concentration were observed in the calibration set of 
Caffeine compared to the calibration set of Acetaminophen. The distribution of MCC and 
Lactose concentrations in the global (225 design points) and selected calibration set (60 design 
points) are shown in Figure 5-20. A wide distribution of excipients was critical to ensure 
calibration model robustness against excipient variation. Figure 5-21 shows the distribution of 
compaction forces in the selected calibration set for Caffeine. This calibration set also contained 
more design points at low compaction force compared to the high compaction force. 
 
Figure 5-20. Distribution of MCC (left) and Lactose (right) concentration in global 
calibration set and spectrally selected calibration set 
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Justification of low compaction force 
It was assumed that more design points were selected at the low compaction force due to wide 
range of spectral variation and solid fraction. These tablet design points were in-silico tablets and 
its spectra were simulated from actual pure component and target tablets at different compression 
forces. It was assumed that, tablets prepared at low compaction forces had wider spectral 
variation compared to the tablets prepared at high compaction forces. And the wide spectral 
variation was caused by wide range of solid fraction usually seen at low compaction forces. 
 
 
Figure 5-21. Distribution of compaction forces in global calibration set and spectrally 
selected calibration set 
Actual tablets were prepared at different compression forces to test this assumption. The solid 
fraction of each tablet was measured by the following equation 5.2. Figure 5 22 (left) shows the 
tablet solid fractions at each compaction force. At low compaction force, a wider range of solid 
fraction was present as expected. The spectral variances were calculated at each wavelength in 
the simulated spectral set of each compaction force. Figure 5 22 (right) shows the spectral 
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variance at each wavelength for all three compaction forces of in-silico tablets.  In contrast to the 
initial assumption, it was found that the wide distribution of solid fractions did not cause wide 
range of spectral variation. 
The spectral variation was minimum at the low compaction force in-silico tablets. The spectral 
variation was maximum at the high compaction force in-silico tablets. It was further investigated 
to understand the cause behind the selection of more design points from low compaction force 
in-silico tablets associated with smaller amount of spectral variation. 
 
Figure 5-22. Solid fraction of tablets at different compaction forces (A). Spectral variation 
of the tablet sets prepared at different compaction forces (B). 
 
It was expected to have more design points at high compaction force in the selected calibration 
set due to the large spectral variance observed at high compaction force. However, after the MSC 
correction of the spectral data during PLS model development, more spectral variance was 
observed at low compaction force as shown in  Figure 5-23. It might be due to the greater extent 
of non-linearity caused by the wider distribution of solid fractions at the low compaction force. 
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MSC preprocessing technique corrects for linear scattering effect. The non-linear scattering 
effect could not be corrected by MSC preprocessing, resulting in wide range of spectral variation 
in the preprocess data at low compaction force. Such wide range of spectral variation resulted in 
wide distribution of scores in the PLS score plots as shown in Figure 5-24. 
 
 
 
 
 
 
 
 
 
 Figure 5-23. Spectral variation before (A) and after MSC correction of the spectral data.  
The area inside the box represents the range of score distribution for each respective compression 
force. The distribution of scores was wider for low compaction force tablets compared to the 
high compaction force tablets.  This wider distribution of scores of low compaction force tablets 
resulted in higher k-nearest neighbor (KNN) distance scores. Since, the Kennard stone algorithm 
selects samples based on inter sample distances and the highly distant samples are included in 
the selected subset, more samples were selected from the low compaction force during the 
selection of calibration candidates.  
Figure 5-25 shows the KNN distance scores of tablets at three different compaction forces for 
both Acetaminophen and Caffeine. For both APIs, the higher KNN distances of low compaction 
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force tablets resulted in large number of low compaction design points in the selected calibration 
candidates. 
 
Figure 5-24. PLS scores of first two loading vectors at three different compaction forces  
 
5.2.3 Spectral calibration set for Acetaminophen 
A set of 60 design points was selected to develop the calibration set for Acetaminophen 
prediction. Actual tablets at the selected design points were prepared by direct compression. The 
required amounts of Acetaminophen, Caffeine, MCC, Lactose, Crosscarmellose Na and MgSt at 
each design point were weighed and placed in a 10 ml scintillation vial. The ingredients were 
mixed by rotating the scintillation vial. Tablets were compressed on a Carver Automatic Tablet 
Press (Model 3887.1SD0A00, Wabash, IN, USA) at respective compaction force using a 13 mm 
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die and flat-faced punches. The target tablet weight was 700 mg. This tablet set was defined as 
the ‘spectral calibration set’ for Acetaminophen. 
 
Figure 5-25. KNN distance scores of samples at three different compaction forces for PLS 
models of Acetaminophen (A) and Caffeine (B)  
All the tablets were scanned using a bench top NIR instrument (XDS Rapid Content Analyzer, 
FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at 0.5 nm increment 
over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum. Spectra from both faces of 
each compact were averaged to produce a single representative spectrum. Spectral calibration set 
and their respective spectra were used to develop a quantitative NIR calibration model to 
quantify the amount of Acetaminophen in tablets of interest. 
5.2.4 Traditional calibration set for Acetaminophen 
The traditional calibration set was developed using the 4-factor full factorial design previously 
used to simulate the spectral response. The factors were Acetaminophen concentration, Caffeine 
concentration, MCC: Lactose ratio and compaction force. Each of the APIs (Acetaminophen and 
Caffeine) concentrations was varied at five levels and other two factors (MCC: Lactose ratio and 
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compaction force) were varied at three levels resulting in 225 (5x5x3x3) design points in the 
traditional full factorial calibration set. The calibration design is different from the design in 
chapter 3 in that, the levels of compaction forces are 2000, 4000 and 6000 lb in the current 
design contrary to 4000, 5000 and 6000 lb in the earlier design. 
Each of the 225 tablets was individually prepared by direct compression. All the components for 
a single design point were weighed using a digital weighing machine (Data Range, Model No. 
AX504DR, Mettler Toledo) and placed in a 10 ml scintillation vial. The ingredients were mixed 
in a bin blender (L.B. Bohle LLC, Warminster, PA, USA) for 10 mins followed by a high shear 
mixing using a vortex machine (Vortex-2 Genie, Model G-560, Scientific Industries, IN, USA). 
The final mixing was performed in the bin blender before compression. Tablets were compressed 
on a Carver Automatic Tablet Press (Model 3887.1SD0A00, Wabash, IN, USA) at respective 
compression forces using a 13 mm die and flat-faced punches. The target tablet weight was 700 
mg. 
All the tablets were scanned using a bench top NIR instrument (XDS Rapid Content Analyzer, 
FOSS NIRSystems, Inc) in reflectance mode. Spectral data were collected at 0.5 nm increment 
over a range of 400 nm – 2499.5 nm with 32 co-adds per spectrum. Spectra from both faces of 
each compact were averaged to produce a single representative spectrum. Traditional calibration 
set and their respective spectra were used to develop a quantitative NIR calibration model to 
quantify the amount of APPA in tablets of interest. 
5.2.5 Spectral calibration set for Caffeine 
The spectral calibration set for Caffeine was developed using the similar strategy as used for 
spectral calibration set for Acetaminophen. A set of 60 design points was selected as the 
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calibration candidates from the PLS scores of Caffeine calibration model of in-silico samples. 
Only 29 design points were found to be common between the selected design points of 
Acetaminophen and Caffeine. Actual tablets at these design points were prepared by the direct 
compression technique described earlier. The NIR spectra of these tablets were collected using 
the same instrument and method described earlier. This calibration set was described as ‘spectral 
calibration set’ for Caffeine. Spectral calibration set and their respective spectra were used to 
develop a quantitative NIR calibration model to quantify the amount of Caffeine in tablets of 
interest. 
 Design Factors Design levels 
Test 1 
(5x5x3x1) 
75 samples 
 
Acetaminophen (%) L.C.-40% L.C.-20% L.C. L.C. +20% L.C. +40% 
Caffeine (%) L.C.-80% L.C.-40% L.C. L.C. +40% L.C. +80% 
MCC/Lac 1 1.5 2 
Force (lb) 5000 
Test 2 
(3x3x1x4) 
36 samples 
Acetaminophen (%) L.C.-35% L.C. L.C.+35% 
Caffeine (%) L.C.-70% L.C. L.C.+70% 
MCC/Lac 
 
1.5 
 
Force (lb) 2000 4000 5000 6000 
Table 5-2.  Design of the two test sets 
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5.2.6 Traditional calibration set for Caffeine 
The same full factorial calibration set for Acetaminophen (225 samples) was used to develop a 
traditional calibration method for Caffeine prediction. 
5.2.7 Test sets to evaluate model performance 
Two test sets were used to evaluate the performance of the calibration designs. The first test was 
developed by varying Acetaminophen and Caffeine concentration at five levels and MCC to 
Lactose ratio at 3 levels resulting in 75 design points. In the first test set, the compaction force 
was kept constant. The second test set was developed by varying Acetaminophen and Caffeine 
concentration at three levels and compaction force at four levels resulting in total 36 design 
 
Figure 5-26. Selection and preparation method of spectral calibration set and test set for 
Acetaminophen and Caffeine  
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points. In the second test set, the excipient ratio was kept constant. Table 5-2 describes the 
structure of the two test sets.  The method for preparing calibration and test set is depicted in 
Figure 5-26. 
5.2.8 Quantitative model development 
Quantitative models were developed using Partial Least Squares (PLS) modeling technique in 
MATLAB 2015a environment (The Mathworks, Natick, MA, USA) using PLS_Toolbox v. 7.9.3 
(Eigenvector Research Inc., Wenatchee, WA, USA). Data independent spectral preprocessing 
techniques were used to optimize model performance. Two calibration models were developed 
for each API (Acetaminophen and Caffeine), one calibration model from the 225 actual tablets of 
the full factorial design and another calibration model from the 60 actual tablets of the spectral 
design. Models developed from each calibration design were independently optimized for each 
API. The preprocessing techniques and loading vectors were selected independently. Selection of 
the loading vector is critical for PLS model performance. Latent variables were chosen based on 
a parsimonious approach. A minimum number of latent variables with acceptable performance 
were selected. Model performance was assessed based on the prediction of Acetaminophen and 
Caffeine concentration in calibration and test set tablets. 
The effect of the incorporation of physico-chemical information into the spectral calibration sets 
was analyzed by evaluating calibration model performance and comparing it with the global 
calibration model performance. Root mean squared error (RMSE) was used to evaluate the 
model predictive performance in the two independent test sets (RMSEP). A two-way analysis of 
variance (ANOVA) test was performed to compare the prediction errors of the full factorial and 
spectral calibration sets for each API [22]. The underlying model for the ANOVA analysis is 
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described in equation 5.3, where index ‘i’ refers to the calibration model and index ‘j’ refers to 
the sample number. The symbol 𝛼𝛼𝑖𝑖 and 𝛽𝛽𝑗𝑗refer to the effect of calibration model ‘i’ and sample 
number ‘j’ on prediction error, respectively.  
 (𝑑𝑑�𝑖𝑖𝑗𝑗 − 𝑑𝑑𝑖𝑖𝑗𝑗)2 =  𝜇𝜇 + 𝛼𝛼𝑖𝑖 + 𝛽𝛽𝑗𝑗 + 𝑡𝑡𝑖𝑖𝑗𝑗 (5.3) 
The calibration models are considered significantly different in terms of prediction performance, 
if the calibration model parameter 𝛼𝛼 is found to be significant in the ANOVA analysis. 
5.3 Results and discussion 
5.3.1 Prediction of Acetaminophen 
A PLS model was developed from the traditional calibration set (225 samples). The 
preprocessing techniques were selected as MSC and mean centering for spectral data and auto 
scaling for concentration data. A set of 6 loading vectors was selected for model development. 
Figure 5-27 shows the performance of the traditional calibration set for predicting 
Acetaminophen in the first test set (75 samples). The score plot shows that the spectral variation 
in the test set was covered by the calibration set. The calibration, cross validation and prediction 
errors were found to be similar (~1% w/w). A reasonable prediction performance was achieved 
due to similar spectral variation between calibration and test set samples. 
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Figure 5-27. PLS model performance of the global calibration set predicting 
Acetaminophen in test set 1   
 
Another PLS model was developed from the spectral calibration set for Acetaminophen 
prediction. Same preprocessing techniques (MSC and mean centering for spectral data and auto 
scaling for concentration data) were found to be optimum for this model. A set of 6 loading 
vector was selected for model development. Figure 5-28 shows the performance of the spectral 
calibration set for predicting Acetaminophen in the first test set. The calibration samples had 
similar and wider spectral variation compared to the test set samples. Similar prediction 
performance (RMSEP ~ 1% w/w) was achieved by the spectral calibration set compared to the 
traditional calibration set in spite of having fewer samples (60 vs 225). 
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Figure 5-28. PLS model performance of the spectral calibration set predicting 
Acetaminophen in test set 1   
The same calibration models of traditional calibration set and spectral calibration set were used 
to predict the concentration of Acetaminophen in the second test set. In the second test set (36 
samples), the prediction errors of the two models were slightly higher compared to the first test 
set (RMSEPs ~ 1.2 % w/w). The higher error was caused by the compaction force variation in 
the test set samples. The prediction performances between the two calibration models were found 
to be equivalent. Figure 5-29 shows the score plot and reference vs prediction plot for two 
calibration models predicting Acetaminophen in the second test set. 
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Figure 5-29. PLS model performance of the traditional (A) and spectral calibration sets (B) 
predicting Acetaminophen in test set 2   
5.3.2 Prediction of Caffeine 
A PLS model was developed from the traditional calibration set (225 samples) to predict 
Caffeine concentration in the first test set (75 samples). The preprocessing techniques were 
MSC, Savitzky-Golay derivative (window size 15, second order polynomial, first derivative) and 
mean centering for spectral data and auto scaling for the concentration data. A set of 5 loading 
vectors was selected for model development. Figure 5-30 shows the score plot and reference vs 
prediction plot for the calibration model. Similar ranges of spectral variation were observed 
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between traditional calibration and first prediction set. The RMSEC and RMSEP were 0.35% 
w/w and 0.46% w/w, respectively. 
 
Figure 5-30. PLS model performance of the traditional calibration set predicting Caffeine 
in test set 1   
 
Another PLS model was developed from the spectral calibration set (60 samples) of Caffeine. 
The preprocessing techniques were MSC, Savitzky-Golay derivative (window size 15, second 
order polynomial, first derivative) and mean centering for spectral data and auto scaling for the 
concentration data. A set of 5 loading vectors was selected for model development. Figure 5-31 
shows the score plot and reference vs prediction plot for the calibration model. Similar ranges of 
spectral variation were observed between the calibration and prediction sets. The prediction 
performance of the spectral calibration set (RMSEP 0.46% w/w) was found to be similar to the 
traditional calibration set in spite of having fewer calibration samples (60 vs 225). 
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Figure 5-31. PLS model performance of the spectral calibration set predicting Caffeine in 
test set 1   
The same calibration models of the traditional and spectral calibration sets were used to predict 
the concentration of Caffeine in the second test set (36 samples). The prediction performances 
for both calibration models were improved in the second calibration set. The extents of 
improvement were similar between the traditional and spectral calibration sets. The RMSEPs for 
both calibration models were ~ 0.35% w/w. Figure 5-32 shows the score plot and reference vs 
prediction plots for the two calibration models of traditional and spectral calibration sets. 
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Figure 5-32. PLS model performance of the traditional (A) and spectral calibration sets (B) 
predicting Caffeine in test set 2   
5.4 Conclusion 
The spectral calibration sets (60 samples) were found to provide equivalent prediction 
performances compared to the traditional calibration set (225 samples) for both Acetaminophen 
and Caffeine. Equivalent prediction performances were observed in both test sets containing 
compositional and physico-chemical variation. The summary of the prediction performances is 
given in Table 5-3. The spectral calibration sets were designed by using prior information about 
the spectral effect of physico-chemical information. This information was utilized to efficiently 
design a small calibration set to incorporate wide range of information. Such incorporation was 
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successful in building a robust calibration model against compositional and physico-chemical 
variation. 
 
Acetaminophen model Caffeine model 
 
Full factorial 
design Spectral design 
Full factorial 
design Spectral design 
No. of Samples 225 60 225 60 
RMSEC (% w/w) 0.983 0.907 0.351 0.271 
RMSECV (% w/w) 1.032 1.148 0.365 0.309 
R2 Calibration 0.988 0.990 0.977 0.987 
RMSEP1 (% w/w) 1.001 0.996 0.457 0.459 
Prediction Bias 1 
(% w/w) -0.472 -0.338 0.087 0.062 
R2 Prediction 1 0.990 0.989 0.963 0.962 
RMSEP2 (% w/w) 1.171 1.202 0.351 0.347 
Prediction Bias 2 
(% w/w) -0.101 -0.014 -0.069 -0.084 
R2 Prediction 2 0.984 0.983 0.982 0.982 
Table 5-3. Summary of the calibration model performance of the traditional and spectral 
calibration set 
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6 Chapter 6: Optimum calibration structure for pharmaceutical formulation and 
spectroscopic techniques  
6.1 Introduction 
Calibration structure is a critical factor for ensuring desired performance of the spectroscopic 
method for quantitative analysis of pharmaceutical formulation. The optimum calibration 
structure depends on the sample formulation and spectroscopic technique. An optimum 
calibration structure for an NIR method can be sub-optimum for a different spectroscopic method 
such as Raman or THz spectroscopy due to inherent differences in spectral responses. An 
optimum calibration structure for one formulation can also be sub-optimum for another 
formulation. This is the fundamental concept leading to the development of spectral design 
strategy for calibration development. In the traditional strategy, same set of samples designed in 
the concentration space is usually used for both NIR and Raman calibration method 
development. These samples are designed to allow wide concentration and physical variation to 
follow the traditional concept of incorporating as much variance as possible into the calibration 
set. However, all the variance information in the calibration set may not be relevant to the 
particular technique of interest. For instance, a NIR method can be sensitive to a particular type 
of physical variation that needs to be incorporated into the calibration set to develop a robust 
quantitative model, whereas the same physical variation may not affect Raman spectra and be 
unnecessary to incorporate into the Raman calibration set. 
Spectral design strategy allows optimization of the calibration structure depending on the 
formulation and technique. Since the strategy utilizes pure component spectral information, the 
resultant calibration structure depends on the interaction between formulation and spectroscopic 
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technique. A unique calibration set is developed for each formulation and spectroscopic 
technique. However, the criticality of having unique calibration structure to ensure optimum 
calibration performance has not been investigated. In this study the optimum calibration structure 
between NIR and Raman were compared. The optimum calibration structures between two APIs 
(Acetaminophen and Caffeine) were also compared. This study also provided the basis for 
utilizing spectral design strategy to design a formulation and technique specific calibration set. 
6.2 Material and Method: 
6.2.1 Calibration and test set 
The multiple API formulation was selected for this study. The multiple API tablets contained two 
APIs as Acetaminophen (Acetaminophen; Mallinckrodt Inc., Raleigh, NC, USA) and Caffeine 
anhydrous (Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA). The excipients were 
Microcrystalline cellulose (MCC; Avicel PH 200, FMC Biopolymer, Mechanicsburg, PA, USA), 
Lactose (modified spray-dried; Foremost Farms USA, Rothschild, WI, USA), Crosscarmellose 
sodium (Crosscarmellose Na, Spectrum Chemical Mfg. Corp., New Brunswick, NJ, USA) and 
Magnesium stearate (MgSt; Fisher Scientific, Waltham, MA, USA). The target formulation was 
set as Acetaminophen (31.25% w/w), Caffeine (4.05% w/w), MCC (37.32% w/w), Lactose 
(24.89% w/w), Crosscarmellose Na (2% w/w) and MgSt (0.5% w/w). 
A full-factorial experimental design was created to vary the concentration of Acetaminophen, 
Caffeine, MCC:Lactose ratio and compaction force of the tablets. The Acetaminophen and 
Caffeine concentration was varied at 5 levels and MCC : Lactose ratio and compaction force 
were varied at 3 levels resulting in a total of 225 design points. A test set was developed by 
varying all the calibration factors except MCC: Lactose ratio, each at three levels resulting in a 
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total of 27 design points. Table 6-1 provides the details of the full factorial calibration and test 
design. 
Each tablet of the calibration and test design points was individually prepared by direct 
compression. All the components for a single design point were weighed using a digital weighing 
machine (Data Range, Model No. AX504DR, Mettler Toledo) and placed in a 10 ml scintillation 
vial. The ingredients were mixed in a bin blender (L.B. Bohle LLC, Warminster, PA, USA) for 
10 mins followed by a high shear mixing using a vortex machine (Vortex-2 Genie, Model G-560, 
Scientific Industries, IN, USA). The final mixing was performed in the bin blender before 
compression. Tablets were compressed on a Carver Automatic Tablet Press (Model 
3887.1SD0A00, Wabash, IN, USA) at respective compression forces using a 13 mm die and flat-
faced punches. The target tablet weight was 700 mg. 
 Design Factors Design Levels 
Calibration Design 
(5x5x3x3) 
225 
samples 
Acetaminophen 
(%) 
L.C.-
40% 
L.C.-
20% L.C. L.C.+20% 
L.C.+40% 
Caffeine (%) L.C.-80% 
L.C.-
40% L.C. 
L.C. 
+40% 
L.C.+80% 
MCC/Lac 1 1.5 2 
Force (lb) 4000 5000 6000 
Test Design 
(3x3x3) 
27 
samples 
Acetaminophen 
(%) L.C.-35% L.C. 
L.C.+35% 
Caffeine (%) L.C.-70% L.C. L.C.+70% 
Force (lb) 4000 5000 6000 
MCC/Lac 1.5 
Table 6-1. Calibration and test design 
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NIR reflectance measurements for both sides of each compact were collected using a bench top 
scanning monochromator instrument (XDS Rapid Content Analyzer, FOSS NIRSystems, Inc., 
Laurel, MD, USA) after tablets reached stable dimensions (viscoelastic relaxation). Spectra 
corresponding to each side of a compact were averaged to give one spectrum per compact. 
Gravimetric measurement was used as reference for all tablets. 
  
Figure 6-1. NIR (A) and Raman (B) spectra of the calibration sets 
Raman measurements for both sides of each compact were collected using a PhAT System 
spectrometer coupled with a probe head (HoloGRAMS version 4.0, Kaiser Optical Systems, Inc, 
Ann Arbor, MI). The laser excitation wavelength was 785 nm. The PhAT System samples a spot 
size of ~6 mm. The integration time and co-adds were 15 seconds and 3, respectively. Spectra 
corresponding to each side of a compact were averaged to give one spectrum per compact over 
the range of 150 to 1890 cm–1 at a 0.2 cm–1 increment. The NIR and Raman spectra of the 
tablet are given in Figure 6-1.  
All the analyses were performed in MATLAB 2015a environment (The Mathworks, Natick, MA, 
USA). Quantitative models were developed using Partial Least Squares (PLS) modeling 
A B 
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technique using PLS_Toolbox v. 7.9.3 (Eigenvector Research Inc., Wenatchee, WA, USA). Data 
independent spectral preprocessing techniques were used to optimize the model performance. 
 
Figure 6-2. NIR PLS model for Acetaminophen from traditional calibration set 
 
6.2.2 Quantitative model development 
6.2.2.1 NIR infrared spectroscopy 
6.2.2.1.1 Acetaminophen prediction 
A PLS model was developed for predicting Acetaminophen concentration in calibration and test 
set tablets. During PLS model development, the optimum preprocessing techniques were found 
to be SNV and mean centering for the spectral data and auto scaling for the concentration data. 
The optimum number of loading vector (6) was selected from a routine cross validation step. The 
projected scores of the calibration and test samples on the first four loading vectors are given in 
Figure 6-2. Similar projections were found between calibration and test set tablets indicating 
similar types of spectral variations on the loading vectors direction. A lower prediction error in 
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both calibration (0.97% w/w) and test (1.04% w/w) set ensured reasonable model performance. 
The reference vs prediction plot is given in Figure 6-3. 
This calibration structure was designed from a full factorial template without any prior 
information. The calibration structure was neither optimized for Acetaminophen, nor for NIR 
spectroscopy. The optimality of the calibration structure and calibration performance was 
unknown. Although the NIR method provided reasonable prediction performance, the best 
possible prediction performance with available resources was unknown. A mathematical search 
was performed to find the optimum calibration set that provided the best prediction performance 
(lowest prediction error) for the test set. It must be noted that the optimum calibration structure 
depends on the test set structure. A different calibration set could provide the best performance 
for a different test set. The search for the optimum calibration set followed the steps provided 
below: 
 
 
 
 
 
 
 
Figure 6-3. Reference vs prediction plot of Acetaminophen from traditional calibration set 
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Figure 6-4. Search for optimum calibration set 
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Figure 6-5. Prediction performance of randomly selected calibration sets and optimally 
selected calibration set 
Initially a PLS calibration model was developed using all the calibration samples (global 
calibration set) and used for predicting Acetaminophen concentration in the test set. The 
calibration set was set as ‘Optimum calibration set’ and resultant RMSEP was set as 
‘RMSEP_TARGET’. Then a second PLS model was developed using randomly selected 3 
calibration samples (initial calibration set) and used for predicting Acetaminophen concentration 
in the same test set. The resultant RMSEP was set as ‘RMSEP_INITIAL’. Then another 
randomly selected calibration sample was added to the initial calibration set, a PLS model was 
developed using the updated calibration set and used to predict Acetaminophen concentration in 
the test set. The resultant RMSEP was set as ‘RMSEP_MODEL’. If RMSEP_MODEL was 
found to be lower than ‘RMSEP_INITIAL’, the newly added sample was kept in the updated 
calibration set, otherwise discarded from the updated calibration set. The RMSEP of the updated 
calibration set was set as ‘RMSEP_INITIAL’ (for sample inclusion it would change (lowered), 
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for sample exclusion it would remain same). Then another randomly selected calibration sample 
was added to the updated calibration set and effect of its inclusion on the prediction performance 
of the test set was calculated. It was kept in case it helped to improve the prediction performance, 
otherwise discarded. This process was iterated until all the calibration samples were tested for 
their effects on the prediction performance. A subset of calibration samples was found after the 
iteration. The RMSEP of the calibration subset (RMSEP_MODEL) was compared with RMSEP 
of the global calibration set (RMSEP_TARGET). If the RMSEP_MODEL was found to be lower 
than RMSEP_TARGET, a set of better calibration candidates was found by sample inclusion 
strategy. The algorithm then went to the next phase to analyze the effect of sample exclusion on 
the prediction performance. If RMSEP_MODEL was found to be higher than 
RMSEP_TARGET, the algorithm started from the beginning by randomly selecting a different 
initial set and calibration candidates. 
 
Figure 6-6. NIR PLS model for Acetaminophen from optimum calibration set 
In the next phase, a randomly selected sample was excluded from the updated calibration set, a 
PLS model was developed and used to predict Acetaminophen concentration in the test set. The 
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sample was excluded in case the exclusion lowered the RMSEP, otherwise it was kept in the 
updated calibration set. In the next step, another randomly selected sample was tested for 
exclusion criteria. This process was iterated until all the samples were individually tested to 
analyze the effect of their exclusion on the prediction performance. A calibration subset 
containing better calibration candidates was found at the end. All these calibration samples were 
tested for both inclusion and exclusion criteria and found to improve the prediction performance. 
The RMSEP of the updated calibration set (RMSEP_MODEL) was calculated and compared 
with the RMSEP_TARGET. If RMSEP_MODEL was found to be lower than the 
RMSEP_TARGET, the RMSEP_MODEL was set as the new RMSEP_TARGET. The updated 
calibration set was stored and set as the ‘Optimum calibration set’. If RMSEP_MODEL was 
found to be higher than the RMSEP_TARGET, the RMSEP_TARGET and ‘Optimum 
calibration set’ remained same. This whole process was repeated iteratively, until 
RMSEP_TARGET (lowest RMSEP at hand) was found to be lower than the RMSEP_MODEL 
for five consecutive iterations. It indicated that the search algorithm found the ‘Optimum 
calibration set’ that provided the best calibration performance (lowest RMSEP). The 
performance of this guided search algorithm was compared with multiple randomized search 
algorithms. The resultant RMSEPs of the search algorithms are shown in Figure 6-5 with the 
calibration sample number. The guided search algorithm was able to find the calibration set that 
provided the best model performance. Following the guided search, the optimum calibration set 
for Acetaminophen was found to contain 35 calibration samples. 
 A PLS model was developed from this optimum calibration set. The preprocessing techniques 
were SNV and mean centering for the spectral data and auto scaling for the concentration data, 
respectively. A set of 6 loading vectors was selected for model development. The scores of the 
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calibration and test samples on the first four loading vectors are given in Figure 6-6. It was found 
that, the small optimum calibration set was able to explain similar spectral variation as the test 
set. An improved prediction performance (RMSEC 0.49 % w/w and RMSEP 0.69% w/w) was 
observed from the optimum calibration set as compared to the global calibration set. The 
reference vs predicted concentration for calibration and test sample is given in Figure 6-7. 
 
Figure 6-7. Reference vs prediction plot of Acetaminophen from optimum calibration set 
6.2.2.1.2 Caffeine prediction 
A PLS model was developed from all the 225 samples to predict the concentration of Caffeine in 
the test set. The optimal preprocessing techniques were SNV and mean centering for spectral 
data and auto scaling for concentration data. A set of 6 latent variables was selected for model 
development. The scores of the calibration and test samples on the first four loading vectors are 
given in Figure 6-8. The calibration and test samples were found to span similar spectral 
variation on the loading vector directions. 
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Figure 6-8. NIR PLS model for Caffeine from traditional calibration set 
Similar projections of calibration and test samples ensured reasonable prediction performance of 
the calibration model. The resultant RMSEC and RMSEP were 0.40% w/w and 0.43% w/w, 
respectively. The reference vs predicted concentration for calibration and test sample is given in 
Figure 6-9. 
 
Figure 6-9. Reference vs prediction plot of Caffeine from traditional calibration set 
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Figure 6-10. NIR PLS model for Caffeine from optimal calibration set 
A guided search was performed following the previously described algorithm to find the 
optimum calibration set for Caffeine prediction. The optimum calibration set of Caffeine was 
selected based on the prediction performance on the test set. The resultant optimized calibration 
set contained 37 samples. A PLS model was developed from the optimum calibration set. The 
preprocessing techniques were SNV and mean centering for the spectral data and auto scaling for 
the concentration data. A set of 6 loading vectors was selected.   
Figure 6-10 shows the calibration and test sample scores on the first four loading vectors. It was 
found that, the small optimum calibration set spanned the entire range of spectral variation of the 
test set samples. Such spectral coverage ensured improved model performance compared to the 
global calibration set in spite of having fewer sample number. The resultant RMSEC and 
RMSEP were 0.19% w/w and 0.28% w/w, respectively. The reference vs prediction plot is given 
in Figure 6-11. A small optimum calibration set was able to provide better model performance 
compared to the global calibration for both Acetaminophen and Caffeine. These optimum 
calibrations sets were found by the search algorithm. The optimum calibration sets between 
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Acetaminophen and Caffeine were different. Only 8 samples were found to be common between 
the optimum calibration set for Acetaminophen (35 samples) and Caffeine (37). 
 
Figure 6-11. Reference vs prediction plot of Caffeine from traditional calibration set 
6.2.2.2 Raman spectroscopy 
The same dataset was scanned with Raman spectroscopy. Quantitative PLS models were 
developed from Raman spectra to predict the concentrations of Acetaminophen and Caffeine in 
the test set. 
 
Figure 6-12. Raman PLS model for Caffeine from traditional calibration set 
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6.2.2.2.1 Acetaminophen prediction 
A PLS model was developed to predict the concentration of Acetaminophen in the test set using 
Raman spectra. The optimum preprocessing techniques were SNV, normalization and mean 
centering for the spectral data and auto scaling for the concentration data. A set of 4 latent 
variables were selected for the model development. Figure 6-12 shows the projection of the 
calibration and test samples on the first four loading vectors. The first two loading vectors 
grouped the calibration (5 groups) and test samples (3 groups) based on the Acetaminophen 
concentration. It was also observed that the calibration and test samples spanned similar ranges 
of spectral variation. A reasonable prediction performance was achieved. The RMSEC and 
RMSEP were 1.02 % w/w and 1.09 % w/w, respectively.  
 
Figure 6-13. Reference vs prediction plot of Acetaminophen from traditional calibration set 
The reference vs prediction plot is shown in Figure 6-13. An optimum subset was selected from 
225 samples using the search algorithm described earlier. The resultant optimum calibration set 
contained 71 samples. A PLS model was developed from the selected 71 samples. The 
preprocessing techniques were SNV, normalization and mean centering for the spectral data and 
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auto scaling for the concentration data. A set of 4 latent variables was selected for model 
development. 
  
Figure 6-14. Raman PLS model for Acetaminophen from optimal calibration set 
  
Figure 6-14 shows the projections of the calibration and test samples on the first four loading 
vectors. Similar to the global calibration set (225 samples), calibration and test samples were 
grouped based on the Acetaminophen concentration on the first two loading vectors. The extents 
of variation explained by the first two loading vectors were also similar to that of global 
calibration set. The calibration and test samples had similar projection on the loading vector. An 
improvement in the prediction performance was observed from the optimum calibration set 
compared to the global calibration set. The RMSEC and RMSEP were 1.05 % w/w and 0.79 % 
w/w, respectively. The reference vs prediction plot is shown in Figure 6-15. 
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Figure 6-15. Reference vs prediction plot of Acetaminophen from optimum calibration set 
6.2.2.2.2 Caffeine prediction 
A PLS model was also developed to predict the concentration of Caffeine in the test set using 
Raman spectra. The optimum preprocessing techniques were SNV and mean centering for the 
spectral data and auto scaling for the concentration data. A set of 4 latent variables was selected 
for model development. Figure 6-16 shows the projections of the calibration and test samples on 
the first four loading vectors. No clear grouping based on the Caffeine concentrations was 
observed in the score plot. The first four loading vectors explained convoluted information from 
Caffeine concentrations and other sources of spectral variation. The Caffeine concentration was 
not a dominant factor due to low concentration in the tablets. 
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The calibration and test samples had similar ranges of spectral variation. A reasonable prediction 
performance was achieved from the global calibration set. The RMSEC and RMSEP were 0.59 
% w/w and 0.55 % w/w, respectively. The reference vs prediction plot is shown in Figure 6-17. 
 
Figure 6-16. Raman PLS model for Caffeine from traditional calibration set 
 
An optimum subset was selected from 225 samples using the search algorithm described earlier. 
The resultant optimum calibration set contained 58 samples. A PLS model was developed from 
this optimum calibration set. The preprocessing techniques were SNV and mean centering for the 
spectral data and auto scaling for the concentration data. A set of 4 latent variables was selected 
for model development. 
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Figure 6-17. Reference vs prediction plot of Caffeine from traditional calibration set.  
Figure 6-18 shows the calibration and test scores on the first four loading vectors. No grouping 
based on Caffeine concentration was observed in the score plot. The calibration and test set had 
similar ranges of spectral variation as shown in the score plot. An improved prediction 
performance was observed from the optimum calibration set as compared to the global 
calibration set. The RMSEC and RMSEP were 0.38 % w/w and 0.46 % w/w, respectively. The 
reference vs prediction plot is shown in Figure 6-19. 
 
Figure 6-18. Raman PLS model for Caffeine from optimum calibration set 
The optimum calibration sets with fewer sample numbers were able to provide better model 
performances compared to the global calibration sets with higher sample numbers for both 
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Acetaminophen and Caffeine. The optimum calibration sets between Acetaminophen and 
Caffeine were found to be different. Only 24 samples were found common between the optimum 
calibration sets for Acetaminophen (71 samples) and Caffeine (58 samples). This scenario was 
similar to the scenario in NIR spectroscopy. 
 
Figure 6-19. Reference vs prediction plot of Caffeine from optimum calibration set.  
 
6.3 Results and discussion 
6.3.1 Comparison between optimum calibration sets of NIR and Raman spectroscopy 
The optimum calibration sets between NIR and Raman spectroscopy were different for both 
Acetaminophen and Caffeine. The comparison of the optimum calibration sets are discussed in 
the following sections. 
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6.3.1.1 Optimum calibration sets of Acetaminophen 
The optimum calibration set of NIR spectroscopy required fewer samples compared to the 
optimum calibration set of Raman spectroscopy (35 vs 71) during the prediction of 
Acetaminophen in the test set. The optimum structures of the calibration sets were different from 
each other. Only 14 samples were common between the two calibration sets.  
 Figure 6-20 shows the compositional points between full global calibration set, optimum NIR 
and Raman calibration sets. The optimum NIR calibration set had lower prediction error 
compared to that of optimum Raman calibration set (RMSEP 0.69% w/w vs 0.79% w/w) in spite 
of having fewer sample number. However, a significant test was performed following the 
method described in section 5.2.8 in chapter 5 and no significant difference were found between 
their prediction performances. 
 
 Figure 6-20. Compositional points between full global, NIR optimized and Raman 
optimized calibration sets for Acetaminophen.  
 
The distribution of Acetaminophen concentration in optimum calibration sets of NIR and Raman 
is provided in Figure 6-21. The NIR calibration set required fewer samples compared to the 
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Raman set, especially at low concentration of Acetaminophen. These samples were selected from 
traditional full factorial calibration set. The traditional full factorial calibration structure was not 
fully orthogonal. In the calibration structure, there was a correlation between Acetaminophen 
concentration and MCC concentration as shown in Figure 6-22. At low Acetaminophen 
concentration, the MCC concentration was usually high. MCC has a strong background features 
on Raman spectra due to fluorescence. Due to such strong spectral features of MCC, Raman 
calibration set required more samples at high MCC concentration to make the calibration set 
robust against fluorescence. 
 
Figure 6-21. Acetaminophen distribution between NIR and Raman optimized calibration 
sets   
MCC does not have any strong fluorescence like unique features on NIR spectra. So, high 
concentration of MCC at the low level of Acetaminophen did not direct the optimum calibration 
set to select higher number of samples. 
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Figure 6-22. Concentrations of Acetaminophen and MCC in full traditional, NIR optimized 
and Raman optimized calibration sets   
These two optimum calibration sets were also different in terms of excipient concentration. The 
distribution of MCC and Lactose between Optimum NIR and Raman calibration sets are shown 
in Figure 6-23. The optimum calibration for NIR required narrower distribution of excipients, 
especially for Lactose.  
 
Figure 6-23. MCC (left) and Lactose (right) distribution between NIR and Raman 
optimized calibration sets for Acetaminophen   
 
The overall required spectral variation from excipient was also small for NIR calibration set 
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responses between MCC and Lactose in NIR spectroscopy. MCC and Lactose has very similar 
NIRS response as shown in Figure 6-24. Due to such similarity, the excipients were not required 
to be varied simultaneously. Variance in MCC would provide necessary spectral variation in the 
calibration structure. As a result, the optimum calibration set provided good prediction 
performance without significant variation in the Lactose concentration. However, in the Raman 
spectroscopy MCC and Lactose have very different spectral responses as shown in Figure 6-24. 
The optimum Raman calibration set required variation in both MCC and Lactose concentration 
due to their unique information. This resulted in higher number of calibration samples in the 
optimum Raman calibration set compared to that of NIR spectroscopy. 
 
Figure 6-24. NIR (left) and Raman (right) spectra of MCC and Lactose 
6.3.1.2 Optimum calibration sets of Caffeine 
The optimum calibration structures of Caffeine were found to be different between NIR and 
Raman spectroscopy. The optimum calibration set of NIR spectroscopy required fewer samples 
compared to the optimum calibration set of Raman spectroscopy (37 vs 58) during the prediction 
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of Caffeine; a scenario similar to the Acetaminophen calibration set. Only 10 samples were 
common between the two calibration sets.  
 
Figure 6-25. Compositional points between full global, NIR optimized and Raman 
optimized calibration sets for Caffeine.  
 
Figure 6-25 shows the compositional points between global calibration set, optimum NIR and 
Raman calibration sets for Caffeine. The prediction performance of the optimum NIR calibration 
set was significantly better than the prediction performance of the optimum Raman calibration 
set (RMSEP 0.28% w/w vs 0.46% w/w). The significance test was performed following the 
method described in section 5.2.8 in chapter 5. 
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Figure 6-26. Caffeine distribution between NIR and Raman optimized calibration sets   
The distribution of Caffeine concentrations between the NIR and Raman calibration sets is 
shown in Figure 6-26. Similar distributions were observed between NIR and Raman spectra. The 
NIR calibration set did not require fewer calibration samples at low Caffeine concentration as it 
did for the optimum calibration set of Acetaminophen. No correlation between Caffeine and 
MCC concentration was found as shown in Figure 6-27. MCC concentrations were relatively 
similar at all levels of Caffeine concentration resulting in similar distribution of Caffeine 
between optimum calibration sets of NIR and Raman spectroscopy. 
The excipient distributions (MCC and Lactose) between two calibration sets are given in Figure 
6-28. The optimum NIR calibration set required fewer calibration samples due to similarity 
between the spectral response of MCC and Lactose. However, the optimum Raman calibration 
set required higher number of calibration samples due to unique information from both 
excipients. 
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Figure 6-27. Concentrations of Caffeine and MCC in full traditional, NIR optimized and 
Raman optimized calibration sets     
The optimum calibration sets of NIR and Raman spectroscopy were found to be significantly 
different from each other for both APIs due to inherent differences in the analytical techniques. 
However, the current practice of calibration design does not account for such variations in the 
analytical techniques. A similar strategy is followed for both techniques resulting in sub-optimal 
calibration performance. A study was performed to analyze the criticality of the calibration sets 
to be technique specific. 
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Figure 6-28. MCC (left) and Lactose (right) distribution between NIR and Raman 
optimized calibration sets for Caffeine 
In this study, a Raman calibration method was developed from the optimal calibration structure 
of NIR spectroscopy for both Acetaminophen and Caffeine. Similarly, an NIR calibration 
method was developed from the optimal calibration structure of Raman spectroscopy. For 
instance, during the prediction of Acetaminophen, the optimal calibration sets for NIR and 
 NIRS Raman 
Calibration set Global NIR Optimum 
Raman 
Optimum Global 
Raman 
Optimum 
NIR 
Optimum 
Sample no. 225 35 71 225 71 35 
LV 6 6 6 4 4 4 
RMSEC 0.97 0.49 1.01 1.02 1.05 0.78 
RMSECV 1.03 0.88 1.17 1.11 1.27 1.01 
RMSEP 1.04 0.69 1.13 1.09 0.79 1.13 
Bias 0.08 0.68 0.15 0.39 0.14 0.4 
SEP 1.04 0.13 1.12 1.02 0.77 1.05 
Table 6-2. Model statistics for global, optimum and cross calibration sets NIR and Raman 
during the prediction of Acetaminophen 
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Raman spectroscopy contained 35 and 71 calibration samples, respectively. A Raman method 
was developed from the optimal NIR calibration set that contained 35 samples and an NIR 
method was developed from the optimal Raman calibration set that contained 71 samples. This 
study was conducted for both Acetaminophen and Caffeine. PLS models were developed from 
the respective calibration sets. Model performances were compared with the optimal and global 
calibration performance. The results for Acetaminophen prediction are provided in Table 6-2. 
It was shown that, the prediction performance of the calibration set deteriorated when the 
optimal structure of a different spectroscopic technique was used. The RMSEP of the optimal 
NIR calibration set (35 samples) was 0.69 % w/w. The prediction performance was affected 
significantly (RMSEP 1.13% w/w) when the optimal structure of Raman calibration set (71 
samples) was used to develop a NIR calibration model to quantify the same API. The 
performance of this same calibration set was significantly better when it was used for Raman 
 NIRS Raman 
Calibration set Global NIR Optimum 
Raman 
Optimum Global 
Raman 
Optimum 
NIR 
Optimum 
Sample no. 225 37 58 225 58 37 
LV 6 6 6 4 4 4 
RMSEC 0.4 0.19 0.4 0.59 0.38 0.48 
RMSECV 0.42 0.27 0.52 0.63 0.49 0.62 
RMSEP 0.43 0.28 0.48 0.55 0.46 0.6 
Bias 0.15 0.02 0.14 0.09 0.02 0.05 
SEP 0.41 0.28 0.45 0.54 0.46 0.6 
Table 6-3. Model statistics for global, optimum and cross calibration sets NIR and Raman 
during the prediction of Caffeine 
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spectroscopy (RMSEP 0.79% w/w). And the prediction performance of the optimal NIR 
calibration set deteriorated significantly when it was used to develop a Raman calibration 
method (RMSEP 0.69% w/w vs 1.13% w/w). 
Similar results were obtained during the calibration model development for Caffeine prediction 
as shown in Table 6-3. When the optimum calibration set of Raman (58 samples) was used to 
develop an NIR method, the prediction error was significantly high (RMSEP 0.48% w/w) 
compared to the prediction error (RMSEP 0.28% w/w) of optimum calibration set of NIR (37 
samples). This optimum set of 37 samples was suitable specifically for NIR spectroscopy. When 
this optimum NIR set of 37 samples was used to develop a Raman calibration model, the 
prediction error was significantly high (RMSEP 0.6% w/w). 
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Table 6-4. Number of common samples between the optimum calibration sets of 
different techniques and different APIs 
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6.4 Conclusion 
The optimum calibration sets for NIR and Raman spectroscopy were found to be different from 
each other. Only a few common samples were found between two APIs and two spectroscopic 
techniques. Table 6-4 summarizes the results. These results indicated that the optimum 
calibration structure depends on the interaction between spectral responses and physico-chemical 
properties of the tablets. An optimum calibration set for one formulation and/or technique can be 
sub-optimum for another formulation and/or technique. A formulation and technique specific 
calibration set should be designed to maximize calibration performance of a spectroscopic 
system for quantitative analysis of pharmaceutical tablets. 
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7 Chapter 7: Summary 
The theory of experimental design is well established and NIR calibration have been widely used 
for wide range of applications, however there is a gap between the theory and practical 
implementation of experimental design during NIR calibration set development. Direct 
application of classical theory of experimental design is still missing in the problem of 
multivariate spectroscopic calibration [76, 194]. Bridging this gap can lead towards better 
understanding of the interaction between calibration structure and NIRS model performance. 
This understanding can be helpful to identify the necessary information for a calibration set and 
challenge the current philosophy of incorporating all possible variances into the calibration set. 
All possible variances may not always be necessary for desired model performance. Moreover, it 
requires a large calibration set to span all possible variances, which may not be an efficient 
approach in terms of time and available resources. Besides, it is almost impossible to anticipate 
and span all possible variances, especially at the early stage of product and process development. 
The current all-inclusive calibration strategy can be replaced by an efficient strategy for 
developing NIR calibration set using spectral space. 
It was demonstrated that, the pure component spectral response of a formulation can be utilized 
to define the spectral space of that formulation. The use of pure component spectral information 
results in a formulation and technique specific spectral space. Such specificity leads towards the 
development of a formulation and technique specific calibration set. The current strategies for 
designing NIR calibration sets do not account for such specificity towards formulations and 
analytical technique. Regulatory guidelines and general rules of thumb are usually followed for 
all types of formulations resulting in similar concentration ranges, levels and number of samples 
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for all types of calibration sets. However, an optimal calibration design for one formulation can 
be sub-optimal for a different formulation. Different NIR responses produced by different 
formulations should be considered during the selection of calibration structure, range, size, 
concentration levels and variance information. It was also demonstrated that the spectral space 
can be used to identify the critical calibration samples. Information regarding the critical sample 
requirement helps to design and prepare a small and efficient calibration set. This strategy was 
defined as the spectral space design strategy for calibration set development during NIR 
quantitative analysis of tablets. 
The spectral space design strategy was compared with the current calibration strategies of 
designing calibration sets. The current strategy is prone to have redundant information. It was 
demonstrated that, a traditionally designed calibration set contained redundant information 
whereas a spectrally designed calibration set identified and eliminated redundant information, 
thus requiring fewer calibration samples to provide similar calibration performance. Multiple 
comparative studies were conducted between commonly employed experimental design 
approaches to calibration development and the newly developed spectral space based technique. 
The comparisons were conducted on single API (Active Pharmaceutical Ingredient) and multiple 
API formulations to quantify drug tablet API using NIR spectroscopy. Partial least squares (PLS) 
models were developed from respective calibration designs. Model performance was 
comprehensively assessed based on the ability to predict API concentrations in independent 
prediction/validation sets. Similar prediction performance was achieved using the smaller 
calibration set designed in spectral space (11 for single API and 33 for multiple API tablets), 
compared to the traditionally designed large calibration sets (45 for single API and 225 for 
multiple API tablets). An improved prediction performance was observed for the spectrally 
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designed calibration sets (33 tablets for spectral design) compared to the traditionally designed 
calibration sets of equal sizes (33 tablets for D-Optimal, CCD and I-Optimal designs). It was 
demonstrated that a calibration set designed in spectral space provided an efficient means of 
developing spectroscopic multivariate calibration for tablet analysis. Such strategy provides 
opportunity to design formulation and technique specific calibration sets to optimize calibration 
capability. 
The spectral design strategy was built on the spectral space of a formulation. The spectral space 
was defined the by pure component spectral information. Initially the spectral space was used to 
identify only compositional design points that are critical to calibration performance. However, it 
is also critical for a calibration set to contain physico-chemical variation besides the 
compositional information to build a robust calibration model. The current strategy for 
incorporating physico-chemical variation into the calibration requires large calibration set. It was 
demonstrated that, spectral space can be used to develop an efficient strategy to incorporate 
physico-chemical information into the calibration set. The density of the tablet was identified as 
a critical physico-chemical information for the NIR calibration set. The pure component tablet 
spectra at different densities were utilized to define a latent variable spectral space containing 
both concentration and density information at different directions. A small set of critical samples 
was selected from the latent variable spectral space. These samples were designed to prepare a 
small calibration set containing both concentration and density information. The performance of 
this small calibration set was compared with the traditionally designed large calibration set 
during quantitative analysis of Acetaminophen and caffeine using NIR. The small calibration set 
provided similar prediction performance compared to the large calibration sets indicating the 
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efficiency of the spectral design strategy to incorporate physico-chemical information into the 
calibration set. 
The spectral design strategy can be generalized to develop efficient calibration sets for other 
formulations. However, it is critical to have pure component spectral information to define the 
spectral space of that formulation. In this study, pure component spectral information was 
collected from pure component tablets. Pure component powder can also be used to collect pure 
component spectra for uncompressible/less compressible powders. The spectral design strategy 
can also be generalized to incorporate other types of physico-chemical information such as 
moisture content, particle size distribution etc. However, it is critical to consider the effects of 
physico-chemical information in the pure component spectra and tablet spectra during such 
analysis. 
The spectral design strategy identifies the critical samples from spectral information whereas the 
current calibration design strategy assumes certain samples to be critical for the calibration set 
development from their compositional information. For instance, the full factorial design 
assumes the orthogonal compositional samples are most critical to calibration set, the D-optimal 
design assumes that the compositionally distant samples are most critical to calibration set. The 
advantage of having large sample set is that, it provides useful and critical information even 
when these assumptions are violated. Such information from a large calibration set can be used 
to develop a successful quantitative NIR method. The advantage of spectral calibration set is 
that, it provides similar performance with a smaller calibration set. It is very critical to consider 
that spectral design is expected to be ‘efficient’ not ‘better / more accurate’ compared to the 
current calibration approaches. 
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It is also critical to consider that the spectral design strategy utilizes a selection technique to 
identify critical calibration samples in the spectral space. Different selection techniques can 
result in slightly different calibration sets in the spectral space. In this study, multiple selection 
techniques (Kennard stone, orthogonal rotation, Euclidian distance) were used to identify critical 
samples and all of these sets gave similar prediction results due to similar spanning of spectral 
variation. Different spectral variation from different selection algorithm would have resulted 
differences in prediction performances. It is critical that the selection technique maximizes the 
variation in spectral space to find the calibration set with optimum performance. Such optimum 
performance can be obtained with the current calibration strategy in case the same samples 
maximize variation in the concentration space. Such case would require linear mapping between 
spectral and compositional spaces. 
In this study, it was also demonstrated that the optimal calibration structure depends on the 
formulation and spectroscopic technique. An optimal calibration set for one formulation can be 
sub-optimal for another formulation. An optimal calibration set for one spectroscopic technique 
can be suboptimal for another spectroscopic technique. The current calibration strategies do not 
allow optimization of calibration set based on formulation variation and specific spectral 
response. The same calibration design is used for different formulations and different techniques. 
This strategy does not provide optimum performance of the calibration efforts. The optimum 
calibration structures between NIR and Raman spectroscopy were compared during the 
quantitative analysis of Acetaminophen and Caffeine. The optimum NIR calibration set was 
found to be different from the optimum Raman calibration set for both APIs. The optimum 
calibration set for Acetaminophen was found to be different from the optimum calibration set for 
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Caffeine for both spectroscopic techniques. The common calibration designs between different 
formulations and different techniques do not provide optimal calibration performance.  
In the spectral design strategy, the use of pure component spectral information allows the 
calibration set to be formulation and technique specific. Such specificity would provide 
additional information to establish method suitability during method validation. However, it 
would not ease the validation steps or make it more difficult. The current validation steps require 
the calibration model to demonstrate accuracy, linearity, specificity, precision, range and 
robustness. The same requirements should be applied to the spectrally design calibration set. It is 
expected that, the spectrally design calibration set should pass the validation steps with fewer 
samples. 
In this study, Partial Least Square (PLS) was used as the modeling technique. It was 
demonstrated that robustness of the PLS calibration model is critical for successful 
implementation of an NIR quantitative method in the pharmaceutical industry. Different sources 
of variations such as scale variations, physical variations and chemical variations can affect the 
PLS model performance during product life cycle. A robust PLS model is required to be 
developed at the outset of calibration to encounter such variations and provide desired predictive 
performance thus avoiding the needs for recurrent model updates. Selecting the optimum number 
of model components (loading vectors) is critical to build a robust model with the available 
dataset. Cross-validation error along with the amount of model variance captured by each model 
component is currently used to select the optimum number of model components. A new method 
was developed to select the optimum number of model components based on weight co-efficient 
of each model component. The new weight coefficient based method was found to be more 
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effective in selecting the optimum number of model components and improving model 
robustness compared to the current selection technique. Several datasets possessing different 
types of critical variations to NIR PLS model were used in this study to demonstrate the 
efficiency of the new weight coefficient based method in selecting the optimum number of 
model components. 
PLS is the most frequently used modeling technique for calibration development. However, there 
are other modeling techniques such as Principal Component Regression, Multiple Linear 
Regression, Support Vector Machine, Artificial Neural Network etc. that can be used for 
calibration model development. The spectral design strategy was tested for PLS modeling 
technique considering its wide applicability. However, for other modeling techniques, the 
efficiency of the spectral design strategy is yet to be tested. This can be a direction of the future 
studies exploring spectral design strategy as an efficient alternative. 
In future, the strategy demonstrated in this dissertation can also be used for other spectroscopic 
techniques including Raman and terahertz spectroscopy to develop an efficient calibration 
strategy. Pure spectrum of each component should be used during the design/selection of the 
calibration set. Comprehensive studies in this direction can lead towards formulation specific 
calibration development and ensure optimal performance of each calibration set. Comparative 
studies are suggested to distinguish the interactions between calibration structures and different 
spectroscopic techniques. 
One of the challenges of the spectral design strategy is to calculate the compositional 
requirements of the spectrally designed samples. In this study, pure component and target tablet 
information was used to define the rotation matrix and calculate the compositional requirements 
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for spectrally designed samples. The rotation matrix was defined using target tablet since the 
calibration set was intended to center around target formulation. In other instances, when 
calibration sets are not intended to center around target formulation, the target tablet and pure 
component tablets might not be sufficient to calculate the rotation matrix. Additional sets of 
actual tablets might be necessary to calculate the rotation matrix and compositional requirements 
of the spectrally designed samples. Other challenge of the spectral design strategy is that, it 
utilizes optimization algorithm during the solution of compositional requirement calculations. 
All the optimization algorithms have the potentials to provide local minima solution. Multiple 
iterations are required to ensure global minima and expected solution.  
There is no best calibration design that works for all purpose. A great deal depends on the 
method requirements [28]. The traditional practices for developing calibration sets are too 
generalized. Spectral design approach offers an efficient and formulation specific alternative 
strategy to the current practices of NIR calibration design for quantitative analysis of 
pharmaceutical tablets. 
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Appendices 
Appendix A (Motivation for using scores as design factors for calibration) 
The motivation for using scores as calibration design factors comes from the multivariate 
regression equation itself. The regression equation 2.1 can be transformed into a linear model 
equation with the concentrations as a response and PLS scores (projection on the orthogonal 
spectral space of the PLS model) as input variables shown in equation 2.9 for the same system 
with “m” samples, “n” spectral variables and “r” eigen vectors/(selected latent variables in PLS) 
using y for the concentrations of samples, T for the score matrix of “r” latent variables and u for 
the regression vector between scores and concentrations 
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗𝐦𝐦∗𝐧𝐧 ∗ 𝐛𝐛𝐧𝐧∗𝟏𝟏 
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐗𝐗𝐦𝐦∗𝐧𝐧 ∗ 𝐖𝐖𝐧𝐧∗𝐫𝐫  ∗ (𝐓𝐓𝐫𝐫∗𝐦𝐦′ ∗  𝐓𝐓𝐦𝐦∗𝐫𝐫 )−𝟏𝟏 ∗ (𝐓𝐓𝐫𝐫∗𝐦𝐦′ ∗  𝐲𝐲𝐦𝐦∗𝟏𝟏) [Here y� is the predicted 
concentration for new samples, y is reference concentration of the calibration samples. Please 
note that, the sample numbers do not have to be equal] 
𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐓𝐓𝐦𝐦∗𝐫𝐫  ∗  (𝐓𝐓𝐫𝐫∗𝐦𝐦′ ∗  𝐓𝐓𝐦𝐦∗𝐫𝐫 )−𝟏𝟏 ∗ (𝐓𝐓𝐫𝐫∗𝐦𝐦′ ∗  𝐲𝐲𝐦𝐦∗𝟏𝟏) 
Thus, the classical idea of design of experiments is best embodied by orthogonally varying the 
PLS scores and measuring the concentrations as response according to equation 2.10. These 
experiments are then used to approximate a linear model between concentrations (y) and scores 
(t) with a limited number of factors. The challenge for designing orthogonal PLS scores is not 
    𝐲𝐲�𝐦𝐦∗𝟏𝟏 = 𝐓𝐓𝐦𝐦∗𝐫𝐫 ∗  𝐏𝐏𝐫𝐫∗𝟏𝟏 (2.9)     ŷ𝑖𝑖=1..𝑚𝑚𝑖𝑖 = 𝑡𝑡1𝑖𝑖 ∗ 𝑇𝑇1 + 𝑡𝑡2𝑖𝑖 ∗ 𝑇𝑇2 + ⋯+  𝑡𝑡𝑟𝑟𝑖𝑖 ∗ 𝑇𝑇𝑟𝑟 (2.10) 
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trivial. The designed scores need to be derived from a set of real pharmaceutical samples. The 
pure component spectra of the samples can be used to define the orthogonal spectral space of the 
PLS model assuming that, the primary model variance is dictated by the formulation variation 
after appropriate preprocessing technique has been applied. 
 
Appendix B (Derivation of equation 2.7) 
𝐂𝐂𝐦𝐦∗𝐤𝐤
𝐂𝐂𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐛𝐛𝐛𝐛𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗ 𝐑𝐑𝐤𝐤∗𝐤𝐤
𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗  𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 =   𝐗𝐗𝐦𝐦∗𝐧𝐧𝐒𝐒𝐭𝐭𝐦𝐦𝐜𝐜𝐭𝐭𝐌𝐌 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐫𝐫𝐭𝐭  
𝐔𝐔𝐦𝐦∗𝐦𝐦
𝐋𝐋𝐌𝐌𝐋𝐋𝐭𝐭 𝐛𝐛𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫 ∗ 𝐒𝐒𝐦𝐦∗𝐤𝐤𝐒𝐒𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫 ∗  𝐕𝐕𝐤𝐤∗𝐤𝐤𝐑𝐑𝐛𝐛𝐑𝐑𝐑𝐑𝐭𝐭 𝐛𝐛𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫 ∗ 𝐑𝐑𝐤𝐤∗𝐤𝐤𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗  𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 =   𝐗𝐗𝐦𝐦∗𝐧𝐧𝐒𝐒𝐭𝐭𝐦𝐦𝐜𝐜𝐭𝐭𝐌𝐌 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐫𝐫𝐭𝐭  
𝐑𝐑𝐤𝐤∗𝐤𝐤
𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 𝐦𝐦𝐭𝐭𝐭𝐭𝐫𝐫𝐛𝐛𝐱𝐱 
= 𝐕𝐕𝐤𝐤∗𝐤𝐤𝐑𝐑𝐛𝐛𝐑𝐑𝐑𝐑𝐭𝐭 𝐛𝐛𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫′ ∗ ��𝐒𝐒𝐤𝐤∗𝐦𝐦𝐒𝐒𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫�′ ∗ �𝐒𝐒𝐦𝐦∗𝐤𝐤𝐒𝐒𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫� ∗ �−𝟏𝟏 ∗  �𝐒𝐒𝐤𝐤∗𝐦𝐦𝐒𝐒𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫�′
∗  �𝐔𝐔𝐦𝐦∗𝐦𝐦𝐋𝐋𝐌𝐌𝐋𝐋𝐭𝐭 𝐛𝐛𝐛𝐛𝐧𝐧𝐑𝐑𝐏𝐏𝐭𝐭𝐭𝐭𝐫𝐫�′ ∗  𝐗𝐗𝐦𝐦∗𝐧𝐧𝐒𝐒𝐭𝐭𝐦𝐦𝐜𝐜𝐭𝐭𝐌𝐌 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 ∗ �𝐏𝐏𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐌𝐌𝐧𝐧𝐭𝐭�′
∗ {�𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐌𝐌𝐧𝐧𝐭𝐭� ∗  �𝐏𝐏𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐌𝐌𝐧𝐧𝐭𝐭�′}−𝟏𝟏 
 
Since, the “S” is a diagonal matrix, a simpler solution can be performed by taking the diagonal 
values and making an inverse of the diagonal elements. However, it would give the exact same 
solution. The readers are encouraged to use either of the solutions. 
Appendix C (Derivation of equation 2.8) 
Using the assumption that the variation in pure component spectra dictates the primary spectral 
variation in the model and resembles the weight factors in the PLS,     
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 𝐗𝐗𝐏𝐏∗𝐧𝐧𝐒𝐒𝐭𝐭𝐦𝐦𝐜𝐜𝐭𝐭𝐌𝐌 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐫𝐫𝐭𝐭 ∗  𝐖𝐖𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐭𝐭𝐛𝐛𝐛𝐛𝐛𝐛 =  𝐓𝐓𝐏𝐏∗𝐫𝐫𝐒𝐒𝐜𝐜𝐌𝐌𝐫𝐫𝐌𝐌 𝐛𝐛𝐜𝐜𝐭𝐭𝐜𝐜𝐌𝐌 
 𝐂𝐂𝐏𝐏∗𝐤𝐤𝐂𝐂𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐛𝐛𝐛𝐛𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗ 𝐑𝐑𝐤𝐤∗𝐤𝐤𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗  𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 ∗  𝐖𝐖𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐭𝐭𝐛𝐛𝐛𝐛𝐛𝐛 =  𝐓𝐓𝐏𝐏∗𝐤𝐤𝐒𝐒𝐜𝐜𝐌𝐌𝐫𝐫𝐌𝐌 𝐛𝐛𝐜𝐜𝐭𝐭𝐜𝐜𝐌𝐌 
𝐂𝐂𝐏𝐏∗𝐤𝐤
𝐂𝐂𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐛𝐛𝐛𝐛𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 ∗ 𝐑𝐑𝐤𝐤∗𝐤𝐤
𝐑𝐑𝐌𝐌𝐭𝐭𝐭𝐭𝐭𝐭𝐛𝐛𝐌𝐌𝐧𝐧 = 𝐓𝐓𝐏𝐏∗𝐤𝐤𝐒𝐒𝐜𝐜𝐌𝐌𝐫𝐫𝐌𝐌 𝐛𝐛𝐜𝐜𝐭𝐭𝐜𝐜𝐌𝐌 ∗ (𝐏𝐏𝐤𝐤∗𝐧𝐧𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐜𝐜𝐌𝐌𝐜𝐜𝐭𝐭𝐫𝐫𝐭𝐭 ∗ 𝐖𝐖𝐧𝐧∗𝐤𝐤𝐏𝐏𝐏𝐏𝐫𝐫𝐌𝐌 𝐜𝐜𝐌𝐌𝐦𝐦𝐜𝐜𝐌𝐌𝐧𝐧𝐌𝐌𝐧𝐧𝐭𝐭 𝐛𝐛𝐭𝐭𝐛𝐛𝐛𝐛𝐛𝐛)−𝟏𝟏 
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